Select Region or Location
Americas
  • Argentina
  • Brazil
  • Canada
  • Mexico
  • United States
  • Other Americas
Europe
  • Austria
  • Belgium
  • Bulgaria
  • Croatia/Hrvatska
  • Cyprus
  • Czech Republic
  • Denmark
  • Estonia
  • Finland
  • France
  • Germany
  • Greece
  • Hungary
  • Ireland
  • Italy
  • Latvia
  • Liechtenstein
  • Lithuania
  • Luxembourg
  • Malta
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Romania
  • Slovak Republic
  • Slovenia
  • Spain
  • Sweden
  • Switzerland
  • Turkey
  • United Kingdom
  • Other Europe
Asia Pacific
  • Australia
  • China
  • India
  • Indonesia
  • Japan
  • Korea, Republic of
  • Malaysia
  • New Zealand
  • Philippines
  • Singapore
  • Thailand
  • Vietnam
  • Other Asia Pacific
Africa And Middle East
  • Egypt
  • Israel
  • Other Africa And Middle East
USD
Home Cart Sign in  
Chemical Structure| 1997302-16-5 Chemical Structure| 1997302-16-5

Structure of 1997302-16-5

Chemical Structure| 1997302-16-5

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

4.5 *For Research Use Only! Not for Human Use. We Do Not Sell to Patients.

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

DE Stock

US Stock

Asia Stock

Global Stock

In Stock
{[ item.pr_size ]}{[ size_append_text(item.pr_size, proInfo.prAm, 'list') ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

  • {[ item.pr_size ]}
    {[ size_append_text(item.pr_size, proInfo.prAm, 'list') ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of [ 1997302-16-5 ]

CAS No. :1997302-16-5
Formula : C28H40N4O5S
M.W : 544.71
SMILES Code : O=C(OC(C)(C)C)N[C@@H](C(C)(C)C)C(N1[C@H](C(N[C@H](C2=CC=C(C3=C(C)N=CS3)C=C2)C)=O)C[C@@H](O)C1)=O
English Name :tert-Butyl ((S)-1-((2S,4R)-4-hydroxy-2-(((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)carbamate
MDL No. :MFCD30748173

Safety of [ 1997302-16-5 ]

Application In Synthesis of [ 1997302-16-5 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Downstream synthetic route of [ 1997302-16-5 ]

[ 1997302-16-5 ] Synthesis Path-Downstream   1~14

  • 1
  • [ 847728-89-6 ]
  • [ 1997302-16-5 ]
YieldReaction ConditionsOperation in experiment
Multi-step reaction with 3 steps 1: palladium diacetate; potassium acetate / N,N-dimethyl acetamide / 18 h / 90 °C / Inert atmosphere 2: hydrogenchloride / methanol / 3 h / 20 °C 3: HATU; N-ethyl-N,N-diisopropylamine / tetrahydrofuran / 2 h / 0 - 20 °C
Multi-step reaction with 3 steps 1: palladium diacetate; potassium acetate / N,N-dimethyl-formamide / 2 h / 90 °C / Inert atmosphere 2: dichloromethane / 0.5 h / 20 °C 3: N-ethyl-N,N-diisopropylamine; N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate / N,N-dimethyl-formamide / 20 °C
Multi-step reaction with 5 steps 1: palladium diacetate; potassium acetate / N,N-dimethyl-formamide / 12 h / 90 °C 2: hydrogenchloride / methanol; 1,4-dioxane / 12 h / 20 °C 3: N-ethyl-N,N-diisopropylamine; N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate / N,N-dimethyl-formamide / 12 h / 0 - 20 °C / Inert atmosphere 4: hydrogenchloride / methanol; 1,4-dioxane / 12 h / 20 °C 5: N-ethyl-N,N-diisopropylamine; N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate / N,N-dimethyl-formamide / 12 h / 0 - 20 °C / Inert atmosphere
Multi-step reaction with 5 steps 1: potassium acetate; palladium diacetate / N,N-dimethyl acetamide / 2 h / 120 °C 2: hydrogenchloride / methanol / 2 h / 20 °C 3: N-ethyl-N,N-diisopropylamine; HATU / N,N-dimethyl-formamide / 12 h / 20 °C 4: hydrogenchloride / methanol / 2 h / 20 °C 5: N-ethyl-N,N-diisopropylamine; HATU / N,N-dimethyl-formamide / 12 h / 20 °C
Multi-step reaction with 3 steps 1: palladium diacetate; potassium acetate / N,N-dimethyl acetamide / 12 h / 90 °C 2: hydrogenchloride / 1,4-dioxane; methanol / 4 h / 20 °C 3: N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate; N-ethyl-N,N-diisopropylamine / N,N-dimethyl-formamide / 12 h / 0 - 20 °C / Inert atmosphere
Multi-step reaction with 3 steps 1: palladium diacetate; potassium acetate / N,N-dimethyl acetamide / 18 h / 90 °C 2: hydrogenchloride / water; 1,4-dioxane / 3 h / 20 °C 3: N-ethyl-N,N-diisopropylamine; N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate / tetrahydrofuran / 5 h / 0 - 20 °C / Inert atmosphere
Multi-step reaction with 3 steps 1: palladium diacetate; potassium acetate / N,N-dimethyl-formamide / 18 h / 90 °C / Inert atmosphere 2: hydrogenchloride / water; methanol / 3 h / 20 °C 3: N-ethyl-N,N-diisopropylamine; N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate / tetrahydrofuran / 2 h / 0 - 20 °C
Multi-step reaction with 5 steps 1: palladium diacetate; potassium acetate / dimethyl amine / 12 h / 90 °C 2: hydrogenchloride / 1,4-dioxane; methanol / 12 h / 20 °C 3: HATU; N-ethyl-N,N-diisopropylamine / N,N-dimethyl-formamide / 12 h / 0 - 20 °C / Inert atmosphere 4: hydrogenchloride / 1,4-dioxane; methanol / 12 h / 20 °C 5: HATU; N-ethyl-N,N-diisopropylamine / N,N-dimethyl-formamide / 12 h / 0 - 20 °C / Inert atmosphere
Multi-step reaction with 5 steps 1: potassium acetate; palladium diacetate / N,N-dimethyl-formamide / 16 h / 80 °C / Inert atmosphere 2: hydrogenchloride / 1,4-dioxane / 25 °C / Inert atmosphere 3: HATU; N-ethyl-N,N-diisopropylamine / N,N-dimethyl-formamide / 0 - 25 °C / Inert atmosphere 4: hydrogenchloride / 1,4-dioxane / 16 h / 25 °C / Inert atmosphere 5: triethylamine; HATU / N,N-dimethyl-formamide / 0 - 25 °C / Inert atmosphere
Multi-step reaction with 3 steps 1: potassium acetate; palladium diacetate / N,N-dimethyl acetamide / 7 h / 90 °C / Inert atmosphere 2: hydrogenchloride / water; 1,4-dioxane / 5 h / 20 °C 3: N-ethyl-N,N-diisopropylamine; N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate / N,N-dimethyl-formamide / 20 °C / Cooling with ice
Multi-step reaction with 3 steps 1: palladium diacetate; potassium acetate / N,N-dimethyl-formamide / 18 h / 90 °C / Inert atmosphere 2: hydrogenchloride / water; methanol / 3 h / 20 °C 3: N-ethyl-N,N-diisopropylamine; N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate / tetrahydrofuran / 2 h / 0 - 20 °C
Multi-step reaction with 5 steps 1: palladium diacetate; potassium acetate / N,N-dimethyl acetamide / 2 h / 120 °C / Inert atmosphere 2: hydrogenchloride / methanol / 2 h / 20 °C 3: N-ethyl-N,N-diisopropylamine; N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate / N,N-dimethyl-formamide / 12 h / 20 °C 4: hydrogenchloride / methanol / 2 h / 20 °C 5: N-ethyl-N,N-diisopropylamine; N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate / N,N-dimethyl-formamide / 12 h / 20 °C
Multi-step reaction with 5 steps 1: palladium diacetate; potassium acetate / N,N-dimethyl-formamide / 4 h / 100 °C / Inert atmosphere 2: hydrogenchloride / ethyl acetate / 12 h / 20 °C 3: N-ethyl-N,N-diisopropylamine; N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate / N,N-dimethyl-formamide / 3 h / 20 °C 4: methanol; hydrogenchloride / ethyl acetate / 20 °C 5: N-ethyl-N,N-diisopropylamine; N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate / N,N-dimethyl-formamide / 3 h / 20 °C
Multi-step reaction with 3 steps 1: palladium diacetate; potassium acetate / N,N-dimethyl acetamide / 4 h / 130 °C / Inert atmosphere 2: trifluoroacetic acid / dichloromethane / 2 h / 20 °C 3: N-ethyl-N,N-diisopropylamine; N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate / N,N-dimethyl-formamide / 18 h / 20 °C / Inert atmosphere
Multi-step reaction with 3 steps 1.1: palladium diacetate; potassium acetate / N,N-dimethyl-formamide / 2 h / 90 °C / Inert atmosphere 2.1: trifluoroacetic acid / dichloromethane / 30 min / 20 °C 2.2: 20 °C 3.1: trifluoroacetic acid / dichloromethane / 30 min / 20 °C 3.2: 20 °C
Multi-step reaction with 5 steps 1: potassium acetate; palladium diacetate / N,N-dimethyl-formamide / 120 °C / Inert atmosphere 2: trifluoroacetic acid / dichloromethane / 16 h / 20 °C 3: triethylamine; N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate / dichloromethane / 16 h / 20 °C 4: dichloromethane / 18 h / 20 °C 5: triethylamine; benzotriazol-1-ol; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride / dichloromethane / 16 h / 20 °C
Multi-step reaction with 3 steps 1: palladium diacetate; potassium acetate / N,N-dimethyl acetamide / 18 h / 90 °C / Inert atmosphere 2: hydrogenchloride / 1,4-dioxane / 3 h / 20 °C 3: N-ethyl-N,N-diisopropylamine; N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate / tetrahydrofuran / 5 h / 0 - 20 °C / Inert atmosphere
Multi-step reaction with 3 steps 1: palladium diacetate; potassium acetate / 90 °C 2: hydrogenchloride / methanol 3: N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate; N-ethyl-N,N-diisopropylamine / 12 h / 20 °C
Multi-step reaction with 5 steps 1: palladium diacetate; potassium acetate / N,N-dimethyl acetamide / 16 h / 90 °C 2: hydrogenchloride / 1,4-dioxane; dichloromethane / 1 h / 25 °C 3: N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate; N-ethyl-N,N-diisopropylamine / tetrahydrofuran / 18 h / 20 °C 4: hydrogenchloride / 1,4-dioxane; dichloromethane / 1 h / 25 °C 5: N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate; N-ethyl-N,N-diisopropylamine / tetrahydrofuran / 18 h / 20 °C
Multi-step reaction with 5 steps 1: palladium diacetate; potassium acetate / N,N-dimethyl acetamide / 12 h / 90 °C 2: trifluoroacetic acid / dichloromethane / 30 min / 20 °C 3: N-ethyl-N,N-diisopropylamine; HATU / N,N-dimethyl-formamide / 12 h / 20 °C 4: trifluoroacetic acid / dichloromethane / 30 min / 20 °C 5: N-ethyl-N,N-diisopropylamine; HATU / N,N-dimethyl-formamide / 12 h / 0 - 20 °C
Multi-step reaction with 5 steps 1.1: potassium acetate; palladium diacetate / N,N-dimethyl acetamide / 4 h / 130 °C / Inert atmosphere 2.1: hydrogenchloride / 1,4-dioxane; dichloromethane / 18 h / 0 - 20 °C 3.1: N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate; triethylamine / N,N-dimethyl-formamide; dichloromethane / 18 h / 0 - 20 °C / Inert atmosphere 4.1: hydrogenchloride / 1,4-dioxane / 18 h / 0 - 20 °C 5.1: N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate; N-ethyl-N,N-diisopropylamine / dichloromethane / 1 h / 0 °C / Inert atmosphere 5.2: 18 h / 20 °C / Inert atmosphere
Multi-step reaction with 5 steps 1: palladium diacetate; potassium acetate / N,N-dimethyl acetamide / 12 h / 90 °C 2: hydrogenchloride / ethyl acetate / 12 h / 20 °C 3: HATU; N-ethyl-N,N-diisopropylamine / N,N-dimethyl-formamide / 2 h / 0 - 20 °C / Inert atmosphere 4: hydrogenchloride / ethyl acetate / 12 h / 20 °C 5: HATU; N-ethyl-N,N-diisopropylamine / N,N-dimethyl-formamide / 12 h / 0 - 20 °C
Multi-step reaction with 5 steps 1: palladium diacetate; potassium acetate / N,N-dimethyl acetamide / 18 h / 150 °C 2: trifluoroacetic acid / dichloromethane / 30 min / 20 °C 3: N-ethyl-N,N-diisopropylamine; N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate / N,N-dimethyl-formamide / 30 min / 20 °C 4: trifluoroacetic acid / dichloromethane / 30 min / 20 °C 5: N-ethyl-N,N-diisopropylamine; N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate / N,N-dimethyl-formamide / 30 min / 20 °C
Multi-step reaction with 5 steps 1: potassium acetate; palladium diacetate / N,N-dimethyl-formamide / 3 h / 16 - 90 °C / Inert atmosphere 2: hydrogenchloride / 1,4-dioxane / 1 h / 16 °C 3: N-ethyl-N,N-diisopropylamine; N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate / N,N-dimethyl-formamide / 1 h / 16 °C 4: hydrogenchloride / 1,4-dioxane / 1 h / 16 °C 5: N-ethyl-N,N-diisopropylamine; N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate / N,N-dimethyl-formamide / 1 h / 16 - 20 °C
Multi-step reaction with 3 steps 1: potassium acetate; palladium diacetate / 12 h / 95 °C / Inert atmosphere 2: hydrogenchloride / methanol; 1,4-dioxane / 2 h / 0 - 20 °C 3: 1-methyl-1H-imidazole / acetonitrile / 3 h / 20 °C
Multi-step reaction with 3 steps 1: palladium diacetate; potassium acetate / 18 h / 90 °C 2: hydrogenchloride / methanol; water / 3 h / 25 - 30 °C 3: TFFH; N-ethyl-N,N-diisopropylamine / tetrahydrofuran / 2 h / 0 - 30 °C
Multi-step reaction with 3 steps 1.1: palladium diacetate; potassium acetate / N,N-dimethyl acetamide / 150 °C 2.1: trifluoroacetic acid / dichloromethane / 1 h / Cooling with ice 2.2: 3 h / 20 °C 3.1: trifluoroacetic acid / 1 h / Cooling with ice 3.2: 3 h / 20 °C

References: [1]Current Patent Assignee: ARVINAS OPERATIONS - US2018/72711, 2018, A1.
[2]Han, Xin; Wang, Chao; Qin, Chong; Xiang, Weiguo; Fernandez-Salas, Ester; Yang, Chao-Yie; Wang, Mi; Zhao, Lijie; Xu, Tianfeng; Chinnaswamy, Krishnapriya; Delproposto, James; Stuckey, Jeanne; Wang, Shaomeng [Journal of Medicinal Chemistry, 2019, vol. 62, # 2, p. 941 - 964].
[3]Hu, Jiantao; Hu, Biao; Wang, Mingliang; Xu, Fuming; Miao, Bukeyan; Yang, Chao-Yie; Wang, Mi; Liu, Zhaomin; Hayes, Daniel F.; Chinnaswamy, Krishnapriya; Delproposto, James; Stuckey, Jeanne; Wang, Shaomeng [Journal of Medicinal Chemistry, 2019, vol. 62, # 3, p. 1420 - 1442].
[4]Current Patent Assignee: YALE UNIVERSITY - WO2019/195609, 2019, A2.
[5]Wang, Mingliang; Lu, Jianfeng; Wang, Mi; Yang, Chao-Yie; Wang, Shaomeng [Journal of Medicinal Chemistry, 2020, vol. 63, # 14, p. 7510 - 7528].
[6]Current Patent Assignee: DBD THERAPEUTICS - US2020/239430, 2020, A1.
[7]Current Patent Assignee: ARVINAS - US2018/125821, 2018, A1.
[8]Current Patent Assignee: UNIVERSITY OF MICHIGAN - WO2020/142227, 2020, A1.
[9]Current Patent Assignee: KYMERA THERAPEUTICS - WO2020/206424, 2020, A1.
[10]Current Patent Assignee: MITSUBISHI TANABE PHARMA - WO2020/9176, 2020, A1.
[11]Current Patent Assignee: ARVINAS OPERATIONS - WO2021/11913, 2021, A1.
[12]Current Patent Assignee: YALE UNIVERSITY - WO2021/207172, 2021, A1.
[13]Current Patent Assignee: JIANGSU YAHONG MEDITECH - WO2022/161166, 2022, A1.
[14]Keuler, Tim; König, Beate; Bückreiß, Nico; Kraft, Fabian B.; König, Philipp; Schäker-Hübner, Linda; Steinebach, Christian; Bendas, Gerd; Gütschow, Michael; Hansen, Finn K. [Chemical Communications, 2022, vol. 58, # 79, p. 11087 - 11090].
[15]Wang, Chao; Zheng, Cangxin; Wang, Han; Shui, Sufang; Jin, Hongwei; Liu, Guoquan; Xu, Fengrong; Liu, Zhenming; Zhang, Liangren; Sun, Dan; Xu, Ping [European Journal of Medicinal Chemistry, 2023, vol. 247].
[16]Current Patent Assignee: HINOVA PHARMACEUTICALS - WO2023/280237, 2023, A1.
[17]Current Patent Assignee: DBD THERAPEUTICS - WO2023/39601, 2023, A1.
[18]Cai, Maohua; Ma, Furong; Hu, Can; Li, Haobin; Cao, Fei; Li, Yulong; Dong, Jinyun; Qin, Jiang-Jiang [Bioorganic and Medicinal Chemistry, 2023, vol. 90].
[19]Current Patent Assignee: SHANGHAI QILU PHARMACEUTICAL RES AND DEVELOPMENT CENTRE - WO2023/143249, 2023, A1.
[20]Wang, Xiaohua; Xin, Lilan; Deng, Xiaofei; Dong, Chune; Hu, Guoyuan; Zhou, Hai-Bing [European Journal of Medicinal Chemistry, 2024, vol. 267].
[21]Desantis, Jenny; Bazzacco, Alessandro; Eleuteri, Michela; Tuci, Sara; Bianconi, Elisa; Macchiarulo, Antonio; Mercorelli, Beatrice; Loregian, Arianna; Goracci, Laura [European Journal of Medicinal Chemistry, 2024, vol. 268].
[22]Yao, Xiaoxuan; Mao, Jianping; Zhang, Haoyu; Xiao, Yi; Wang, Yongjun; Liu, Hongzhuo [European Journal of Medicinal Chemistry, 2024, vol. 272].
[23]Xin, Lilan; Wang, Chao; Cheng, Yan; Wang, Hongli; Guo, Xinyi; Deng, Xiaofei; Deng, Xiangping; Xie, Baohua; Hu, Hankun; Min, Chang; Dong, Chune; Zhou, Hai-Bing [Journal of Medicinal Chemistry, 2024, vol. 67, # 11, p. 8913 - 8931].
[24]Current Patent Assignee: KESMALEA THERAPEUTICS LTD - WO2024/175905, 2024, A1.
[25]Current Patent Assignee: SHANGHAI HAIYAN PHARMACEUTICAL TECHNOLOGY - WO2024/179529, 2024, A1.
[26]Current Patent Assignee: INSTITUTE OF BASIC MEDICAL AND ONCOLOGY CHINESE ACADEMY OF SCIENCES - CN115894439, 2024, B.
[27]Current Patent Assignee: WUHAN UNIVERSITY - CN120247870, 2025, A.
  • 2
  • [ 630421-46-4 ]
  • [ 1948273-01-5 ]
  • [ 1997302-16-5 ]
YieldReaction ConditionsOperation in experiment
79% With N-ethyl-N,N-diisopropylamine; N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate In dichloromethane at 0℃; for 20h; 66.4 Step 4: 7er/-butyl N-GG1 S)- l -ri2S.4R)-4-hvdroxy-2-rin S)- l -r4-(4-methylthiazol-5- yl iphenyllethyllcarba oyllpyrrolidine- 1 -carbonyl] -2.2-dim ethyl -propyl] carbarn ate. To a mixture of (2S,4R)-l-[(2S)-2-(tert-butoxycarbonylamino)-3,3-dimethyl- butanoyl]-4-hydroxy-pyrrolidine-2-carboxylic acid (27.3 g, 79.2 mmol), (1 S)-l-[4-(4- methylthiazol-5-yl)phenyl]ethanamine hydrochloride (20.2 g, 79.2 mmol) and HATU (45.2 g, 119 mmol) in DCM (775 mL) at 0 °C, was slowly added DIEA (68.0 mL, 396 mmol) and the mixture was stirred for 20 h. The mixture was then diluted with 5% citric acid (500 mL) and the layers were separated. The organic layer was washed with 1M NaOH (2 x 300 mL) and brine (300 mL) then dried (Na2S04), filtered and concentrated under reduced pressure. The resulting solid was dissolved into minimal amount of MeOH and then water was added until precipitation is observed. The resulting solid were filtered, washed with ether (400 mL) and then dried in a vacuum oven at 60 °C to afford the title compound as a solid (34 g, 79%). MS (ESI) [M+H]+ 545.3.
74.2% With N-ethyl-N,N-diisopropylamine; HATU In tetrahydrofuran at 0 - 20℃; for 2h; 4 Step 4:
Preparation of (2S,4R)-1-[(2S)-2-amino-3,3-dimethylbutanoyl]-4-hydroxy-N-[(1S)-1-[4-(4-methyl-1,3-thiazol-5-yl)phenyl]ethyl]pyrrolidine-2-carboxamide hydrochloride (7) HATU (1.6 g, 4.2 mmol) was added to a stirred solution of compound 6 (1.21 g, 3.5 mmol), compound 3 (0.9 g, 3.5 mmol), and DIPEA (1.36 g, 10.5 mmol) in anhydrous THF (15 mL) at 0° C. The resulting mixture was allowed to warm up to ambient temperature and continued to stir for 2 h. TLC showed reaction complete. THF was removed by concentration. To the residue was added water (15 mL) and the resulting mixture was stirred for 4 h. The resulting mixture was filtered. The solid was collected and dried in oven at 50° C. to give a white solid. This solid was taken into methanol (10 mL) and activated carbon (150 mg) was added. The resulting mixture was heated at 80° C. and stirred for 1 h. The mixture was filtered while it was hot. Water (5 mL) was added to the filtrate at 80° C. The resulting mixture was cooled to ambient temperature and continued to stir for 18 h. The suspension was filtered. The solid was collected and dried in oven at 50° C. to afford tert-butyl-{(S)-1-[(2S,4R)-4-hydroxy]-2-[(S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethylcarbamoyl]pyrrolidin-1-yl}-3,3-dimethyl-1-oxobutan-2-yl-carbamate (1.41 g, 74.2%) as white solid. 1H NMR (400 MHz, CDCl3): δ 1.05 (s, 9H), 1.42 (s, 9H), 1.47 (d, J=7.2 Hz, 3H), 2.04-2.10 (m, 1H), 2.53 (s, 3H), 2.58-2.64 (m, 1H), 3.23 (s, 1H), 3.58 (dd, J=11.2 Hz, 3.2 Hz, 1H), 4.11 (d, J=11.6 Hz, 1H), 4.22 (d, J=9.2 Hz, 1H), 4.51 (br, 1H), 4.79 (t, J=8.0 Hz, 1H), 5.04-5.11 (m, 1H), 5.22 (d, J=8.8 Hz, 1H), 7.36-7.42 (m, 4H), 7.61 (d, J=7.6 Hz 1H), 8.68 (s, 1H). This solid (1.04 g, 1.9 mmol) was dissolved in 4N hydrogen chloride in methanol (3.0 mL) and the mixture was stirred at ambient temperature for 3 h. TLC showed reaction complete. The reaction mixture was concentrated to remove all volatiles under reduced pressure to give a light yellow solid.The solid was added to TBME (5 mL) and the resulting mixture was stirred at ambient temperature for 4 h. The reaction mixture was filtered and the solid was collected and dried in oven at 50° C. to afford compound 7 (0.92 g, 100%). 1H NMR (400 MHz, DMSO-d6): δ 1.03 (s, 9H), 1.38 (d, J=7.2 Hz, 3H), 1.72-1.79 (m, 1H), 2.09-2.14 (m, 1H), 2.49 (s, 3H), 3.48-3.52 (m, 1H), 3.75-3.79 (m, 1H), 3.88-3.90 (m, 1H), 4.31 (br, 1H), 4.56 (t, J=8.4 Hz, 1H), 4.89-4.95 (m, 1H), 7.41 (d, J=8.4 Hz, 2H), 7.47 (d, J=8.4 Hz, 2H), 8.20 (br, 3H), 8.67 (d, J=7.6 Hz, 1H), 9.22 (s, 1H); 13C NMR (400 MHz, DMSO-d6): δ 170.7, 167.1, 153.0, 146.5, 145.7, 132.5, 129.4, 129.3, 126.9, 69.4, 59.3, 58.5, 56.9, 48.3, 38.4, 34.8, 26.6, 23.0, 15.7; LC-MS [M+1]+: 445.6
74.2% With N-ethyl-N,N-diisopropylamine; N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate In tetrahydrofuran at 0 - 20℃; for 2h; 4 Step 4: Preparation of (25,4R)-l-[(25)-2-amino-3,3-dimethylbutanoyl]-4- hydroxy-N-[(15)-l-[4-(4-methyl-l,3-thiazol-5-yl)phenyl]ethyl]pyrrolidine-2-carboxamide hydrochloride (7) HATU (1.6 g, 4.2 mmol) was added to a stirred solution of intermediate compound 6 (1.21 g, 3.5 mmol), intermediate compound 3 (0.9 g, 3.5 mmol), and DIPEA (1.36 g, 10.5 mmol) in anhydrous THF (15 mL) at 0°C. The resulting mixture was allowed to warm up to ambient temperature and continued to stir for 2 hours. TLC showed reaction complete. THF was removed by concentration. To the residue was added water (15 mL) and the resulting mixture was stirred for 4 hours. The resulting mixture was filtered. The solid was collected and dried in oven at 50°C to give a white solid. This solid was taken into methanol (10 mL) and activated carbon (150 mg) was added. The resulting mixture was heated at 80°C and stirred for 1 hour. The mixture was filtered while it was hot. Water (5 mL) was added to the filtrate at 80°C. The resulting mixture was cooled to ambient temperature and continued to stir for 18 hours. The suspension was filtered. The solid was collected and dried in oven at 50°C to afford tert-butyl-{ (S)-l-[(2S,4R)-4- hydroxy] -2- [ (S)- 1 -(4-(4-methylthiazol-5-yl)phenyl)ethylcarbamoyl]pyrrolidin- 1 -yl } -3 ,3- dimethyl- l-oxobutan-2-yl-carbamate (1.41 g, 74.2%) as white solid. 1H NMR (400 MHz, CDC13): δ 1.05 (s, 9H), 1.42 (s, 9H), 1.47 (d, = 7.2 Hz, 3H), 2.04-2.10 (m, 1H), 2.53 (s, 3H), 2.58-2.64 (m, 1H), 3.23 (s, 1H), 3.58 (dd, = 11.2 Hz, 3.2 Hz, 1H), 4.11 (d, = 11.6 Hz, 1H), 4.22 (d, = 9.2 Hz, 1H), 4.51 (br, 1H), 4.79 (t, = 8.0 Hz, 1H), 5.04-5.11 (m, 1H), 5.22 (d, = 8.8 Hz, 1H), 7.36-7.42 (m, 4H), 7.61 (d, = 7.6 Hz 1H), 8.68 (s, 1H). This solid (1.04 g, 1.9 mmol) was dissolved in 4N hydrogen chloride in methanol (3.0 mL) and the mixture was stirred at ambient temperature for 3 hours. TLC showed reaction complete. The reaction mixture was concentrated to remove all volatiles under reduced pressure to give a light yellow solid. The solid was added to TBME (5 mL) and the resulting mixture was stirred at ambient temperature for 4 h. The reaction mixture was filtered and the solid was collected and dried in oven at 50°C to afford intermediate compound 7 (0.92 g, 100%). 1H NMR (400 MHz, DMSO-d6): δ 1.03 (s, 9H), 1.38 (d, = 7.2 Hz, 3H), 1.72- 1.79 (m, 1H), 2.09-2.14 (m, 1H), 2.49 (s, 3H), 3.48-3.52 (m, 1H), 3.75- 3.79 (m, 1H), 3.88-3.90 (m, 1H), 4.31 (br, 1H), 4.56 (t, = 8.4 Hz, 1H), 4.89-4.95 (m, 1H), 7.41 (d, = 8.4 Hz, 2H), 7.47 (d, = 8.4 Hz, 2H), 8.20 (br, 3H), 8.67 (d, = 7.6 Hz, 1H), 9.22 (s, 1H); 13C NMR (400 MHz, DMSO-d6): δ 170.7, 167.1 , 153.0, 146.5, 145.7, 132.5, 129.4, 129.3, 126.9, 69.4, 59.3, 58.5, 56.9, 48.3, 38.4, 34.8, 26.6, 23.0, 15.7; LC-MS [M+l]+: 445.6
74.2% With N-ethyl-N,N-diisopropylamine; N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate In tetrahydrofuran at 0 - 20℃; for 2h; 4 Step 4:
Preparation of (2S,4R)-1-[(S)-2-amino-3,3-dimethylbutanoyl]-4-hydroxy-N-[(S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl]-pyrrolidine-2-carboxamide hydrochloride (ULM-2)
HATU (1.6 g, 4.2 mmol) was added to a stirred solution containing (2S,4R)-1-{(S)-2-[(tert-butoxycarbonyl)amino]-3,3-dimethylbutanoyl}-4-hydroxypyrrolidine-2-carboxylic acid (1.21 g, 3.5 mmol), (S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethanamine hydrochloride (0.9 g, 3.5 mmol), and DIPEA (1.36 g, 10.5 mmol) in anhydrous THF (15 mL) at 0° C. The resulting mixture was allowed to warm up to ambient temperature and continued to stir for 2 hours. TLC showed reaction completed. THF was removed by concentration. To the residue was added water (15 mL) and the resulting mixture was stirred for 4 hours. The resulting mixture was filtered. The solid was collected and dried in oven at 50° C. to give a white solid. This solid was taken into methanol (10 mL) and activated carbon (150 mg) was added. The resulting mixture was heated at 80° C. and stirred for 1 h. The mixture was filtered while it was hot. Water (5 mL) was added to the filtrate at 80° C. The resulting mixture was cooled to ambient temperature and continued to stir for 18 hours. The suspension was filtered. The solid was collected and dried in oven at 50° C. to afford tert-butyl-{(S)-1-[(2S,4R)-4-hydroxy]-2-[(S)-1-(4-(4-methylthiazol-5-yl)phenyl)-ethylcarbamoyl]pyrrolidin-1-yl}-3,3-dimethyl-1-oxobutan-2-yl-carbamate (1.41 g, 74.2%) as a white solid. 1H NMR (400 MHz, CDCl3): δ 1.05 (s, 9H), 1.42 (s, 9H), 1.47 (d, J=7.2 Hz, 3H), 2.04-2.10 (m, 1H), 2.53 (s, 3H), 2.58-2.64 (m, 1H), 3.23 (s, 1H), 3.58 (dd, J=11.2 Hz, 3.2 Hz, 1H), 4.11 (d, J=11.6 Hz, 1H), 4.22 (d, J=9.2 Hz, 1H), 4.51 (br, 1H), 4.79 (t, J=8.0 Hz, 1H), 5.04-5.11 (m, 1H), 5.22 (d, J=8.8 Hz, 1H), 7.36-7.42 (m, 4H), 7.61 (d, J=7.6 Hz 1H), 8.68 (s, 1H).
74.2% With N-ethyl-N,N-diisopropylamine; N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate In tetrahydrofuran at 0 - 20℃; for 2h; 4 Step 4: Preparation of (2S,4R)- -[fV)-2-amino-3,3-dimethylbutanoyl]-4-hydroxy-N-[fV)-l - (4-(4-methylthiazol-5-yl)phenyl)ethyl]-pyrrolidine-2-carboxamide hydrochloride (ULM-2) HATU (1.6 g, 4.2 mmol) was added to a stirred solution containing (2S, 4R)- - (S)-2- [(/er/-butoxycarbonyl)amino]-3,3-dimethylbutanoyl}-4-hydroxypyrrolidine-2-carboxylic acid (1.21 g, 3.5 mmol), (A)-l-(4-(4-methylthiazol-5-yl)phenyl)ethanamine hydrochloride (0.9 g, 3.5 mmol), and DIPEA (1.36 g, 10.5 mmol) in anhydrous THF (15 mL) at 0°C. The resulting mixture was allowed to warm up to ambient temperature and continued to stir for 2 hours. TLC showed reaction completed. THF was removed by concentration. To the residue was added water (15 mL) and the resulting mixture was stirred for 4 hours. The resulting mixture was filtered. The solid was collected and dried in oven at 50°C to give a white solid. This solid was taken into methanol (10 mL) and activated carbon (150 mg) was added. The resulting mixture was heated at 80°C and stirred for lh. The mixture was filtered while it was hot. Water (5 mL) was added to the filtrate at 80°C. The resulting mixture was cooled to ambient temperature and continued to stir for 18 hours. The suspension was filtered. The solid was collected and dried in oven at 50°C to afford tert- butyl - {( S )- 1 -[(2S, -/A)-4-hydroxy]-2-[(k)- 1 -(4-(4-methylthiazol-5-yl)phenyl)-ethylcarbamoyl]pyrrolidin- l-yl}-3,3-dimethyl-l-oxobutan-2-yl-carbamate (1.41 g, 74.2%) as a white solid. NMR (400 MHz, CDCh): d 1.05 (s, 9H), 1.42 (s, 9H), 1.47 (d, J= 7.2 Hz, 3H), 2.04-2.10 (m, 1H), 2.53 (s, 3H), 2.58-2.64 (m, 1H), 3.23 (s, 1H), 3.58 (dd, 7= 1 1.2 Hz, 3.2 Hz, 1H),4.11 (d, J= 11.6 Hz, 1H), 4.22 (d, 7= 9.2 Hz, 1H), 4.51 (br, 1H), 4.79 (t, 7= 8.0 Hz, 1H), 5.04-5.11 (m, 1H), 5.22 (d, 7= 8.8 Hz, 1H), 7.36-7.42 (m, 4H), 7.61 (d, 7= 7.6 Hz 1H), 8.68 (s, 1H).
74.2% With N-ethyl-N,N-diisopropylamine; TFFH In tetrahydrofuran at 0 - 30℃; for 2h; 1 Synthesis of compound 17: Tetramethyl chlorouronium hexafluorophosphate (1.6 g, 4.2 mmol), compound 16 (1.21 g, 3.5 mmol), compound 14 (0.9 g, 3.5 mmol) and N,N-diisopropylethylamine (1.36 g, 10.5 mmol) were dissolved in anhydrous tetrahydrofuran (15 ml) at 0°C. After the addition was completed, the system was heated to room temperature and stirred for 2 hours. After the reaction was completed, the reaction solution was concentrated under reduced pressure. Water (15 ml) was added to the concentrate and stirred for 4 hours, then filtered. The solid part was collected and placed in a 50°C oven to dry to obtain compound 17 (white solid, 1.41 g, yield 74.2%).
71% With N-ethyl-N,N-diisopropylamine; N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate In tetrahydrofuran at 0 - 20℃; for 5h; Inert atmosphere; Tert-butyl ((S)-1-((2S,4R)-4-hydroxy-2-(((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)carbamate (AQ) The titled compound can be prepared according to the process described by Raina K. et al. Proc. Natl. Acad. Sci. U.S.A. 2016, 113, 7124-7129. Under nitrogen atmosphere, to a stirred solution of (2S,4R)-1-((S)-2-((tert-butoxycarbonyl)amino)-3,3-dimethylbutanoyl)-4-hydroxypyrrolidine-2-carboxylic acid (AP) (1.40 g, 4.06 mmol), (S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethan-1-amine hydrochloride (AM) (1.04 g, 4.06 mmol), and DIPEA (2.12 mL, 1.57 g, 12.19 mmol) in dry THF (20 mL) was added HATU (1.85 g, 4.88 mmol) at 0° C. The resulting mixture was allowed to warm to rt and stirred for 5 h. The organic solvent was removed under vacuo. Water (15 mL) was added to the residue, and the resulting mixture was stirred for 1 h and then was filtered. The solid was collected, dried in an oven at 50° C., and purified by flash column chromatography on SiO2 (DCM/Acetone, 75:25) to give the titled product as a white solid (1.57 g, 71% yield). 1H NMR (400 MHz, CDCl3): δ 8.70 (s, 1H), 7.62 (d, J=7.6 Hz, 1H), 7.45-7.37 (m, 4H), 5.23 (d, J=8.8 Hz, 1H), 5.14-5.02 (m, 1H), 4.82 (t, J=7.9 Hz, 1H), 4.53 (s, 1H), 4.22 (d, J=9.0 Hz, 1H), 4.17 (d, J=11.1 Hz, 1H), 3.58 (d, J=8.6 Hz, 1H), 2.83 (bs, 1H), 2.70-2.59 (m, 1H), 2.55 (s, 3H), 2.14-2.01 (m, 1H), 1.48 (d, J=7.0 Hz, 3H), 1.44 (s, 9H), 1.07 (s, 9H); 13C NMR (101 MHz, CDCl3): δ 173.04, 169.45, 156.57, 150.29, 148.52, 143.14, 131.60, 130.91, 129.60 (2C), 126.43 (2C), 80.57, 70.09, 59.01, 58.10, 56.43, 48.89, 35.07, 34.68, 28.30 (3C), 26.47 (3C), 22.30, 16.10.
33% With 2,4,6-tripropyl-1,3,5,2,4,6-trioxatriphosphinane-2,4,6-trioxide; triethylamine In dichloromethane at 20℃; for 16h;
36.9 g With N-ethyl-N,N-diisopropylamine; N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate In N,N-dimethyl-formamide at 20℃; Cooling with ice; 5.5-6 (5-6) t-Butyl {(2S) -1-[(2S, 4R) -4-hydroxy-2-({(1S) -1-[4-(4-methyl-1,3-thiazole-) 5-Il) Phenyl] Ethyl} Carbamoyl) Pyrrolidine-1-yl] -3,3-Dimethyl-1-oxobutan-2-yl} Carbamate (Reference Example Compound 5-6) Reference Example Compound 5-3 (20.5 g),Reference Example Compound 5-5 (27.8 g),N, N-dimethylformamide (350 mL)N, N-diisopropylethylamine (42.2 mL) and HATU (36.8 g) were added to the mixture under ice-cooling, and the mixture was stirred overnight at room temperature. Water was added to the reaction solution, the mixture was extracted with ethyl acetate, the organic layer was washed successively with saturated brine, dried over anhydrous sodium sulfate, and concentrated. The obtained residue was dissolved in chloroform, hexane was added, and the precipitated solid was coylected by filtration to give the title compound (36.9 g) as a colorless solid.
5.9 g With triethylamine; HATU In dichloromethane at 0℃; for 20h; Inert atmosphere;
71 % With N-ethyl-N,N-diisopropylamine; N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate In tetrahydrofuran at 0 - 20℃; Inert atmosphere; Tert-butyl ((S)-1-((2S,4R)-4-hydroxy-2-(((S)-1-(4-(4-methylthiazol-5- yl)phenyl)ethyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)carbamate (L). Under nitrogen atmosphere, to a stirred solution of (2S,4R)-1-((S)-2-((tert- butoxycarbonyl)amino)-3,3-dimethylbutanoyl)-4-hydroxypyrrolidine-2-carboxylic acid (K) (1.40 g, 4.06 mmol), (S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethan-1-amine hydrochloride (H) (1.04 g, 4.06 mmol), and DIPEA (2.12 mL, 1.57 g, 12.19 mmol) in dry THF (20 mL) is added HATU (1.85 g, 4.88 mmol) at 0 °C. The resulting mixture is allowed to warm to rt and stirred for 5 h. The organic solvent is removed under vacuo. Water (15 mL) is added to the residue, and the resulting mixture is stirred for 1 h and is then filtered. The solid is collected, dried in an oven at 50 °C, and purified by flash column chromatography on SiO2(DCM/Acetone, 75:25) to give the titled product as a white solid (1.57 g, 71% yield).1H NMR (400 MHz, CDCl3): δ 8.70 (s, 1H), 7.62 (d, J = 7.6 Hz, 1H), 7.45- 7.37 (m, 4H), 5.23 (d, J = 8.8 Hz, 1H), 5.14- 5.02 (m, 1H), 4.82 (t, J = 7.9 Hz, 1H), 4.53 (s, 1H), 4.22 (d, J = 9.0 Hz, 1H), 4.17 (d, J = 11.1 Hz, 1H), 3.58 (d, J = 8.6 Hz, 1H), 2.83 (bs, 1H), 2.70- 2.59 (m, 1H), 2.55 (s, 3H), 2.14-2.01 (m, 1H), 1.48 (d, J = 7.0 Hz, 3H), 1.44 (s, 9H), 1.07 (s, 9H);13C NMR (101 MHz, CDCl3): δ 173.04, 169.45, 156.57, 150.29, 148.52, 143.14, 131.60, 130.91, 129.60 (2C), 126.43 (2C), 80.57, 70.09, 59.01, 58.10, 56.43, 48.89, 35.07, 34.68, 28.30 (3C), 26.47 (3C), 22.30, 16.10
71 % With N-ethyl-N,N-diisopropylamine; N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate In tetrahydrofuran at 0 - 20℃; Inert atmosphere; Tert-butyl ((S)-1-((2S,4R)-4-hydroxy-2-(((S)-1-(4-(4-methylthiazol-5- yl)phenyl)ethyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)carbamate (L). Under nitrogen atmosphere, to a stirred solution of (2S,4R)-1-((S)-2-((tert- butoxycarbonyl)amino)-3,3-dimethylbutanoyl)-4-hydroxypyrrolidine-2-carboxylic acid (K) (1.40 g, 4.06 mmol), (S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethan-1-amine hydrochloride (H) (1.04 g, 4.06 mmol), and DIPEA (2.12 mL, 1.57 g, 12.19 mmol) in dry THF (20 mL) is added HATU (1.85 g, 4.88 mmol) at 0 °C. The resulting mixture is allowed to warm to rt and stirred for 5 h. The organic solvent is removed under vacuo. Water (15 mL) is added to the residue, and the resulting mixture is stirred for 1 h and is then filtered. The solid is collected, dried in an oven at 50 °C, and purified by flash column chromatography on SiO2(DCM/Acetone, 75:25) to give the titled product as a white solid (1.57 g, 71% yield).1H NMR (400 MHz, CDCl3): δ 8.70 (s, 1H), 7.62 (d, J = 7.6 Hz, 1H), 7.45- 7.37 (m, 4H), 5.23 (d, J = 8.8 Hz, 1H), 5.14- 5.02 (m, 1H), 4.82 (t, J = 7.9 Hz, 1H), 4.53 (s, 1H), 4.22 (d, J = 9.0 Hz, 1H), 4.17 (d, J = 11.1 Hz, 1H), 3.58 (d, J = 8.6 Hz, 1H), 2.83 (bs, 1H), 2.70- 2.59 (m, 1H), 2.55 (s, 3H), 2.14-2.01 (m, 1H), 1.48 (d, J = 7.0 Hz, 3H), 1.44 (s, 9H), 1.07 (s, 9H);13C NMR (101 MHz, CDCl3): δ 173.04, 169.45, 156.57, 150.29, 148.52, 143.14, 131.60, 130.91, 129.60 (2C), 126.43 (2C), 80.57, 70.09, 59.01, 58.10, 56.43, 48.89, 35.07, 34.68, 28.30 (3C), 26.47 (3C), 22.30, 16.10
With N-ethyl-N,N-diisopropylamine; N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate at 20℃; General Procedure for the amide condensation (A): General procedure: To a stirredsolution of carboxylic acid containing intermediate (1.2 eq.) in DCM wasadded HATU (1.2 eq.), DIPEA (6 eq.), and amino-containing intermediate(1.2 eq.), and the reaction mixture was stirred at room temperaturefor 12 h. The reaction solution was diluted with water, extracted with DCM three times, washed with brine, dried over Na2SO4, filtered, and concentrated. The residue obtained was purified with column chromatography.
71 % With N-ethyl-N,N-diisopropylamine; HATU In tetrahydrofuran at 0 - 20℃; Inert atmosphere; Tert-butyl ((S)-1-((2S,4R)-4-hydroxy-2-(((S)-1-(4-(4-methylthiazol-5-yl)phenyl) ethyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)carbamate (L). The titled compound can be prepared according to the process described by Raina K. et al., Proc. Natl. Acad. Sci. U.S.A. 2016, 113, 7124-7129.[00154] Under nitrogen atmosphere, to a stirred solution of (2S,4R)-1-((S)-2-((tert-butoxycarbonyl)amino)-3,3-dimethylbutanoyl)-4-hydroxypyrrolidine-2-carboxylic acid (K) (1.40 g, 4.06 mmol), (S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethan-1-amine hydrochloride (H) (1.04 g, 4.06 mmol), and DIPEA (2.12 mL, 1.57 g, 12.19 mmol) in dry THF (20 mL) is added HATU (1.85 g, 4.88 mmol) at 0 °C. The resulting mixture is allowed to warm to rt and stirred for 5 h. The organic solvent is removed under vacuo. Water (15 mL) is added to the residue, and the resulting mixture is stirred for 1 h and is then filtered. The solid is collected, dried in an oven at 50 °C, and purified by flash column chromatography on SiO2 (DCM/Acetone, 75:25) to give the titled product as a white solid (1.57 g, 71% yield).1H NMR (400 MHz, CDCl3): δ 8.70 (s, 1H), 7.62 (d, J = 7.6 Hz, 1H), 7.45- 7.37 (m, 4H), 5.23 (d, J = 8.8 Hz, 1H), 5.14- 5.02 (m, 1H), 4.82 (t, J = 7.9 Hz, 1H), 4.53 (s, 1H), 4.22 (d, J = 9.0 Hz, 1H), 4.17 (d, J = 11.1 Hz, 1H), 3.58 (d, J = 8.6 Hz, 1H), 2.83 (bs, 1H), 2.70- 2.59 (m, 1H), 2.55 (s, 3H), 2.14-2.01 (m, 1H), 1.48 (d, J = 7.0 Hz, 3H), 1.44 (s, 9H), 1.07 (s, 9H);13C NMR (101 MHz, CDCl3): δ 173.04, 169.45, 156.57, 150.29, 148.52, 143.14, 131.60, 130.91, 129.60 (2C), 126.43 (2C), 80.57, 70.09, 59.01, 58.10, 56.43, 48.89, 35.07, 34.68, 28.30 (3C), 26.47 (3C), 22.30, 16.10.
71 % With N-ethyl-N,N-diisopropylamine; HATU In tetrahydrofuran at 0 - 20℃; Inert atmosphere; Tert-butyl ((S)-1-((2S,4R)-4-hydroxy-2-(((S)-1-(4-(4-methylthiazol-5-yl)phenyl) ethyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)carbamate (L). The titled compound can be prepared according to the process described by Raina K. et al., Proc. Natl. Acad. Sci. U.S.A. 2016, 113, 7124-7129.[00154] Under nitrogen atmosphere, to a stirred solution of (2S,4R)-1-((S)-2-((tert-butoxycarbonyl)amino)-3,3-dimethylbutanoyl)-4-hydroxypyrrolidine-2-carboxylic acid (K) (1.40 g, 4.06 mmol), (S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethan-1-amine hydrochloride (H) (1.04 g, 4.06 mmol), and DIPEA (2.12 mL, 1.57 g, 12.19 mmol) in dry THF (20 mL) is added HATU (1.85 g, 4.88 mmol) at 0 °C. The resulting mixture is allowed to warm to rt and stirred for 5 h. The organic solvent is removed under vacuo. Water (15 mL) is added to the residue, and the resulting mixture is stirred for 1 h and is then filtered. The solid is collected, dried in an oven at 50 °C, and purified by flash column chromatography on SiO2 (DCM/Acetone, 75:25) to give the titled product as a white solid (1.57 g, 71% yield).1H NMR (400 MHz, CDCl3): δ 8.70 (s, 1H), 7.62 (d, J = 7.6 Hz, 1H), 7.45- 7.37 (m, 4H), 5.23 (d, J = 8.8 Hz, 1H), 5.14- 5.02 (m, 1H), 4.82 (t, J = 7.9 Hz, 1H), 4.53 (s, 1H), 4.22 (d, J = 9.0 Hz, 1H), 4.17 (d, J = 11.1 Hz, 1H), 3.58 (d, J = 8.6 Hz, 1H), 2.83 (bs, 1H), 2.70- 2.59 (m, 1H), 2.55 (s, 3H), 2.14-2.01 (m, 1H), 1.48 (d, J = 7.0 Hz, 3H), 1.44 (s, 9H), 1.07 (s, 9H);13C NMR (101 MHz, CDCl3): δ 173.04, 169.45, 156.57, 150.29, 148.52, 143.14, 131.60, 130.91, 129.60 (2C), 126.43 (2C), 80.57, 70.09, 59.01, 58.10, 56.43, 48.89, 35.07, 34.68, 28.30 (3C), 26.47 (3C), 22.30, 16.10.
79 % With N-ethyl-N,N-diisopropylamine; N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate In dichloromethane at 0℃; 7 Synthesis of tert-butyl N-[(1S)-1-[(2S,4R)-4-hydroxy-2-[[(1S)-1-[4-(4- methylthiazol-5-yl)phenyl]ethyl]carbamoyl]pyrrolidine-1-carbonyl]-2,2-dimethyl- propyl]carbamate(HB7n) methyl- butanoyl]-4-hydroxy-pyrrolidine-2-carboxylic acid (HB7m) (27.3 g, 79.2 mmol), (1S)-1-[4-(4- methylthiazol-5-yl)phenyl]ethanamine hydrochloride (HB7h) (20.2 g, 79.2 mmol), and HATU (45.2 g, 119 mmol) in DCM (775 mL) at 0 °C was slowly added DIEA (68.0 mL, 396 mmol), and the mixture was stirred for 20 h. The mixture was then diluted with 5% citric acid (500 mL) and the layers were separated. The organic layer was washed with 1 M NaOH (2 x 300 mL) and brine (300 mL) and then dried (Na2SO4), filtered, and concentrated under reduced pressure. The resulting solid was dissolved into a minimal amount of MeOH and then water was added until precipitation was observed. The resulting solids were filtered, washed with ether (400 mL), and then dried in a vacuum oven at 60 °C to afford the title compound HB7n as a solid (34 g, 79%). MS (ESI) [M+H]+ 545.3.
79 % With N-ethyl-N,N-diisopropylamine; N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate In dichloromethane at 0℃; 7 Synthesis of tert-butyl N-[(1S)-1-[(2S,4R)-4-hydroxy-2-[[(1S)-1-[4-(4- methylthiazol-5-yl)phenyl]ethyl]carbamoyl]pyrrolidine-1-carbonyl]-2,2-dimethyl- propyl]carbamate(HB7n) methyl- butanoyl]-4-hydroxy-pyrrolidine-2-carboxylic acid (HB7m) (27.3 g, 79.2 mmol), (1S)-1-[4-(4- methylthiazol-5-yl)phenyl]ethanamine hydrochloride (HB7h) (20.2 g, 79.2 mmol), and HATU (45.2 g, 119 mmol) in DCM (775 mL) at 0 °C was slowly added DIEA (68.0 mL, 396 mmol), and the mixture was stirred for 20 h. The mixture was then diluted with 5% citric acid (500 mL) and the layers were separated. The organic layer was washed with 1 M NaOH (2 x 300 mL) and brine (300 mL) and then dried (Na2SO4), filtered, and concentrated under reduced pressure. The resulting solid was dissolved into a minimal amount of MeOH and then water was added until precipitation was observed. The resulting solids were filtered, washed with ether (400 mL), and then dried in a vacuum oven at 60 °C to afford the title compound HB7n as a solid (34 g, 79%). MS (ESI) [M+H]+ 545.3.

References: [1]Current Patent Assignee: NURIX THERAPEUTICS - WO2020/81450, 2020, A1 Location in patent: Paragraph 0880; 0887; 0888.
[2]Current Patent Assignee: ARVINAS OPERATIONS - US2018/72711, 2018, A1 Location in patent: Paragraph 0333; 0335; 0340.
[3]Current Patent Assignee: ARVINAS OPERATIONS - WO2018/140809, 2018, A1 Location in patent: Paragraph 00538; 00539; 00547; 00548.
[4]Current Patent Assignee: ARVINAS - US2018/125821, 2018, A1 Location in patent: Paragraph 0613; 0622; 0623.
[5]Current Patent Assignee: ARVINAS OPERATIONS - WO2021/11913, 2021, A1 Location in patent: Paragraph 0341.
[6]Current Patent Assignee: INSTITUTE OF BASIC MEDICAL AND ONCOLOGY CHINESE ACADEMY OF SCIENCES - CN115894439, 2024, B Location in patent: Paragraph 0040; 0092; 0103-0104.
[7]Current Patent Assignee: DBD THERAPEUTICS - US2020/239430, 2020, A1 Location in patent: Paragraph 0127; 0133.
[8]Current Patent Assignee: JOHNSON JOHNSON CHINA INVESTMENT - WO2021/18118, 2021, A1 Location in patent: Page/Page column 56; 57; 58.
[9]Current Patent Assignee: MITSUBISHI TANABE PHARMA - WO2020/9176, 2020, A1 Location in patent: Paragraph 0228; 0243-0245.
[10]Current Patent Assignee: AMGEN - WO2021/142247, 2021, A1 Location in patent: Page/Page column 40-42.
[11]Current Patent Assignee: DBD THERAPEUTICS - WO2023/39601, 2023, A1 Location in patent: Paragraph 00149; 00168; 00170.
[12]Current Patent Assignee: DBD THERAPEUTICS - WO2023/39601, 2023, A1 Location in patent: Paragraph 00149; 00168; 00170.
[13]Cai, Maohua; Ma, Furong; Hu, Can; Li, Haobin; Cao, Fei; Li, Yulong; Dong, Jinyun; Qin, Jiang-Jiang [Bioorganic and Medicinal Chemistry, 2023, vol. 90].
[14]Current Patent Assignee: DBD THERAPEUTICS - WO2023/39602, 2023, A1 Location in patent: Paragraph 00133; 00152-00154.
[15]Current Patent Assignee: DBD THERAPEUTICS - WO2023/39602, 2023, A1 Location in patent: Paragraph 00133; 00152-00154.
[16]Current Patent Assignee: NURIX THERAPEUTICS - WO2023/69514, 2023, A2 Location in patent: Paragraph 000245; 000248.
[17]Current Patent Assignee: NURIX THERAPEUTICS - WO2023/69514, 2023, A2 Location in patent: Paragraph 000245; 000248.
  • 3
  • [ 62965-35-9 ]
  • [ 1997302-16-5 ]
YieldReaction ConditionsOperation in experiment
Multi-step reaction with 3 steps 1: HATU; N-ethyl-N,N-diisopropylamine / N,N-dimethyl-formamide / 18 h / 0 - 20 °C 2: lithium hydroxide monohydrate; water / tetrahydrofuran / 18 h / 20 °C 3: HATU; N-ethyl-N,N-diisopropylamine / tetrahydrofuran / 2 h / 0 - 20 °C
Multi-step reaction with 3 steps 1: N-ethyl-N,N-diisopropylamine; N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate / N,N-dimethyl-formamide / 18 h / 0 - 20 °C / Inert atmosphere 2: lithium hydroxide hydrate; water / tetrahydrofuran / 18 h / 20 °C 3: N-ethyl-N,N-diisopropylamine; N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate / tetrahydrofuran / 2 h / 0 - 20 °C
Multi-step reaction with 3 steps 1: N-ethyl-N,N-diisopropylamine; N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate / N,N-dimethyl-formamide / 20 °C 2: lithium hydroxide / water; tetrahydrofuran / 20 °C 3: N-ethyl-N,N-diisopropylamine; N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate / N,N-dimethyl-formamide / 20 °C
Multi-step reaction with 3 steps 1: N-ethyl-N,N-diisopropylamine; N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate / N,N-dimethyl-formamide / 18 h / 0 - 20 °C / Inert atmosphere 2: water; lithium hydroxide monohydrate / tetrahydrofuran / 18 h / 20 °C 3: N-ethyl-N,N-diisopropylamine; N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate / tetrahydrofuran / 2 h / 0 - 20 °C
Multi-step reaction with 3 steps 1: N-ethyl-N,N-diisopropylamine; N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate / N,N-dimethyl-formamide / 20 °C / Cooling with ice 2: lithium hydroxide; water / tetrahydrofuran / 20 °C 3: N-ethyl-N,N-diisopropylamine; N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate / N,N-dimethyl-formamide / 20 °C / Cooling with ice
Multi-step reaction with 3 steps 1.1: N-ethyl-N,N-diisopropylamine; N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate / N,N-dimethyl-formamide / 0.5 h / 20 °C 1.2: 20 °C 2.1: water; lithium hydroxide hydrate / tetrahydrofuran / 18 h / 20 °C 3.1: triethylamine; 2,4,6-tripropyl-1,3,5,2,4,6-trioxatriphosphinane-2,4,6-trioxide / dichloromethane / 16 h / 20 °C
Multi-step reaction with 3 steps 1: N-ethyl-N,N-diisopropylamine; N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate / N,N-dimethyl-formamide / 18 h / 0 - 20 °C / Inert atmosphere 2: lithium hydroxide monohydrate; water / tetrahydrofuran / 18 h / 20 °C 3: N-ethyl-N,N-diisopropylamine; N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate / tetrahydrofuran / 2 h / 0 - 20 °C
Multi-step reaction with 3 steps 1: HATU; triethylamine / dichloromethane / 18 h / 0 - 25 °C 2: water; lithium hydroxide monohydrate / tetrahydrofuran / 18 h / 25 °C / Inert atmosphere 3: HATU; triethylamine / dichloromethane / 20 h / 0 °C / Inert atmosphere
Multi-step reaction with 3 steps 1.1: N-ethyl-N,N-diisopropylamine; N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate / N,N-dimethyl-formamide / 30 min / 0 °C 1.2: 18 h / 20 °C / Inert atmosphere 2.1: 10% Pd/C; hydrogen / ethanol / 18 h / 760.05 Torr 3.1: N-ethyl-N,N-diisopropylamine; N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate / N,N-dimethyl-formamide / 18 h / 20 °C / Inert atmosphere
Multi-step reaction with 3 steps 1: N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate; N-ethyl-N,N-diisopropylamine / 12 h / 20 °C 2: lithium hydroxide; water / tetrahydrofuran 3: N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate; N-ethyl-N,N-diisopropylamine / 12 h / 20 °C
Multi-step reaction with 3 steps 1: N-ethyl-N,N-diisopropylamine; HATU / N,N-dimethyl-formamide / 16 h / 0 - 20 °C / Inert atmosphere 2: lithium hydroxide monohydrate; water / tetrahydrofuran / 18 h / 0 - 20 °C 3: N-ethyl-N,N-diisopropylamine; HATU / tetrahydrofuran / 5 h / 0 - 20 °C / Inert atmosphere
Multi-step reaction with 3 steps 1: TFFH; N-ethyl-N,N-diisopropylamine / N,N-dimethyl-formamide / 18 h / 25 - 30 °C / Inert atmosphere; Enzymatic reaction 2: lithium hydroxide monohydrate / water; tetrahydrofuran / 18 h / 25 - 30 °C 3: TFFH; N-ethyl-N,N-diisopropylamine / tetrahydrofuran / 2 h / 0 - 30 °C

  • 4
  • [ 40216-83-9 ]
  • [ 1997302-16-5 ]
YieldReaction ConditionsOperation in experiment
Multi-step reaction with 3 steps 1: HATU; N-ethyl-N,N-diisopropylamine / N,N-dimethyl-formamide / 18 h / 0 - 20 °C 2: lithium hydroxide monohydrate; water / tetrahydrofuran / 18 h / 20 °C 3: HATU; N-ethyl-N,N-diisopropylamine / tetrahydrofuran / 2 h / 0 - 20 °C
Multi-step reaction with 3 steps 1: N-ethyl-N,N-diisopropylamine; N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate / N,N-dimethyl-formamide / 20 °C 2: lithium hydroxide / water; tetrahydrofuran / 20 °C 3: N-ethyl-N,N-diisopropylamine; N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate / N,N-dimethyl-formamide / 20 °C
Multi-step reaction with 3 steps 1: N-ethyl-N,N-diisopropylamine; N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate / N,N-dimethyl-formamide / 16 h / 0 - 20 °C 2: lithium hydroxide monohydrate / tetrahydrofuran / 18 h / 0 - 20 °C 3: N-ethyl-N,N-diisopropylamine; N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate / tetrahydrofuran / 5 h / 0 - 20 °C / Inert atmosphere
Multi-step reaction with 3 steps 1: N-ethyl-N,N-diisopropylamine; N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate / N,N-dimethyl-formamide / 18 h / 0 - 20 °C / Inert atmosphere 2: water; lithium hydroxide monohydrate / tetrahydrofuran / 18 h / 20 °C 3: N-ethyl-N,N-diisopropylamine; N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate / tetrahydrofuran / 2 h / 0 - 20 °C
Multi-step reaction with 3 steps 1: N-ethyl-N,N-diisopropylamine; N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate / N,N-dimethyl-formamide / 20 °C / Cooling with ice 2: lithium hydroxide; water / tetrahydrofuran / 20 °C 3: N-ethyl-N,N-diisopropylamine; N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate / N,N-dimethyl-formamide / 20 °C / Cooling with ice
Multi-step reaction with 3 steps 1: N-ethyl-N,N-diisopropylamine; N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate / N,N-dimethyl-formamide / 16 h / 0 - 20 °C / Inert atmosphere 2: lithium hydroxide monohydrate; water / tetrahydrofuran / 18 h / 0 - 20 °C 3: N-ethyl-N,N-diisopropylamine; N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate / tetrahydrofuran / 5 h / 0 - 20 °C / Inert atmosphere

  • 5
  • [ 630421-45-3 ]
  • [ 1997302-16-5 ]
YieldReaction ConditionsOperation in experiment
Multi-step reaction with 2 steps 1: lithium hydroxide monohydrate; water / tetrahydrofuran / 18 h / 20 °C 2: HATU; N-ethyl-N,N-diisopropylamine / tetrahydrofuran / 2 h / 0 - 20 °C
Multi-step reaction with 2 steps 1: lithium hydroxide hydrate; water / tetrahydrofuran / 18 h / 20 °C 2: N-ethyl-N,N-diisopropylamine; N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate / tetrahydrofuran / 2 h / 0 - 20 °C
Multi-step reaction with 2 steps 1: lithium hydroxide / water; tetrahydrofuran / 20 °C 2: N-ethyl-N,N-diisopropylamine; N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate / N,N-dimethyl-formamide / 20 °C
Multi-step reaction with 2 steps 1: methanol; lithium hydroxide monohydrate / tetrahydrofuran; methanol / 48 h / 20 °C 2: N-ethyl-N,N-diisopropylamine; N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate / dichloromethane / 20 h / 0 °C
Multi-step reaction with 2 steps 1: lithium hydroxide monohydrate / tetrahydrofuran / 18 h / 0 - 20 °C 2: N-ethyl-N,N-diisopropylamine; N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate / tetrahydrofuran / 5 h / 0 - 20 °C / Inert atmosphere
Multi-step reaction with 2 steps 1: water; lithium hydroxide monohydrate / tetrahydrofuran / 18 h / 20 °C 2: N-ethyl-N,N-diisopropylamine; N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate / tetrahydrofuran / 2 h / 0 - 20 °C
Multi-step reaction with 2 steps 1: lithium hydroxide; water / tetrahydrofuran / 20 °C 2: N-ethyl-N,N-diisopropylamine; N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate / N,N-dimethyl-formamide / 20 °C / Cooling with ice
Multi-step reaction with 2 steps 1: lithium hydroxide monohydrate; water / tetrahydrofuran / 18 h / 20 °C 2: N-ethyl-N,N-diisopropylamine; N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate / tetrahydrofuran / 2 h / 0 - 20 °C
Multi-step reaction with 2 steps 1: water; lithium hydroxide monohydrate / tetrahydrofuran / 18 h / 25 °C / Inert atmosphere 2: HATU; triethylamine / dichloromethane / 20 h / 0 °C / Inert atmosphere
Multi-step reaction with 2 steps 1: lithium hydroxide monohydrate; water / tetrahydrofuran / 18 h / 0 - 20 °C 2: N-ethyl-N,N-diisopropylamine; N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate / tetrahydrofuran / 5 h / 0 - 20 °C / Inert atmosphere
Multi-step reaction with 2 steps 1: lithium hydroxide; water / tetrahydrofuran 2: N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate; N-ethyl-N,N-diisopropylamine / 12 h / 20 °C
Multi-step reaction with 2 steps 1: lithium hydroxide monohydrate; water / tetrahydrofuran / 18 h / 0 - 20 °C 2: N-ethyl-N,N-diisopropylamine; HATU / tetrahydrofuran / 5 h / 0 - 20 °C / Inert atmosphere
Multi-step reaction with 2 steps 1: lithium hydroxide hydrate; methanol / tetrahydrofuran / 48 h / 20 °C 2: N-ethyl-N,N-diisopropylamine; N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate / dichloromethane / 20 h / 0 °C
Multi-step reaction with 2 steps 1: lithium hydroxide monohydrate / water; tetrahydrofuran / 18 h / 25 - 30 °C 2: TFFH; N-ethyl-N,N-diisopropylamine / tetrahydrofuran / 2 h / 0 - 30 °C

  • 6
  • [ 1997302-16-5 ]
  • [ 1948273-03-7 ]
YieldReaction ConditionsOperation in experiment
100% With hydrogenchloride In methanol at 20℃; for 3h; 4 Step 4:
Preparation of (2S,4R)-1-[(2S)-2-amino-3,3-dimethylbutanoyl]-4-hydroxy-N-[(1S)-1-[4-(4-methyl-1,3-thiazol-5-yl)phenyl]ethyl]pyrrolidine-2-carboxamide hydrochloride (7) HATU (1.6 g, 4.2 mmol) was added to a stirred solution of compound 6 (1.21 g, 3.5 mmol), compound 3 (0.9 g, 3.5 mmol), and DIPEA (1.36 g, 10.5 mmol) in anhydrous THF (15 mL) at 0° C. The resulting mixture was allowed to warm up to ambient temperature and continued to stir for 2 h. TLC showed reaction complete. THF was removed by concentration. To the residue was added water (15 mL) and the resulting mixture was stirred for 4 h. The resulting mixture was filtered. The solid was collected and dried in oven at 50° C. to give a white solid. This solid was taken into methanol (10 mL) and activated carbon (150 mg) was added. The resulting mixture was heated at 80° C. and stirred for 1 h. The mixture was filtered while it was hot. Water (5 mL) was added to the filtrate at 80° C. The resulting mixture was cooled to ambient temperature and continued to stir for 18 h. The suspension was filtered. The solid was collected and dried in oven at 50° C. to afford tert-butyl-{(S)-1-[(2S,4R)-4-hydroxy]-2-[(S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethylcarbamoyl]pyrrolidin-1-yl}-3,3-dimethyl-1-oxobutan-2-yl-carbamate (1.41 g, 74.2%) as white solid. 1H NMR (400 MHz, CDCl3): δ 1.05 (s, 9H), 1.42 (s, 9H), 1.47 (d, J=7.2 Hz, 3H), 2.04-2.10 (m, 1H), 2.53 (s, 3H), 2.58-2.64 (m, 1H), 3.23 (s, 1H), 3.58 (dd, J=11.2 Hz, 3.2 Hz, 1H), 4.11 (d, J=11.6 Hz, 1H), 4.22 (d, J=9.2 Hz, 1H), 4.51 (br, 1H), 4.79 (t, J=8.0 Hz, 1H), 5.04-5.11 (m, 1H), 5.22 (d, J=8.8 Hz, 1H), 7.36-7.42 (m, 4H), 7.61 (d, J=7.6 Hz 1H), 8.68 (s, 1H). This solid (1.04 g, 1.9 mmol) was dissolved in 4N hydrogen chloride in methanol (3.0 mL) and the mixture was stirred at ambient temperature for 3 h. TLC showed reaction complete. The reaction mixture was concentrated to remove all volatiles under reduced pressure to give a light yellow solid.The solid was added to TBME (5 mL) and the resulting mixture was stirred at ambient temperature for 4 h. The reaction mixture was filtered and the solid was collected and dried in oven at 50° C. to afford compound 7 (0.92 g, 100%). 1H NMR (400 MHz, DMSO-d6): δ 1.03 (s, 9H), 1.38 (d, J=7.2 Hz, 3H), 1.72-1.79 (m, 1H), 2.09-2.14 (m, 1H), 2.49 (s, 3H), 3.48-3.52 (m, 1H), 3.75-3.79 (m, 1H), 3.88-3.90 (m, 1H), 4.31 (br, 1H), 4.56 (t, J=8.4 Hz, 1H), 4.89-4.95 (m, 1H), 7.41 (d, J=8.4 Hz, 2H), 7.47 (d, J=8.4 Hz, 2H), 8.20 (br, 3H), 8.67 (d, J=7.6 Hz, 1H), 9.22 (s, 1H); 13C NMR (400 MHz, DMSO-d6): δ 170.7, 167.1, 153.0, 146.5, 145.7, 132.5, 129.4, 129.3, 126.9, 69.4, 59.3, 58.5, 56.9, 48.3, 38.4, 34.8, 26.6, 23.0, 15.7; LC-MS [M+1]+: 445.6
100% With hydrogenchloride In methanol at 20℃; for 3h; 4 Step 4: Preparation of (25,4R)-l-[(25)-2-amino-3,3-dimethylbutanoyl]-4- hydroxy-N-[(15)-l-[4-(4-methyl-l,3-thiazol-5-yl)phenyl]ethyl]pyrrolidine-2-carboxamide hydrochloride (7) HATU (1.6 g, 4.2 mmol) was added to a stirred solution of intermediate compound 6 (1.21 g, 3.5 mmol), intermediate compound 3 (0.9 g, 3.5 mmol), and DIPEA (1.36 g, 10.5 mmol) in anhydrous THF (15 mL) at 0°C. The resulting mixture was allowed to warm up to ambient temperature and continued to stir for 2 hours. TLC showed reaction complete. THF was removed by concentration. To the residue was added water (15 mL) and the resulting mixture was stirred for 4 hours. The resulting mixture was filtered. The solid was collected and dried in oven at 50°C to give a white solid. This solid was taken into methanol (10 mL) and activated carbon (150 mg) was added. The resulting mixture was heated at 80°C and stirred for 1 hour. The mixture was filtered while it was hot. Water (5 mL) was added to the filtrate at 80°C. The resulting mixture was cooled to ambient temperature and continued to stir for 18 hours. The suspension was filtered. The solid was collected and dried in oven at 50°C to afford tert-butyl-{ (S)-l-[(2S,4R)-4- hydroxy] -2- [ (S)- 1 -(4-(4-methylthiazol-5-yl)phenyl)ethylcarbamoyl]pyrrolidin- 1 -yl } -3 ,3- dimethyl- l-oxobutan-2-yl-carbamate (1.41 g, 74.2%) as white solid. 1H NMR (400 MHz, CDC13): δ 1.05 (s, 9H), 1.42 (s, 9H), 1.47 (d, = 7.2 Hz, 3H), 2.04-2.10 (m, 1H), 2.53 (s, 3H), 2.58-2.64 (m, 1H), 3.23 (s, 1H), 3.58 (dd, = 11.2 Hz, 3.2 Hz, 1H), 4.11 (d, = 11.6 Hz, 1H), 4.22 (d, = 9.2 Hz, 1H), 4.51 (br, 1H), 4.79 (t, = 8.0 Hz, 1H), 5.04-5.11 (m, 1H), 5.22 (d, = 8.8 Hz, 1H), 7.36-7.42 (m, 4H), 7.61 (d, = 7.6 Hz 1H), 8.68 (s, 1H). This solid (1.04 g, 1.9 mmol) was dissolved in 4N hydrogen chloride in methanol (3.0 mL) and the mixture was stirred at ambient temperature for 3 hours. TLC showed reaction complete. The reaction mixture was concentrated to remove all volatiles under reduced pressure to give a light yellow solid. The solid was added to TBME (5 mL) and the resulting mixture was stirred at ambient temperature for 4 h. The reaction mixture was filtered and the solid was collected and dried in oven at 50°C to afford intermediate compound 7 (0.92 g, 100%). 1H NMR (400 MHz, DMSO-d6): δ 1.03 (s, 9H), 1.38 (d, = 7.2 Hz, 3H), 1.72- 1.79 (m, 1H), 2.09-2.14 (m, 1H), 2.49 (s, 3H), 3.48-3.52 (m, 1H), 3.75- 3.79 (m, 1H), 3.88-3.90 (m, 1H), 4.31 (br, 1H), 4.56 (t, = 8.4 Hz, 1H), 4.89-4.95 (m, 1H), 7.41 (d, = 8.4 Hz, 2H), 7.47 (d, = 8.4 Hz, 2H), 8.20 (br, 3H), 8.67 (d, = 7.6 Hz, 1H), 9.22 (s, 1H); 13C NMR (400 MHz, DMSO-d6): δ 170.7, 167.1 , 153.0, 146.5, 145.7, 132.5, 129.4, 129.3, 126.9, 69.4, 59.3, 58.5, 56.9, 48.3, 38.4, 34.8, 26.6, 23.0, 15.7; LC-MS [M+l]+: 445.6
100% With hydrogenchloride In methanol; water at 20℃; for 3h; 4 Step 4: Preparation of (2S,4R)-1-[(S)-2-amino-3,3-dimethylbutanoyl]-4-hydroxy-N-[(S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl]-pyrrolidine-2-carboxamide hydrochloride (ULM-2) HATU (1.6 g, 4.2 mmol) was added to a stirred solution containing (2S,4R)-1-{(S)-2-[(tert-butoxycarbonyl)amino]-3,3-dimethylbutanoyl}-4-hydroxypyrrolidine-2-carboxylic acid (1.21 g, 3.5 mmol), (S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethanamine hydrochloride (0.9 g, 3.5 mmol), and DIPEA (1.36 g, 10.5 mmol) in anhydrous THF (15 mL) at 0° C. The resulting mixture was allowed to warm up to ambient temperature and continued to stir for 2 hours. TLC showed reaction completed. THF was removed by concentration. To the residue was added water (15 mL) and the resulting mixture was stirred for 4 hours. The resulting mixture was filtered. The solid was collected and dried in oven at 50° C. to give a white solid. This solid was taken into methanol (10 mL) and activated carbon (150 mg) was added. The resulting mixture was heated at 80° C. and stirred for 1 h. The mixture was filtered while it was hot. Water (5 mL) was added to the filtrate at 80° C. The resulting mixture was cooled to ambient temperature and continued to stir for 18 hours. The suspension was filtered. The solid was collected and dried in oven at 50° C. to afford tert-butyl-{(S)-1-[(2S,4R)-4-hydroxy]-2-[(S)-1-(4-(4-methylthiazol-5-yl)phenyl)-ethylcarbamoyl]pyrrolidin-1-yl}-3,3-dimethyl-1-oxobutan-2-yl-carbamate (1.41 g, 74.2%) as a white solid.1H NMR (400 MHz, CDCl3): δ 1.05 (s, 9H), 1.42 (s, 9H), 1.47 (d, J=7.2 Hz, 3H), 2.04-2.10 (m, 1H), 2.53 (s, 3H), 2.58-2.64 (m, 1H), 3.23 (s, 1H), 3.58 (dd, J=11.2 Hz, 3.2 Hz, 1H), 4.11 (d, J=11.6 Hz, 1H), 4.22 (d, J=9.2 Hz, 1H), 4.51 (br, 1H), 4.79 (t, J=8.0 Hz, 1H), 5.04-5.11 (m, 1H), 5.22 (d, J=8.8 Hz, 1H), 7.36-7.42 (m, 4H), 7.61 (d, J=7.6 Hz 1H), 8.68 (s, 1H). This solid (1.04 g, 1.9 mmol) was dissolved in 4N hydrogen chloride in methanol (3.0 mL) and the mixture was stirred at ambient temperature for 3 hours. TLC showed reaction complete. The reaction mixture was concentrated to remove all volatiles under reduced pressure to give a light yellow solid. The solid was added to TBME (5 mL) and the resulting mixture was stirred at ambient temperature for 4 hours. The reaction mixture was filtered and the solid was collected and dried in oven at 50° C. to afford the title compound (0.92 g, 100%). 1H NMR (400 MHz, DMSO-d6): δ 1.03 (s, 9H), 1.38 (d, J=7.2 Hz, 3H), 1.72-1.79 (m, 1H), 2.09-2.14 (m, 1H), 2.49 (s, 3H), 3.48-3.52 (m, 1H), 3.75-3.79 (m, 1H), 3.88-3.90 (m, 1H), 4.31 (br, 1H), 4.56 (t, J=8.4 Hz, 1H), 4.89-4.95 (m, 1H), 7.41 (d, J=8.4 Hz, 2H), 7.47 (d, J=8.4 Hz, 2H), 8.20 (br, 3H), 8.67 (d, J=7.6 Hz, 1H), 9.22 (s, 1H); 13C NMR (400 MHz, DMSO-d6): δ 170.7, 167.1, 153.0, 146.5, 145.7, 132.5, 129.4, 129.3, 126.9, 69.4, 59.3, 58.5, 56.9, 48.3, 38.4, 34.8, 26.6, 23.0, 15.7; LC-MS [M+1]+: 445.6.
100% With hydrogenchloride In methanol; water at 20℃; for 3h; 4 This solid (1.04 g, 1.9 mmol) was dissolved in 4N hydrogen chloride in methanol (3.0 mL) and the mixture was stirred at ambient temperature for 3 hours. TLC showed reaction complete. The reaction mixture was concentrated to remove all volatiles under reduced pressure to give a light yellow solid. The solid was added to TBME (5 mL) and the resulting mixture was stirred at ambient temperature for 4 hours. The reaction mixture was filtered and the solid was collected and dried in oven at 50°C to afford the title compound (0.92 g, 100%). NMR (400 MHz, DMSO-d6): d 1.03 (s, 9H), 1.38 (d, J= 7.2 Hz, 3H), 1.72-1.79 (m,1H), 2.09-2.14 (m, 1H), 2.49 (s, 3H), 3.48-3.52 (m, 1H), 3.75-3.79 (m, 1H), 3.88-3.90 (m, 1H), 4.31 (br, 1H), 4.56 (t, J= 8.4 Hz, 1H), 4.89-4.95 (m, 1H), 7.41 (d, J= 8.4 Hz, 2H), 7.47 (d, J= 8.4 Hz, 2H), 8.20 (br, 3H), 8.67 (d, J= 7.6 Hz, 1H), 9.22 (s, 1H);13C NMR (400 MHz, DMSO-d6): d170.7, 167.1, 153.0, 146.5, 145.7, 132.5, 129.4, 129.3, 126.9, 69.4, 59.3, 58.5, 56.9, 48.3, 38.4, 34.8, 26.6, 23.0, 15.7; LC-MS [M+l]+: 445.6
99% With hydrogenchloride In 1,4-dioxane; water at 20℃; for 3h; (2S,4R)-1-((S)-2-Amino-3,3-dimethylbutanoyl)-4-hydroxy-N-((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)pyrrolidine-2-carboxamide Hydrochloride (E3LB-3) The titled compound can be prepared according to the process described by Raina K. et al. Proc. Natl. Acad. Sci. U.S.A. 2016, 113, 7124-7129. A solution of 4N HCl in dioxane (6.0 mL) was added to tert-butyl ((S)-1-((2S,4R)-4-hydroxy-2-(((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)carbamate (AQ) (1.55 g, 2.85 mmol) and the mixture was stirred at rt for 3 h. The solvent was evaporated to dryness and the crude residue was triturated with DEE, filtered off, and dried in an oven at 50° C. to give the titled compound as a white solid (1.36 g, 99% yield). 1H NMR (400 MHz, DMSO-d6): δ 9.11 (s, 1H), 8.62 (d, J=7.8 Hz, 1H), 8.16 (s, 3H), 7.50-7.34 (m, 4H), 6.83 (s, 1H), 4.91 (q, J=7.2 Hz, 1H), 4.55 (t, J=8.4 Hz, 1H), 4.31 (s, 1H), 3.89 (d, J=5.3 Hz, 1H), 3.75 (d, J=10.8 Hz, 1H), 3.50 (dd, J=3.7, 10.9 Hz, 1H), 2.47 (s, 3H), 2.21-1.65 (m, 2H), 1.38 (d, J=7.0 Hz, 3H), 1.03 (s, 9H); 13C NMR (101 MHz, DMSO-d6): δ 170.68, 167.08, 151.52, 147.47, 145.31, 131.96, 129.84, 129.32 (2C), 126.85 (2C), 69.35, 59.30, 58.51, 56.94, 48.24, 38.39, 34.85, 26.53 (3C), 22.97, 16.14.
99.98% With hydrogenchloride; methanol In ethyl acetate 1.1.3 The ((S)-1-((2S,4R)-4-hydroxy-2-((S)-1-(4-methylthiazole-5-yl)phenyl)carbamoyl)pyrrolidine-1-yl)-3,3-dimethyl-1-oxobutane-2-yl) carbamic acid tert-butyl ester (compound C-11) (17.94g, 33mmol) in methanol (36mL) solution was slowly added to the solution of hydrogen chloride in ethyl acetate (2M, 66mL, 132mmol) and the reaction was stirred overnight. Concentrated reaction solution, methyl tert-butyl ether (180mL), beat overnight, filtered, dried filter cake, to give a bright yellow solid product ((S)-1-((2S,4R)-4-hydroxy-2-((S)-1-(4-(4-methylthiazole-5-yl)phenyl)ethyl)carbamoyl)pyrrolidine-1-yl)-3,3-dimethyl-1-oxobutane-2-yl) amine hydrochloride (Compound C) (15.84g, yield 99.98%).
98% With hydrogenchloride In 1,4-dioxane at 25℃; for 16h; Inert atmosphere; 6 Step 6: (2S, 4R)-1-[(2S)-2-amino-3,3-dimethylbutanoyl]-4-hydroxy-N-[(1S)-1-[4-(4- methyl-1,3-thiazol-5-yl)phenyl]ethyl]pyrrolidine-2-carboxamide hydrochloride (Intermediate N). To a stirred mixture of tert-butyl N-[(2S)-1-[(2S,4R)-4-hydroxy-2-[[(1S)-1-[4-(4-methyl-1,3- thiazol-5-yl)phenyl]ethyl]carbamoyl]pyrrolidin-1-yl]-3,3-dimethyl-1-oxobutan-2-yl]carbamate (49.0 g, 90.0 mmol) in MeOH (100 mL) and dioxane (400 mL) was added a solution of HCl (gas) in 1,4-dioxane (4 M, 200 mL) dropwise at 25 °C under nitrogen atmosphere. The resulting mixture was stirred for 16 h at 25 °C under nitrogen atmosphere. The resulting mixture was concentrated under reduced pressure. This resulted in the title compound as a light yellow solid (50.0 g, 98%): 1H NMR (400 MHz, CD3OD) d 10.10 (s, 1H), 7.66-7.57 (d, J = 8.4 Hz, 2H), 7.55 (d, J = 8.4 Hz, 2H), 5.03 (q, J = 7.0 Hz, 1H), 4.73 (dd, J = 9.5, 7.7 Hz, 1H), 4.53-4.46 (m, 1H), 4.11 (s, 1H), 3.90 (dt, J = 11.3, 1.6 Hz, 1H), 3.7-3.64 (m, 1H), 3.71-3.60 (m, 1H), 2.65 (s, 3H), 2.35 (ddt, J = 13.3, 7.7, 1.8 Hz, 1H), 1.94 (ddd, J = 13.5, 9.5, 4.2 Hz, 1H), 1.54 (d, J = 7.0 Hz, 3H), 1.16 (s, 9H); LC/MS (ESI, m/z): [(M + H)]+ = 445.20.
97% With hydrogenchloride In 1,4-dioxane at 0 - 20℃; for 16h; Step-g: Synthesis of (2S,4R)-1-((S)-2-amino-3,3-dimethylbutanoyl)-4-hydroxy-N-((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)pyrrolidine-2-carboxamide hydrochloride (17g) To a stirred solution of tert-butyl ((S)-1-((2S,4R)-4-hydroxy-2-(((S)-1-(4-(4-ethylthiazol-5-yl)phenyl)ethyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)carbamate (5.0 g, 9.19 mmol) in l,4-dioxane (25 mL) at 0 °C was added 4M HCl in l,4-dioxane (25 mL). The reaction mixture was stirred at RT for 16 h. Solvents from the reaction mixture was evaporated under reduced pressure and the residue was washed with diethyl ether to afford the title compound (4.5 g, 97 %). 1H NMR (400 MHz, DMSO-d6) d 9.60 (s, 1H), 8.58 (d, / = 7.2 Hz, 1H), 8.12 (s, 3H), 7.44 (d, / = 8.4 Hz, 2H), 7.38 (d, / = 8.4 Hz, 2H), 4.92 (d, / = 7.0 Hz, 1H), 4.54 (t, / = 8.4 Hz, 1H), 4.30 (s, 1H), 3.89-3.88 (m, 1H), 3.75-3.72 (m, 1H), 3.51-3.48 (m, 2H), 2.46 (s, 3H), 2.12-2.08 (m, 1H), 1.80-1.75 (m, 1H), l.38(d, / = 6.8 Hz, 3H), 1.05 (s, 9H); LC-MS: m/z 445.3 (M+l)+.
92% With hydrogenchloride In 1,4-dioxane; dichloromethane at 0 - 20℃; for 0.25h; 66.5 Step 5: (2S.4R)- 1 -r(2S)-2-amino-3.3-dimethyl-butanoyl1-4-hvdroxy-N-r( l S)- l -G4- (4-methylthiazol-5-vnphenyl1ethyl1pyrrolidine-2-carboxamide hydrochloride. To a solution of /er/-butyl N-[(l S)-l-[(2S,4R)-4-hydroxy-2-[[(l S)-l-[4-(4- methylthiazol-5-yl)phenyl]ethyl]carbamoyl]pyrrolidine-l-carbonyl]-2,2-dimethyl- propyl]carbamate (34.0 g, 62.0 mmol) in DCM (200 mL) at 0 °C, was added an HC1 solution (4M in dioxane, 200 mL, 800 mmol) and the mixture was warmed to rt and stirred for 15 min. The mixture was diluted with MeOH (150 mL) and the mixture was stirred for 30 min. The volatiles were evaporated under reduced pressure and coevaporated with PhMe (2 x 100 mL) to afford the title compound as a solid (30.6 g, 92%, contains 9% PhMe by weight). 'H NMR (500 MHz, DMSO) d 9.04 (s, 1H), 8.59 (d, J = 7.8 Hz, 1H), 8.09 (d, J = 4.3 Hz, 3H), 7.47 - 7.43 (m, 2H), 7.42 - 7.37 (m, 2H), 4.93 (p, J = 7.0 Hz, 1H), 4.55 (t, J = 8.4 Hz, 1H), 4.33 (br s, 1H), 3.91 (q, J = 5.7 Hz, 1H), 3.73 (d, J = 10.6 Hz, 1H), 3.50 (dd, J = 10.9, 3.9 Hz, 1H), 2.70 (s, 1H), 2.47 (s, 3H), 2.12 (dd, J = 12.9, 7.7 Hz, 1H), 1.81 - 1.72 (m, 1H), 1.39 (d, J = 7.0 Hz, 3H), 1.03 (s, 9H). MS (ESI) [M+H]+ 445.2.
3.5 g With hydrogenchloride In methanol at 20℃; for 2h; 7 Step 7: Preparation of (2S,4R)-l-((S)-2-amino-3,3-dimethylbutanoyl)-4-hydroxy-N- ((S)-l-(4-(4-methylthiazol-5-yl)phenyl)ethyl)pyrrolidine-2-carboxamide hydrochloride Into a lOO-mL round-bottom flask, was placed a solution of tert-butyl N-[(2S)-l- [(2S,4R)-4-hydroxy-2-[[(lS)-l-[4-(4-methyl-l,3-thiazol-5-yl)phenyl]ethyl]carbamoyl]pyrrolidin- l-yl]-3, 3-dimethyl- l-oxobutan-2-yl]carbamate (4.0 g, 7.34 mmol, 1.00 equiv) in methanol (30 mL), then hydrogen chloride (gas) was bubbled into the reaction mixture for 2 hours at room temperature. The resulting mixture was concentrated under vacuum. This resulted in 3.5 g of (2S ,4R)- 1 - [(2S )-2-amino-3 ,3 -dimethylbutanoyl] -4-hydroxy-N- [( 1 S )- 1 - [4-(4-methyl- 1 ,3 -thiazol- 5-yl)phenyl]ethyl]pyrrolidine-2-carboxamide hydrochloride as a yellow solid. LC/MS (ESI) m/z : 445.05 [M+l] +; 1H-NMR (400MHz, DMSO-ifc) d 8.99 (s, 1 H), 8.57-8.55 (d, J = 7.8 Hz, 1 H), 8.01 (b, 3 H), 7.46-7.43 (d, J = 8.4 Hz, 2 H), 7.39-7.37 (d, J = 8.4 Hz, 2 H), 4.98-4.90 (m, 1 H), 4.57-4.51 (m, 1 H), 4.34 (b, 1 H), 3.94-3.92 (m, 1 H), 3.69-3.66 (m, 1 H), 3.53-3.49 (m, 1 H), 2.52 (s, 3 H), 2.10-2.07 (m, 1 H), 1.83-1.81 (m, 1 H), 1.40-1.30 (m, 3 H), 1.03 (s, 9 H).
3.5 g With hydrogenchloride In methanol at 20℃; for 2h; 7 Step 7: Preparation of (2S,4R)-1-((S)-2-amino-3,3-dimethylbutanoyl)-4-hydroxy-N- ((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)pyrrolidine-2-carboxamide hydrochloride Into a 100-mL round-bottom flask, was placed a solution of tert-butyl N-[(2S)-1- [(2S,4R)-4-hydroxy-2-[[(1S)-1-[4-(4-methyl-1,3-thiazol-5-yl)phenyl]ethyl]carbamoyl]pyrrolidin- 1-yl]-3,3-dimethyl-1-oxobutan-2-yl]carbamate (4.0 g, 7.34 mmol, 1.00 equiv) in methanol (30 mL), then hydrogen chloride (gas) was bubbled into the reaction mixture for 2 h at room temperature. The resulting mixture was concentrated under vacuum. This resulted in 3.5 g of (2S,4R)-1-[(2S)-2-amino-3,3-dimethylbutanoyl]-4-hydroxy-N-[(1S)-1-[4-(4-methyl-1,3-thiazol- 5-yl)phenyl]ethyl]pyrrolidine-2-carboxamide hydrochloride as a yellow solid. LC/MS (ESI) m/z: 445.05 [M+1] +; 1H-NMR (400MHz, DMSO-d6) d 8.99 (s, 1 H), 8.57-8.55 (d, J = 7.8 Hz, 1 H), 8.01 (b, 3 H), 7.46-7.43 (d, J = 8.4 Hz, 2 H), 7.39-7.37 (d, J = 8.4 Hz, 2 H), 4.98-4.90 (m, 1 H), 4.57-4.51 (m, 1 H), 4.34 (b, 1 H), 3.94-3.92 (m, 1 H), 3.69-3.66 (m, 1 H), 3.53-3.49 (m, 1 H), 2.52 (s, 3 H), 2.10-2.07 (m, 1 H), 1.83-1.81 (m, 1 H), 1.40-1.30 (m, 3 H), 1.03 (s, 9 H).
30 g With hydrogenchloride In 1,4-dioxane; chloroform; water at 20℃; Cooling with ice; 5.5-7 (5-7) (2S, 4R) -1-[(2S) -2-amino-3,3-dimethylbutanoyl] -4-hydroxy-N-{(1S) -1-[4-(4-(4-(4-(4-) Methyl-1,3-thiazole-5-yl) phenyl] ethyl} pyrrolidine-2-carboxamide hydrochloride (Reference Example Compound 5) In a mixture of Reference Example Compound 5-6 (34.8 g), chloroform (160 mL), 1,4-dioxane (500 mL), a 4M hydrogen chloride / dioxane solution was added dropwise under ice-cooling, and the mixture was stirred overnight at room temperature.After concentrating the reaction solution, acetonitrile was added and concentrated to give the title compound (30.0 g) as a pale yellow solid.
With hydrogenchloride In 1,4-dioxane; dichloromethane at 20℃; for 2h;
3.5 g With hydrogenchloride In methanol at 20℃; for 2h; 7 Step 7: Preparation of (2S,4R)-1-((S)-2-amino-3,3-dimethylbutanoyl)-4-hydroxy-N-((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)pyrrolidine-2-carboxamide hydrochloride Into a 100-mL round-bottom flask, was placed a solution of tert-butyl N-[(2S)-1-[(2S,4R)-4-hydroxy-2-[[(1S)-1-[4-(4-methyl-1,3-thiazol-5-yl)phenyl]ethyl]carbamoyl]pyrrolidin-1-yl]-3,3-dimethyl-1-oxobutan-2-yl]carbamate (4.0 g, 7.34 mmol, 1.00 equiv) in methanol (30 mL), then hydrogen chloride (gas) was bubbled into the reaction mixture for 2 hours at room temperature. The resulting mixture was concentrated under vacuum. This resulted in 3.5 g of (2S,4R)-1-[(2S)-2-amino-3,3-dimethylbutanoyl]-4-hydroxy-N-[(1S)-1-[4-(4-methyl-1,3-thiazol-5-yl)phenyl]ethyl]pyrrolidine-2-carboxamide hydrochloride as a yellow solid. LC/MS (ESI) m/z: 445.05 [M+1] +; 1H-NMR (400MHz, DMSO-d6) δ 8.99 (s, 1H), 8.57-8.55 (d, J = 7.8 Hz, 1H), 8.01 (b, 3 H), 7.46-7.43 (d, J = 8.4 Hz, 2 H), 7.39-7.37 (d, J = 8.4 Hz, 2 H), 4.98-4.90 (m, 1H), 4.57-4.51 (m, 1H), 4.34 (b, 1H), 3.94-3.92 (m, 1H), 3.69-3.66 (m, 1H), 3.53-3.49 (m, 1H), 2.52 (s, 3 H), 2.10-2.07 (m, 1H), 1.83-1.81 (m, 1H), 1.40-1.30 (m, 3 H), 1.03 (s, 9 H).
99 % With hydrogenchloride In 1,4-dioxane at 20℃; (2S,4R)-1-((S)-2-Amino-3,3-dimethylbutanoyl)-4-hydroxy-N-((S)-1-(4-(4- methylthiazol-5-yl)phenyl)ethyl)pyrrolidine-2-carboxamide hydrochloride (E3LB-1) A solution of 4N HCl in dioxane (6.0 mL) is added to tert-butyl ((S)-1-((2S,4R)-4- hydroxy-2-(((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)carbamoyl)pyrrolidin-1-yl)-3,3- dimethyl-1-oxobutan-2-yl)carbamate (L) (1.55 g, 2.85 mmol) and the mixture is stirred at rt for 3 h. The solvent is evaporated to dryness and the crude residue is triturated with DEE, filtered off, and dried in an oven at 50 °C to give the titled compound as a white solid (1.36 g, 99% yield).1H NMR (400 MHz, DMSO-d6): δ 9.11 (s, 1H), 8.62 (d, J = 7.8 Hz, 1H), 8.16 (s, 3H), 7.50-7.34 (m, 4H), 6.83 (s, 1H), 4.91 (q, J = 7.2 Hz, 1H), 4.55 (t, J = 8.4 Hz, 1H), 4.31 (s, 1H), 3.89 (d, J = 5.3 Hz, 1H), 3.75 (d, J = 10.8 Hz, 1H), 3.50 (dd, J = 3.7, 10.9 Hz, 1H), 2.47 (s, 3H), 2.21-1.65 (m, 2H), 1.38 (d, J = 7.0 Hz, 3H), 1.03 (s, 9H);13C NMR (101 MHz, DMSO-d6): δ 170.68, 167.08, 151.52, 147.47, 145.31, 131.96, 129.84, 129.32 (2C), 126.85 (2C), 69.35, 59.30, 58.51, 56.94, 48.24, 38.39, 34.85, 26.53 (3C), 22.97, 16.14
99 % With hydrogenchloride In 1,4-dioxane at 20℃; (2S,4R)-1-((S)-2-Amino-3,3-dimethylbutanoyl)-4-hydroxy-N-((S)-1-(4-(4- methylthiazol-5-yl)phenyl)ethyl)pyrrolidine-2-carboxamide hydrochloride (E3LB-1) A solution of 4N HCl in dioxane (6.0 mL) is added to tert-butyl ((S)-1-((2S,4R)-4- hydroxy-2-(((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)carbamoyl)pyrrolidin-1-yl)-3,3- dimethyl-1-oxobutan-2-yl)carbamate (L) (1.55 g, 2.85 mmol) and the mixture is stirred at rt for 3 h. The solvent is evaporated to dryness and the crude residue is triturated with DEE, filtered off, and dried in an oven at 50 °C to give the titled compound as a white solid (1.36 g, 99% yield).1H NMR (400 MHz, DMSO-d6): δ 9.11 (s, 1H), 8.62 (d, J = 7.8 Hz, 1H), 8.16 (s, 3H), 7.50-7.34 (m, 4H), 6.83 (s, 1H), 4.91 (q, J = 7.2 Hz, 1H), 4.55 (t, J = 8.4 Hz, 1H), 4.31 (s, 1H), 3.89 (d, J = 5.3 Hz, 1H), 3.75 (d, J = 10.8 Hz, 1H), 3.50 (dd, J = 3.7, 10.9 Hz, 1H), 2.47 (s, 3H), 2.21-1.65 (m, 2H), 1.38 (d, J = 7.0 Hz, 3H), 1.03 (s, 9H);13C NMR (101 MHz, DMSO-d6): δ 170.68, 167.08, 151.52, 147.47, 145.31, 131.96, 129.84, 129.32 (2C), 126.85 (2C), 69.35, 59.30, 58.51, 56.94, 48.24, 38.39, 34.85, 26.53 (3C), 22.97, 16.14
99 % With hydrogenchloride In 1,4-dioxane at 20℃; (2S,4R)-1-((S)-2-Amino-3,3-dimethylbutanoyl)-4-hydroxy-N-((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)pyrrolidine-2-carboxamide hydrochloride (E3LB-1). The titled compound can be prepared according to the process described by Raina K. et al., Proc. Natl. Acad. Sci. U.S.A. 2016, 113, 7124-7129.[00157] A solution of 4N HCl in dioxane (6.0 mL) is added to tert-butyl ((S)-1-((2S,4R)-4-hydroxy-2-(((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)carbamate (L) (1.55 g, 2.85 mmol) and the mixture is stirred at rt for 3 h. The solvent is evaporated to dryness and the crude residue is triturated with DEE, filtered off, and dried in an oven at 50 °C to give the titled compound as a white solid (1.36 g, 99% yield).1H NMR (400 MHz, DMSO-d6): δ 9.11 (s, 1H), 8.62 (d, J = 7.8 Hz, 1H), 8.16 (s, 3H), 7.50-7.34 (m, 4H), 6.83 (s, 1H), 4.91 (q, J = 7.2 Hz, 1H), 4.55 (t, J = 8.4 Hz, 1H), 4.31 (s, 1H), 3.89 (d, J = 5.3 Hz, 1H), 3.75 (d, J = 10.8 Hz, 1H), 3.50 (dd, J = 3.7, 10.9 Hz, 1H), 2.47 (s, 3H), 2.21-1.65 (m,2H), 1.38 (d, J = 7.0 Hz, 3H), 1.03 (s, 9H);13C NMR (101 MHz, DMSO-d6): δ 170.68, 167.08, 151.52, 147.47, 145.31, 131.96, 129.84, 129.32 (2C), 126.85 (2C), 69.35, 59.30, 58.51, 56.94, 48.24, 38.39, 34.85, 26.53 (3C), 22.97, 16.14.
99 % With hydrogenchloride In 1,4-dioxane at 20℃; (2S,4R)-1-((S)-2-Amino-3,3-dimethylbutanoyl)-4-hydroxy-N-((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)pyrrolidine-2-carboxamide hydrochloride (E3LB-1). The titled compound can be prepared according to the process described by Raina K. et al., Proc. Natl. Acad. Sci. U.S.A. 2016, 113, 7124-7129.[00157] A solution of 4N HCl in dioxane (6.0 mL) is added to tert-butyl ((S)-1-((2S,4R)-4-hydroxy-2-(((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)carbamate (L) (1.55 g, 2.85 mmol) and the mixture is stirred at rt for 3 h. The solvent is evaporated to dryness and the crude residue is triturated with DEE, filtered off, and dried in an oven at 50 °C to give the titled compound as a white solid (1.36 g, 99% yield).1H NMR (400 MHz, DMSO-d6): δ 9.11 (s, 1H), 8.62 (d, J = 7.8 Hz, 1H), 8.16 (s, 3H), 7.50-7.34 (m, 4H), 6.83 (s, 1H), 4.91 (q, J = 7.2 Hz, 1H), 4.55 (t, J = 8.4 Hz, 1H), 4.31 (s, 1H), 3.89 (d, J = 5.3 Hz, 1H), 3.75 (d, J = 10.8 Hz, 1H), 3.50 (dd, J = 3.7, 10.9 Hz, 1H), 2.47 (s, 3H), 2.21-1.65 (m,2H), 1.38 (d, J = 7.0 Hz, 3H), 1.03 (s, 9H);13C NMR (101 MHz, DMSO-d6): δ 170.68, 167.08, 151.52, 147.47, 145.31, 131.96, 129.84, 129.32 (2C), 126.85 (2C), 69.35, 59.30, 58.51, 56.94, 48.24, 38.39, 34.85, 26.53 (3C), 22.97, 16.14.
With hydrogenchloride In 1,4-dioxane; dichloromethane at 20℃; 7 Synthesis of (2S,4R)-1-[(2S)-2-amino-3,3-dimethyl-butanoyl]-4-hydroxy-N-[(1S)- 1-[4-(4-methylthiazol-5-yl)phenyl]ethyl]pyrrolidine-2-carboxamide;hydrochloride (HB7) )-1-[4-(4- methylthiazol-5-yl)phenyl]ethyl]carbamoyl]pyrrolidine-1-carbonyl]-2,2-dimethyl- propyl]carbamate (HB7h) (34.0 g, 62.0 mmol) in DCM (200 mL) at 0 °C was added an HCl solution (4 M in dioxane, 200 mL, 800 mmol) and the mixture was warmed to rt and then stirred for 15 min. The mixture was then diluted with MeOH (150 mL) and the mixture was further stirred for 30 min. The volatiles were evaporated under reduced pressure and coevaporated with PhMe (2 x 100 mL) to afford the title compound HB7 as a solid (30.6 g, 92%, contained 9% PhMe by weight).1H NMR (500 MHz, DMSO-d6) δ 9.04 (s, 1H), 8.59 (d, J = 7.8 Hz, 1H), 8.09 (d, J = 4.3 Hz, 3H), 7.47 - 7.43 (m, 2H), 7.42 - 7.37 (m, 2H), 4.93 (p, J = 7.0 Hz, 1H), 4.55 (t, J = 8.4 Hz, 1H), 4.33 (br s, 1H), 3.91 (q, J = 5.7 Hz, 1H), 3.73 (d, J = 10.6 Hz, 1H), 3.50 (dd, J = 10.9, 3.9 Hz, 1H), 2.70 (s, 1H), 2.47 (s, 3H), 2.12 (dd, J = 12.9, 7.7 Hz, 1H), 1.81 - 1.72 (m, 1H), 1.39 (d, J = 7.0 Hz, 3H), 1.03 (s, 9H). MS (ESI) [M+H]+ 445.2
With hydrogenchloride In 1,4-dioxane; dichloromethane at 20℃; 7 Synthesis of (2S,4R)-1-[(2S)-2-amino-3,3-dimethyl-butanoyl]-4-hydroxy-N-[(1S)- 1-[4-(4-methylthiazol-5-yl)phenyl]ethyl]pyrrolidine-2-carboxamide;hydrochloride (HB7) )-1-[4-(4- methylthiazol-5-yl)phenyl]ethyl]carbamoyl]pyrrolidine-1-carbonyl]-2,2-dimethyl- propyl]carbamate (HB7h) (34.0 g, 62.0 mmol) in DCM (200 mL) at 0 °C was added an HCl solution (4 M in dioxane, 200 mL, 800 mmol) and the mixture was warmed to rt and then stirred for 15 min. The mixture was then diluted with MeOH (150 mL) and the mixture was further stirred for 30 min. The volatiles were evaporated under reduced pressure and coevaporated with PhMe (2 x 100 mL) to afford the title compound HB7 as a solid (30.6 g, 92%, contained 9% PhMe by weight).1H NMR (500 MHz, DMSO-d6) δ 9.04 (s, 1H), 8.59 (d, J = 7.8 Hz, 1H), 8.09 (d, J = 4.3 Hz, 3H), 7.47 - 7.43 (m, 2H), 7.42 - 7.37 (m, 2H), 4.93 (p, J = 7.0 Hz, 1H), 4.55 (t, J = 8.4 Hz, 1H), 4.33 (br s, 1H), 3.91 (q, J = 5.7 Hz, 1H), 3.73 (d, J = 10.6 Hz, 1H), 3.50 (dd, J = 10.9, 3.9 Hz, 1H), 2.70 (s, 1H), 2.47 (s, 3H), 2.12 (dd, J = 12.9, 7.7 Hz, 1H), 1.81 - 1.72 (m, 1H), 1.39 (d, J = 7.0 Hz, 3H), 1.03 (s, 9H). MS (ESI) [M+H]+ 445.2
60 % With hydrogenchloride In 1,4-dioxane; methanol; dichloromethane at 0 - 20℃; 4.6.7. (2S,4R)-1-((S)-2-amino-3,3-dimethylbutanoyl)-4-hydroxy-N-((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)pyrrolidine-2-carboxamidehydrochloride (17) To a solution of 54 in a mixture of dry DCM (6.0 mL) and dry MeOH(2.0 mL), 4.0 N HCl in dioxane (4.7 mL) was added dropwise at 0 C forover 30 min. The mixture was stirred at room temperature overnight.Then, the reaction mixture was concentrated, water (50 mL) was added,and the solution was extracted with DCM (20 mL x 3). The aqueousphase was then transferred to a beaker, and solid NaHCO3 (2.5 g) wasadded to the solution to adjust the pH to 8. Then, the aqueous phase wasextracted with DCM (30 mL x 3); the reunited organic phase was washedwith brine (20 mL), dried over Na2SO4 and concentrated in vacuo. Theresulting beige foam was dissolved in dioxane (20 mL), and 4.0 N HCl indioxane (3.0 mL) was added dropwise for over 30 min at 0 C. Theresulting mixture was concentrated in vacuo and dissolved in MeOH (7.0mL). The solution was added dropwise to EA (60.0 mL) over 2 h. Theprecipitated solid was filtered and dried in vacuo to give a 0.664 g beigesolid (two-step yield 68 %; and overall yield 60 %). 1H NMR (400 MHz,DMSO-d6) 9.08 (s, 1H), 8.61 (d, J = 7.6 Hz, 1H), 8.16 (bs, 3H), 7.42 (dd,J = 25.4, 8.1 Hz, 4H), 4.99-4.85 (m, 1H), 4.58-4.51 (m, 1H), 4.34-4.27(m, 1H), 3.92-3.84 (m, 1H), 3.79-3.70 (m, 1H), 3.55-3.44 (m, 1H), 2.46(s, 3H), 2.16-2.06 (m, 1H), 1.81-1.69 (m, 1H), 1.38 (d, J = 6.9 Hz, 3H),1.02 (s, 9H). 13C NMR (101 MHz, DMSO-d6) δ 170.68, 167.08, 152.32,147.62, 145.27, 131.88, 129.91, 129.32 (2C), 126.84 (2C), 69.35,60.22, 59.30, 58.51, 56.94, 48.24, 34.85, 26.54 (3C), 22.97, 16.20.HRMS (ESI) m/z [M + H]+ calcd for C23H32N4O3S 445.22679, found445.2275. UPLC retention time: 3.211 min.
60 % With hydrogenchloride In 1,4-dioxane; methanol; dichloromethane at 0 - 20℃; 4.6.7. (2S,4R)-1-((S)-2-amino-3,3-dimethylbutanoyl)-4-hydroxy-N-((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)pyrrolidine-2-carboxamidehydrochloride (17) To a solution of 54 in a mixture of dry DCM (6.0 mL) and dry MeOH(2.0 mL), 4.0 N HCl in dioxane (4.7 mL) was added dropwise at 0 C forover 30 min. The mixture was stirred at room temperature overnight.Then, the reaction mixture was concentrated, water (50 mL) was added,and the solution was extracted with DCM (20 mL x 3). The aqueousphase was then transferred to a beaker, and solid NaHCO3 (2.5 g) wasadded to the solution to adjust the pH to 8. Then, the aqueous phase wasextracted with DCM (30 mL x 3); the reunited organic phase was washedwith brine (20 mL), dried over Na2SO4 and concentrated in vacuo. Theresulting beige foam was dissolved in dioxane (20 mL), and 4.0 N HCl indioxane (3.0 mL) was added dropwise for over 30 min at 0 C. Theresulting mixture was concentrated in vacuo and dissolved in MeOH (7.0mL). The solution was added dropwise to EA (60.0 mL) over 2 h. Theprecipitated solid was filtered and dried in vacuo to give a 0.664 g beigesolid (two-step yield 68 %; and overall yield 60 %). 1H NMR (400 MHz,DMSO-d6) 9.08 (s, 1H), 8.61 (d, J = 7.6 Hz, 1H), 8.16 (bs, 3H), 7.42 (dd,J = 25.4, 8.1 Hz, 4H), 4.99-4.85 (m, 1H), 4.58-4.51 (m, 1H), 4.34-4.27(m, 1H), 3.92-3.84 (m, 1H), 3.79-3.70 (m, 1H), 3.55-3.44 (m, 1H), 2.46(s, 3H), 2.16-2.06 (m, 1H), 1.81-1.69 (m, 1H), 1.38 (d, J = 6.9 Hz, 3H),1.02 (s, 9H). 13C NMR (101 MHz, DMSO-d6) δ 170.68, 167.08, 152.32,147.62, 145.27, 131.88, 129.91, 129.32 (2C), 126.84 (2C), 69.35,60.22, 59.30, 58.51, 56.94, 48.24, 34.85, 26.54 (3C), 22.97, 16.20.HRMS (ESI) m/z [M + H]+ calcd for C23H32N4O3S 445.22679, found445.2275. UPLC retention time: 3.211 min.
8.12 g With hydrogenchloride In methanol at 4℃;
With hydrogenchloride In 1,4-dioxane; water at 20℃;

References: [1]Current Patent Assignee: ARVINAS OPERATIONS - US2018/72711, 2018, A1 Location in patent: Paragraph 0333; 0335; 0340.
[2]Current Patent Assignee: ARVINAS OPERATIONS - WO2018/140809, 2018, A1 Location in patent: Paragraph 00538; 00539; 00547; 00548.
[3]Current Patent Assignee: ARVINAS - US2018/125821, 2018, A1 Location in patent: Paragraph 0613; 0622-0625.
[4]Current Patent Assignee: ARVINAS OPERATIONS - WO2021/11913, 2021, A1 Location in patent: Paragraph 0342.
[5]Current Patent Assignee: DBD THERAPEUTICS - US2020/239430, 2020, A1 Location in patent: Paragraph 0127; 0134.
[6]Current Patent Assignee: JIANGSU YAHONG MEDITECH - WO2022/161166, 2022, A1 Location in patent: Page/Page column 30; 32-34.
[7]Current Patent Assignee: KYMERA THERAPEUTICS - WO2020/206424, 2020, A1 Location in patent: Paragraph 0001131.
[8]Current Patent Assignee: AURIGENE ONCOLOGY - WO2019/207538, 2019, A1 Location in patent: Page/Page column 86.
[9]Current Patent Assignee: NURIX THERAPEUTICS - WO2020/81450, 2020, A1 Location in patent: Paragraph 0880; 0889; 0890.
[10]Current Patent Assignee: YALE UNIVERSITY - WO2019/195609, 2019, A2 Location in patent: Paragraph 00487-00488.
[11]Current Patent Assignee: YALE UNIVERSITY - WO2020/51564, 2020, A1 Location in patent: Paragraph 1071; 1072.
[12]Current Patent Assignee: MITSUBISHI TANABE PHARMA - WO2020/9176, 2020, A1 Location in patent: Paragraph 0228; 0246-0248.
[13]Current Patent Assignee: JOHNSON JOHNSON CHINA INVESTMENT - WO2021/18118, 2021, A1 Location in patent: Page/Page column 56; 58.
[14]Current Patent Assignee: YALE UNIVERSITY - WO2021/207172, 2021, A1 Location in patent: Paragraph 00237.
[15]Current Patent Assignee: DBD THERAPEUTICS - WO2023/39601, 2023, A1 Location in patent: Paragraph 00149; 00171; 00173.
[16]Current Patent Assignee: DBD THERAPEUTICS - WO2023/39601, 2023, A1 Location in patent: Paragraph 00149; 00171; 00173.
[17]Current Patent Assignee: DBD THERAPEUTICS - WO2023/39602, 2023, A1 Location in patent: Paragraph 00155-00157; 00133.
[18]Current Patent Assignee: DBD THERAPEUTICS - WO2023/39602, 2023, A1 Location in patent: Paragraph 00155-00157; 00133.
[19]Current Patent Assignee: NURIX THERAPEUTICS - WO2023/69514, 2023, A2 Location in patent: Paragraph 000245; 000250.
[20]Current Patent Assignee: NURIX THERAPEUTICS - WO2023/69514, 2023, A2 Location in patent: Paragraph 000245; 000250.
[21]Desantis, Jenny; Bazzacco, Alessandro; Eleuteri, Michela; Tuci, Sara; Bianconi, Elisa; Macchiarulo, Antonio; Mercorelli, Beatrice; Loregian, Arianna; Goracci, Laura [European Journal of Medicinal Chemistry, 2024, vol. 268].
[22]Desantis, Jenny; Bazzacco, Alessandro; Eleuteri, Michela; Tuci, Sara; Bianconi, Elisa; Macchiarulo, Antonio; Mercorelli, Beatrice; Loregian, Arianna; Goracci, Laura [European Journal of Medicinal Chemistry, 2024, vol. 268].
[23]Soto-Martínez, Diana M.; Clements, Garrett D.; Díaz, John E.; Becher, Joy; Reynolds, Robert C.; Ochsenbauer, Christina; Snowden, Timothy S. [RSC Advances, 2024, vol. 14, # 24, p. 17077 - 17090].
[24]Leconte, Georges A.; Gadbois, Gillian E.; Sepulveda, Yadira; Schwarz, Ady; Chang, Erin; Suhandynata, Raymond T.; Momper, Jeremiah D.; Ferguson, Fleur M. [Journal of Medicinal Chemistry, 2025, vol. 68, # 16, p. 17339 - 17349].
  • 7
  • [ 1973408-97-7 ]
  • [ 1997302-16-5 ]
YieldReaction ConditionsOperation in experiment
Multi-step reaction with 2 steps 1: hydrogenchloride / methanol / 3 h / 20 °C 2: HATU; N-ethyl-N,N-diisopropylamine / tetrahydrofuran / 2 h / 0 - 20 °C
Multi-step reaction with 2 steps 1: dichloromethane / 0.5 h / 20 °C 2: N-ethyl-N,N-diisopropylamine; N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate / N,N-dimethyl-formamide / 20 °C
Multi-step reaction with 4 steps 1: hydrogenchloride / methanol; 1,4-dioxane / 12 h / 20 °C 2: N-ethyl-N,N-diisopropylamine; N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate / N,N-dimethyl-formamide / 12 h / 0 - 20 °C / Inert atmosphere 3: hydrogenchloride / methanol; 1,4-dioxane / 12 h / 20 °C 4: N-ethyl-N,N-diisopropylamine; N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate / N,N-dimethyl-formamide / 12 h / 0 - 20 °C / Inert atmosphere
Multi-step reaction with 4 steps 1: hydrogenchloride / methanol / 2 h / 20 °C 2: N-ethyl-N,N-diisopropylamine; HATU / N,N-dimethyl-formamide / 12 h / 20 °C 3: hydrogenchloride / methanol / 2 h / 20 °C 4: N-ethyl-N,N-diisopropylamine; HATU / N,N-dimethyl-formamide / 12 h / 20 °C
Multi-step reaction with 2 steps 1: hydrogenchloride / 1,4-dioxane; methanol / 4 h / 20 °C 2: N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate; N-ethyl-N,N-diisopropylamine / N,N-dimethyl-formamide / 12 h / 0 - 20 °C / Inert atmosphere
Multi-step reaction with 2 steps 1: hydrogenchloride / water; 1,4-dioxane / 3 h / 20 °C 2: N-ethyl-N,N-diisopropylamine; N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate / tetrahydrofuran / 5 h / 0 - 20 °C / Inert atmosphere
Multi-step reaction with 2 steps 1: hydrogenchloride / water; methanol / 3 h / 20 °C 2: N-ethyl-N,N-diisopropylamine; N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate / tetrahydrofuran / 2 h / 0 - 20 °C
Multi-step reaction with 4 steps 1: hydrogenchloride / 1,4-dioxane; methanol / 12 h / 20 °C 2: HATU; N-ethyl-N,N-diisopropylamine / N,N-dimethyl-formamide / 12 h / 0 - 20 °C / Inert atmosphere 3: hydrogenchloride / 1,4-dioxane; methanol / 12 h / 20 °C 4: HATU; N-ethyl-N,N-diisopropylamine / N,N-dimethyl-formamide / 12 h / 0 - 20 °C / Inert atmosphere
Multi-step reaction with 4 steps 1: hydrogenchloride / 1,4-dioxane / 25 °C / Inert atmosphere 2: HATU; N-ethyl-N,N-diisopropylamine / N,N-dimethyl-formamide / 0 - 25 °C / Inert atmosphere 3: hydrogenchloride / 1,4-dioxane / 16 h / 25 °C / Inert atmosphere 4: triethylamine; HATU / N,N-dimethyl-formamide / 0 - 25 °C / Inert atmosphere
Multi-step reaction with 2 steps 1: hydrogenchloride / water; 1,4-dioxane / 5 h / 20 °C 2: N-ethyl-N,N-diisopropylamine; N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate / N,N-dimethyl-formamide / 20 °C / Cooling with ice
Multi-step reaction with 2 steps 1: hydrogenchloride / water; methanol / 3 h / 20 °C 2: N-ethyl-N,N-diisopropylamine; N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate / tetrahydrofuran / 2 h / 0 - 20 °C
Multi-step reaction with 4 steps 1: hydrogenchloride / methanol / 2 h / 20 °C 2: N-ethyl-N,N-diisopropylamine; N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate / N,N-dimethyl-formamide / 12 h / 20 °C 3: hydrogenchloride / methanol / 2 h / 20 °C 4: N-ethyl-N,N-diisopropylamine; N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate / N,N-dimethyl-formamide / 12 h / 20 °C
Multi-step reaction with 4 steps 1: hydrogenchloride / ethyl acetate / 12 h / 20 °C 2: N-ethyl-N,N-diisopropylamine; N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate / N,N-dimethyl-formamide / 3 h / 20 °C 3: methanol; hydrogenchloride / ethyl acetate / 20 °C 4: N-ethyl-N,N-diisopropylamine; N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate / N,N-dimethyl-formamide / 3 h / 20 °C
Multi-step reaction with 2 steps 1: trifluoroacetic acid / dichloromethane / 2 h / 20 °C 2: N-ethyl-N,N-diisopropylamine; N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate / N,N-dimethyl-formamide / 18 h / 20 °C / Inert atmosphere
Multi-step reaction with 2 steps 1.1: trifluoroacetic acid / dichloromethane / 30 min / 20 °C 1.2: 20 °C 2.1: trifluoroacetic acid / dichloromethane / 30 min / 20 °C 2.2: 20 °C
Multi-step reaction with 4 steps 1: trifluoroacetic acid / dichloromethane / 16 h / 20 °C 2: triethylamine; N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate / dichloromethane / 16 h / 20 °C 3: dichloromethane / 18 h / 20 °C 4: triethylamine; benzotriazol-1-ol; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride / dichloromethane / 16 h / 20 °C
Multi-step reaction with 2 steps 1: hydrogenchloride / methanol 2: N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate; N-ethyl-N,N-diisopropylamine / 12 h / 20 °C
Multi-step reaction with 4 steps 1: hydrogenchloride / 1,4-dioxane; dichloromethane / 1 h / 25 °C 2: N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate; N-ethyl-N,N-diisopropylamine / tetrahydrofuran / 18 h / 20 °C 3: hydrogenchloride / 1,4-dioxane; dichloromethane / 1 h / 25 °C 4: N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate; N-ethyl-N,N-diisopropylamine / tetrahydrofuran / 18 h / 20 °C
Multi-step reaction with 2 steps 1.1: hydrogenchloride / 1,4-dioxane; methanol / 12 h / 20 °C / Inert atmosphere 1.2: 12 h / 0 - 20 °C / Inert atmosphere 2.1: hydrogenchloride / 1,4-dioxane; methanol / 12 h / 20 °C / Inert atmosphere 2.2: 12 h / 0 - 20 °C / Inert atmosphere
Multi-step reaction with 4 steps 1: trifluoroacetic acid / dichloromethane / 30 min / 20 °C 2: N-ethyl-N,N-diisopropylamine; HATU / N,N-dimethyl-formamide / 12 h / 20 °C 3: trifluoroacetic acid / dichloromethane / 30 min / 20 °C 4: N-ethyl-N,N-diisopropylamine; HATU / N,N-dimethyl-formamide / 12 h / 0 - 20 °C
Multi-step reaction with 4 steps 1.1: hydrogenchloride / 1,4-dioxane; dichloromethane / 18 h / 0 - 20 °C 2.1: N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate; triethylamine / N,N-dimethyl-formamide; dichloromethane / 18 h / 0 - 20 °C / Inert atmosphere 3.1: hydrogenchloride / 1,4-dioxane / 18 h / 0 - 20 °C 4.1: N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate; N-ethyl-N,N-diisopropylamine / dichloromethane / 1 h / 0 °C / Inert atmosphere 4.2: 18 h / 20 °C / Inert atmosphere
Multi-step reaction with 4 steps 1: hydrogenchloride / ethyl acetate / 12 h / 20 °C 2: HATU; N-ethyl-N,N-diisopropylamine / N,N-dimethyl-formamide / 2 h / 0 - 20 °C / Inert atmosphere 3: hydrogenchloride / ethyl acetate / 12 h / 20 °C 4: HATU; N-ethyl-N,N-diisopropylamine / N,N-dimethyl-formamide / 12 h / 0 - 20 °C
Multi-step reaction with 4 steps 1: trifluoroacetic acid / dichloromethane / 30 min / 20 °C 2: N-ethyl-N,N-diisopropylamine; N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate / N,N-dimethyl-formamide / 30 min / 20 °C 3: trifluoroacetic acid / dichloromethane / 30 min / 20 °C 4: N-ethyl-N,N-diisopropylamine; N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate / N,N-dimethyl-formamide / 30 min / 20 °C
Multi-step reaction with 4 steps 1: hydrogenchloride / 1,4-dioxane / 1 h / 16 °C 2: N-ethyl-N,N-diisopropylamine; N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate / N,N-dimethyl-formamide / 1 h / 16 °C 3: hydrogenchloride / 1,4-dioxane / 1 h / 16 °C 4: N-ethyl-N,N-diisopropylamine; N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate / N,N-dimethyl-formamide / 1 h / 16 - 20 °C
Multi-step reaction with 2 steps 1: hydrogenchloride / methanol; 1,4-dioxane / 2 h / 0 - 20 °C 2: 1-methyl-1H-imidazole / acetonitrile / 3 h / 20 °C
Multi-step reaction with 2 steps 1.1: trifluoroacetic acid / dichloromethane / 1 h / Cooling with ice 1.2: 3 h / 20 °C 2.1: trifluoroacetic acid / 1 h / Cooling with ice 2.2: 3 h / 20 °C

References: [1]Current Patent Assignee: ARVINAS OPERATIONS - US2018/72711, 2018, A1.
[2]Han, Xin; Wang, Chao; Qin, Chong; Xiang, Weiguo; Fernandez-Salas, Ester; Yang, Chao-Yie; Wang, Mi; Zhao, Lijie; Xu, Tianfeng; Chinnaswamy, Krishnapriya; Delproposto, James; Stuckey, Jeanne; Wang, Shaomeng [Journal of Medicinal Chemistry, 2019, vol. 62, # 2, p. 941 - 964].
[3]Hu, Jiantao; Hu, Biao; Wang, Mingliang; Xu, Fuming; Miao, Bukeyan; Yang, Chao-Yie; Wang, Mi; Liu, Zhaomin; Hayes, Daniel F.; Chinnaswamy, Krishnapriya; Delproposto, James; Stuckey, Jeanne; Wang, Shaomeng [Journal of Medicinal Chemistry, 2019, vol. 62, # 3, p. 1420 - 1442].
[4]Current Patent Assignee: YALE UNIVERSITY - WO2019/195609, 2019, A2.
[5]Wang, Mingliang; Lu, Jianfeng; Wang, Mi; Yang, Chao-Yie; Wang, Shaomeng [Journal of Medicinal Chemistry, 2020, vol. 63, # 14, p. 7510 - 7528].
[6]Current Patent Assignee: DBD THERAPEUTICS - US2020/239430, 2020, A1.
[7]Current Patent Assignee: ARVINAS - US2018/125821, 2018, A1.
[8]Current Patent Assignee: UNIVERSITY OF MICHIGAN - WO2020/142227, 2020, A1.
[9]Current Patent Assignee: KYMERA THERAPEUTICS - WO2020/206424, 2020, A1.
[10]Current Patent Assignee: MITSUBISHI TANABE PHARMA - WO2020/9176, 2020, A1.
[11]Current Patent Assignee: ARVINAS OPERATIONS - WO2021/11913, 2021, A1.
[12]Current Patent Assignee: YALE UNIVERSITY - WO2021/207172, 2021, A1.
[13]Current Patent Assignee: JIANGSU YAHONG MEDITECH - WO2022/161166, 2022, A1.
[14]Keuler, Tim; König, Beate; Bückreiß, Nico; Kraft, Fabian B.; König, Philipp; Schäker-Hübner, Linda; Steinebach, Christian; Bendas, Gerd; Gütschow, Michael; Hansen, Finn K. [Chemical Communications, 2022, vol. 58, # 79, p. 11087 - 11090].
[15]Wang, Chao; Zheng, Cangxin; Wang, Han; Shui, Sufang; Jin, Hongwei; Liu, Guoquan; Xu, Fengrong; Liu, Zhenming; Zhang, Liangren; Sun, Dan; Xu, Ping [European Journal of Medicinal Chemistry, 2023, vol. 247].
[16]Current Patent Assignee: HINOVA PHARMACEUTICALS - WO2023/280237, 2023, A1.
[17]Cai, Maohua; Ma, Furong; Hu, Can; Li, Haobin; Cao, Fei; Li, Yulong; Dong, Jinyun; Qin, Jiang-Jiang [Bioorganic and Medicinal Chemistry, 2023, vol. 90].
[18]Current Patent Assignee: SHANGHAI QILU PHARMACEUTICAL RES AND DEVELOPMENT CENTRE - WO2023/143249, 2023, A1.
[19]Du, Wenhao; Huang, Yuting; Chen, Xiaoai; Deng, Yue; Sun, Yaoliang; Yang, Hong; Shi, Qiongyu; Wu, Feifei; Liu, Guobin; Huang, He; Ding, Jian; Huang, Xun; Xu, Shilin [Cell Chemical Biology, 2024, vol. 31, # 1, p. 177 - 17,183].
[20]Wang, Xiaohua; Xin, Lilan; Deng, Xiaofei; Dong, Chune; Hu, Guoyuan; Zhou, Hai-Bing [European Journal of Medicinal Chemistry, 2024, vol. 267].
[21]Desantis, Jenny; Bazzacco, Alessandro; Eleuteri, Michela; Tuci, Sara; Bianconi, Elisa; Macchiarulo, Antonio; Mercorelli, Beatrice; Loregian, Arianna; Goracci, Laura [European Journal of Medicinal Chemistry, 2024, vol. 268].
[22]Yao, Xiaoxuan; Mao, Jianping; Zhang, Haoyu; Xiao, Yi; Wang, Yongjun; Liu, Hongzhuo [European Journal of Medicinal Chemistry, 2024, vol. 272].
[23]Xin, Lilan; Wang, Chao; Cheng, Yan; Wang, Hongli; Guo, Xinyi; Deng, Xiaofei; Deng, Xiangping; Xie, Baohua; Hu, Hankun; Min, Chang; Dong, Chune; Zhou, Hai-Bing [Journal of Medicinal Chemistry, 2024, vol. 67, # 11, p. 8913 - 8931].
[24]Current Patent Assignee: KESMALEA THERAPEUTICS LTD - WO2024/175905, 2024, A1.
[25]Current Patent Assignee: SHANGHAI HAIYAN PHARMACEUTICAL TECHNOLOGY - WO2024/179529, 2024, A1.
[26]Current Patent Assignee: WUHAN UNIVERSITY - CN120247870, 2025, A.
  • 8
  • [ 27298-97-1 ]
  • [ 1997302-16-5 ]
YieldReaction ConditionsOperation in experiment
Multi-step reaction with 4 steps 1: sodium hydrogencarbonate / water; ethyl acetate / 2 h / 5 °C 2: palladium diacetate; potassium acetate / N,N-dimethyl acetamide / 18 h / 90 °C / Inert atmosphere 3: hydrogenchloride / methanol / 3 h / 20 °C 4: HATU; N-ethyl-N,N-diisopropylamine / tetrahydrofuran / 2 h / 0 - 20 °C
Multi-step reaction with 4 steps 1: sodium hydrogencarbonate / water; ethyl acetate / 1 h / 20 °C 2: palladium diacetate; potassium acetate / N,N-dimethyl-formamide / 2 h / 90 °C / Inert atmosphere 3: dichloromethane / 0.5 h / 20 °C 4: N-ethyl-N,N-diisopropylamine; N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate / N,N-dimethyl-formamide / 20 °C
Multi-step reaction with 6 steps 1: sodium hydrogencarbonate / water; ethyl acetate / 2 h 2: palladium diacetate; potassium acetate / N,N-dimethyl-formamide / 12 h / 90 °C 3: hydrogenchloride / methanol; 1,4-dioxane / 12 h / 20 °C 4: N-ethyl-N,N-diisopropylamine; N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate / N,N-dimethyl-formamide / 12 h / 0 - 20 °C / Inert atmosphere 5: hydrogenchloride / methanol; 1,4-dioxane / 12 h / 20 °C 6: N-ethyl-N,N-diisopropylamine; N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate / N,N-dimethyl-formamide / 12 h / 0 - 20 °C / Inert atmosphere
Multi-step reaction with 6 steps 1: triethylamine / dichloromethane / 2 h / 20 °C 2: potassium acetate; palladium diacetate / N,N-dimethyl acetamide / 2 h / 120 °C 3: hydrogenchloride / methanol / 2 h / 20 °C 4: N-ethyl-N,N-diisopropylamine; HATU / N,N-dimethyl-formamide / 12 h / 20 °C 5: hydrogenchloride / methanol / 2 h / 20 °C 6: N-ethyl-N,N-diisopropylamine; HATU / N,N-dimethyl-formamide / 12 h / 20 °C
Multi-step reaction with 4 steps 1: sodium hydrogencarbonate / ethyl acetate; water / 2 h / 20 °C 2: palladium diacetate; potassium acetate / N,N-dimethyl acetamide / 12 h / 90 °C 3: hydrogenchloride / 1,4-dioxane; methanol / 4 h / 20 °C 4: N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate; N-ethyl-N,N-diisopropylamine / N,N-dimethyl-formamide / 12 h / 0 - 20 °C / Inert atmosphere
Multi-step reaction with 4 steps 1: sodium hydrogencarbonate / ethyl acetate; water / 2 h / 5 - 20 °C 2: palladium diacetate; potassium acetate / N,N-dimethyl acetamide / 18 h / 90 °C 3: hydrogenchloride / water; 1,4-dioxane / 3 h / 20 °C 4: N-ethyl-N,N-diisopropylamine; N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate / tetrahydrofuran / 5 h / 0 - 20 °C / Inert atmosphere
Multi-step reaction with 4 steps 1: sodium hydrogencarbonate / water; ethyl acetate / 2 h / 5 °C 2: palladium diacetate; potassium acetate / N,N-dimethyl-formamide / 18 h / 90 °C / Inert atmosphere 3: hydrogenchloride / water; methanol / 3 h / 20 °C 4: N-ethyl-N,N-diisopropylamine; N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate / tetrahydrofuran / 2 h / 0 - 20 °C
Multi-step reaction with 6 steps 1: sodium hydrogencarbonate / water; ethyl acetate / 2 h 2: palladium diacetate; potassium acetate / dimethyl amine / 12 h / 90 °C 3: hydrogenchloride / 1,4-dioxane; methanol / 12 h / 20 °C 4: HATU; N-ethyl-N,N-diisopropylamine / N,N-dimethyl-formamide / 12 h / 0 - 20 °C / Inert atmosphere 5: hydrogenchloride / 1,4-dioxane; methanol / 12 h / 20 °C 6: HATU; N-ethyl-N,N-diisopropylamine / N,N-dimethyl-formamide / 12 h / 0 - 20 °C / Inert atmosphere
Multi-step reaction with 4 steps 1: sodium hydrogencarbonate / ethyl acetate; water / 20 °C / Cooling with ice 2: potassium acetate; palladium diacetate / N,N-dimethyl acetamide / 7 h / 90 °C / Inert atmosphere 3: hydrogenchloride / water; 1,4-dioxane / 5 h / 20 °C 4: N-ethyl-N,N-diisopropylamine; N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate / N,N-dimethyl-formamide / 20 °C / Cooling with ice
Multi-step reaction with 4 steps 1: sodium hydrogencarbonate / water; ethyl acetate / 2 h / 5 °C 2: palladium diacetate; potassium acetate / N,N-dimethyl-formamide / 18 h / 90 °C / Inert atmosphere 3: hydrogenchloride / water; methanol / 3 h / 20 °C 4: N-ethyl-N,N-diisopropylamine; N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate / tetrahydrofuran / 2 h / 0 - 20 °C
Multi-step reaction with 6 steps 1: triethylamine / dichloromethane / 2 h / 20 °C 2: palladium diacetate; potassium acetate / N,N-dimethyl acetamide / 2 h / 120 °C / Inert atmosphere 3: hydrogenchloride / methanol / 2 h / 20 °C 4: N-ethyl-N,N-diisopropylamine; N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate / N,N-dimethyl-formamide / 12 h / 20 °C 5: hydrogenchloride / methanol / 2 h / 20 °C 6: N-ethyl-N,N-diisopropylamine; N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate / N,N-dimethyl-formamide / 12 h / 20 °C
Multi-step reaction with 6 steps 1: triethylamine / dichloromethane / 12 h / 20 °C 2: palladium diacetate; potassium acetate / N,N-dimethyl-formamide / 4 h / 100 °C / Inert atmosphere 3: hydrogenchloride / ethyl acetate / 12 h / 20 °C 4: N-ethyl-N,N-diisopropylamine; N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate / N,N-dimethyl-formamide / 3 h / 20 °C 5: methanol; hydrogenchloride / ethyl acetate / 20 °C 6: N-ethyl-N,N-diisopropylamine; N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate / N,N-dimethyl-formamide / 3 h / 20 °C
Multi-step reaction with 4 steps 1: sodium hydrogencarbonate / ethyl acetate; water / 2 h / 0 °C 2: palladium diacetate; potassium acetate / N,N-dimethyl acetamide / 4 h / 130 °C / Inert atmosphere 3: trifluoroacetic acid / dichloromethane / 2 h / 20 °C 4: N-ethyl-N,N-diisopropylamine; N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate / N,N-dimethyl-formamide / 18 h / 20 °C / Inert atmosphere
Multi-step reaction with 4 steps 1.1: sodium hydrogencarbonate / ethyl acetate; water / 1 h / 20 °C 2.1: palladium diacetate; potassium acetate / N,N-dimethyl-formamide / 2 h / 90 °C / Inert atmosphere 3.1: trifluoroacetic acid / dichloromethane / 30 min / 20 °C 3.2: 20 °C 4.1: trifluoroacetic acid / dichloromethane / 30 min / 20 °C 4.2: 20 °C
Multi-step reaction with 4 steps 1: sodium hydrogencarbonate / ethyl acetate; water / 2 h / 5 - 20 °C 2: palladium diacetate; potassium acetate / N,N-dimethyl acetamide / 18 h / 90 °C / Inert atmosphere 3: hydrogenchloride / 1,4-dioxane / 3 h / 20 °C 4: N-ethyl-N,N-diisopropylamine; N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate / tetrahydrofuran / 5 h / 0 - 20 °C / Inert atmosphere
Multi-step reaction with 4 steps 1: sodium hydrogencarbonate / water; ethyl acetate 2: palladium diacetate; potassium acetate / 90 °C 3: hydrogenchloride / methanol 4: N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate; N-ethyl-N,N-diisopropylamine / 12 h / 20 °C
Multi-step reaction with 6 steps 1: sodium hydrogencarbonate / water; ethyl acetate / 1 h / 25 °C 2: palladium diacetate; potassium acetate / N,N-dimethyl acetamide / 16 h / 90 °C 3: hydrogenchloride / 1,4-dioxane; dichloromethane / 1 h / 25 °C 4: N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate; N-ethyl-N,N-diisopropylamine / tetrahydrofuran / 18 h / 20 °C 5: hydrogenchloride / 1,4-dioxane; dichloromethane / 1 h / 25 °C 6: N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate; N-ethyl-N,N-diisopropylamine / tetrahydrofuran / 18 h / 20 °C
Multi-step reaction with 3 steps 1.1: triethylamine / dichloromethane / 2 h / 20 °C / Cooling with ice 1.2: 12 h / 90 °C / Inert atmosphere 2.1: hydrogenchloride / 1,4-dioxane; methanol / 12 h / 20 °C / Inert atmosphere 2.2: 12 h / 0 - 20 °C / Inert atmosphere 3.1: hydrogenchloride / 1,4-dioxane; methanol / 12 h / 20 °C / Inert atmosphere 3.2: 12 h / 0 - 20 °C / Inert atmosphere
Multi-step reaction with 6 steps 1: triethylamine / dichloromethane / 2 h / 20 °C 2: palladium diacetate; potassium acetate / N,N-dimethyl acetamide / 12 h / 90 °C 3: trifluoroacetic acid / dichloromethane / 30 min / 20 °C 4: N-ethyl-N,N-diisopropylamine; HATU / N,N-dimethyl-formamide / 12 h / 20 °C 5: trifluoroacetic acid / dichloromethane / 30 min / 20 °C 6: N-ethyl-N,N-diisopropylamine; HATU / N,N-dimethyl-formamide / 12 h / 0 - 20 °C
Multi-step reaction with 6 steps 1.1: sodium hydrogencarbonate / water / 18 h / 20 °C 2.1: potassium acetate; palladium diacetate / N,N-dimethyl acetamide / 4 h / 130 °C / Inert atmosphere 3.1: hydrogenchloride / 1,4-dioxane; dichloromethane / 18 h / 0 - 20 °C 4.1: N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate; triethylamine / N,N-dimethyl-formamide; dichloromethane / 18 h / 0 - 20 °C / Inert atmosphere 5.1: hydrogenchloride / 1,4-dioxane / 18 h / 0 - 20 °C 6.1: N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate; N-ethyl-N,N-diisopropylamine / dichloromethane / 1 h / 0 °C / Inert atmosphere 6.2: 18 h / 20 °C / Inert atmosphere
Multi-step reaction with 6 steps 1: sodium hydrogencarbonate / water; ethyl acetate / 2 h / 20 °C 2: palladium diacetate; potassium acetate / N,N-dimethyl acetamide / 12 h / 90 °C 3: hydrogenchloride / ethyl acetate / 12 h / 20 °C 4: HATU; N-ethyl-N,N-diisopropylamine / N,N-dimethyl-formamide / 2 h / 0 - 20 °C / Inert atmosphere 5: hydrogenchloride / ethyl acetate / 12 h / 20 °C 6: HATU; N-ethyl-N,N-diisopropylamine / N,N-dimethyl-formamide / 12 h / 0 - 20 °C
Multi-step reaction with 6 steps 1: triethylamine / dichloromethane / 2 h / 20 °C 2: palladium diacetate; potassium acetate / N,N-dimethyl acetamide / 18 h / 150 °C 3: trifluoroacetic acid / dichloromethane / 30 min / 20 °C 4: N-ethyl-N,N-diisopropylamine; N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate / N,N-dimethyl-formamide / 30 min / 20 °C 5: trifluoroacetic acid / dichloromethane / 30 min / 20 °C 6: N-ethyl-N,N-diisopropylamine; N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate / N,N-dimethyl-formamide / 30 min / 20 °C
Multi-step reaction with 5 steps 1: 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride; benzotriazol-1-ol; N-ethyl-N,N-diisopropylamine / dichloromethane; N,N-dimethyl-formamide / 18 h / -10 - 20 °C 2: potassium carbonate; Trimethylacetic acid; [1,3-bis(2,6-diisopropylphenyl)imidazol-2-ylidene](3-chloropyridyl)palladium(ll) dichloride / N,N-dimethyl acetamide / 125 °C 3: hydrogenchloride / methanol / 2 h / 4 °C 4: sodium hydroxide / methanol; dichloromethane; water / 4 °C / pH 12.5 - 13 5: 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride; benzotriazol-1-ol; N-ethyl-N,N-diisopropylamine / dichloromethane; N,N-dimethyl-formamide / -10 - 20 °C
Multi-step reaction with 4 steps 1: sodium hydrogencarbonate; ethanol / water / 2 h / 25 - 30 °C 2: palladium diacetate; potassium acetate / 18 h / 90 °C 3: hydrogenchloride / methanol; water / 3 h / 25 - 30 °C 4: TFFH; N-ethyl-N,N-diisopropylamine / tetrahydrofuran / 2 h / 0 - 30 °C
Multi-step reaction with 4 steps 1.1: sodium hydrogencarbonate / water; ethyl acetate / 3 h / 20 °C / Cooling with ice 2.1: palladium diacetate; potassium acetate / N,N-dimethyl acetamide / 150 °C 3.1: trifluoroacetic acid / dichloromethane / 1 h / Cooling with ice 3.2: 3 h / 20 °C 4.1: trifluoroacetic acid / 1 h / Cooling with ice 4.2: 3 h / 20 °C

References: [1]Current Patent Assignee: ARVINAS OPERATIONS - US2018/72711, 2018, A1.
[2]Han, Xin; Wang, Chao; Qin, Chong; Xiang, Weiguo; Fernandez-Salas, Ester; Yang, Chao-Yie; Wang, Mi; Zhao, Lijie; Xu, Tianfeng; Chinnaswamy, Krishnapriya; Delproposto, James; Stuckey, Jeanne; Wang, Shaomeng [Journal of Medicinal Chemistry, 2019, vol. 62, # 2, p. 941 - 964].
[3]Hu, Jiantao; Hu, Biao; Wang, Mingliang; Xu, Fuming; Miao, Bukeyan; Yang, Chao-Yie; Wang, Mi; Liu, Zhaomin; Hayes, Daniel F.; Chinnaswamy, Krishnapriya; Delproposto, James; Stuckey, Jeanne; Wang, Shaomeng [Journal of Medicinal Chemistry, 2019, vol. 62, # 3, p. 1420 - 1442].
[4]Current Patent Assignee: YALE UNIVERSITY - WO2019/195609, 2019, A2.
[5]Wang, Mingliang; Lu, Jianfeng; Wang, Mi; Yang, Chao-Yie; Wang, Shaomeng [Journal of Medicinal Chemistry, 2020, vol. 63, # 14, p. 7510 - 7528].
[6]Current Patent Assignee: DBD THERAPEUTICS - US2020/239430, 2020, A1.
[7]Current Patent Assignee: ARVINAS - US2018/125821, 2018, A1.
[8]Current Patent Assignee: UNIVERSITY OF MICHIGAN - WO2020/142227, 2020, A1.
[9]Current Patent Assignee: MITSUBISHI TANABE PHARMA - WO2020/9176, 2020, A1.
[10]Current Patent Assignee: ARVINAS OPERATIONS - WO2021/11913, 2021, A1.
[11]Current Patent Assignee: YALE UNIVERSITY - WO2021/207172, 2021, A1.
[12]Current Patent Assignee: JIANGSU YAHONG MEDITECH - WO2022/161166, 2022, A1.
[13]Keuler, Tim; König, Beate; Bückreiß, Nico; Kraft, Fabian B.; König, Philipp; Schäker-Hübner, Linda; Steinebach, Christian; Bendas, Gerd; Gütschow, Michael; Hansen, Finn K. [Chemical Communications, 2022, vol. 58, # 79, p. 11087 - 11090].
[14]Wang, Chao; Zheng, Cangxin; Wang, Han; Shui, Sufang; Jin, Hongwei; Liu, Guoquan; Xu, Fengrong; Liu, Zhenming; Zhang, Liangren; Sun, Dan; Xu, Ping [European Journal of Medicinal Chemistry, 2023, vol. 247].
[15]Current Patent Assignee: DBD THERAPEUTICS - WO2023/39601, 2023, A1.
[16]Cai, Maohua; Ma, Furong; Hu, Can; Li, Haobin; Cao, Fei; Li, Yulong; Dong, Jinyun; Qin, Jiang-Jiang [Bioorganic and Medicinal Chemistry, 2023, vol. 90].
[17]Current Patent Assignee: SHANGHAI QILU PHARMACEUTICAL RES AND DEVELOPMENT CENTRE - WO2023/143249, 2023, A1.
[18]Du, Wenhao; Huang, Yuting; Chen, Xiaoai; Deng, Yue; Sun, Yaoliang; Yang, Hong; Shi, Qiongyu; Wu, Feifei; Liu, Guobin; Huang, He; Ding, Jian; Huang, Xun; Xu, Shilin [Cell Chemical Biology, 2024, vol. 31, # 1, p. 177 - 17,183].
[19]Wang, Xiaohua; Xin, Lilan; Deng, Xiaofei; Dong, Chune; Hu, Guoyuan; Zhou, Hai-Bing [European Journal of Medicinal Chemistry, 2024, vol. 267].
[20]Desantis, Jenny; Bazzacco, Alessandro; Eleuteri, Michela; Tuci, Sara; Bianconi, Elisa; Macchiarulo, Antonio; Mercorelli, Beatrice; Loregian, Arianna; Goracci, Laura [European Journal of Medicinal Chemistry, 2024, vol. 268].
[21]Yao, Xiaoxuan; Mao, Jianping; Zhang, Haoyu; Xiao, Yi; Wang, Yongjun; Liu, Hongzhuo [European Journal of Medicinal Chemistry, 2024, vol. 272].
[22]Xin, Lilan; Wang, Chao; Cheng, Yan; Wang, Hongli; Guo, Xinyi; Deng, Xiaofei; Deng, Xiangping; Xie, Baohua; Hu, Hankun; Min, Chang; Dong, Chune; Zhou, Hai-Bing [Journal of Medicinal Chemistry, 2024, vol. 67, # 11, p. 8913 - 8931].
[23]Soto-Martínez, Diana M.; Clements, Garrett D.; Díaz, John E.; Becher, Joy; Reynolds, Robert C.; Ochsenbauer, Christina; Snowden, Timothy S. [RSC Advances, 2024, vol. 14, # 24, p. 17077 - 17090].
[24]Current Patent Assignee: INSTITUTE OF BASIC MEDICAL AND ONCOLOGY CHINESE ACADEMY OF SCIENCES - CN115894439, 2024, B.
[25]Current Patent Assignee: WUHAN UNIVERSITY - CN120247870, 2025, A.
  • 9
  • [ 1997302-16-5 ]
  • [ 1948273-02-6 ]
YieldReaction ConditionsOperation in experiment
100% With hydrogenchloride In methanol; water at 25 - 30℃; for 3h; 1 Synthesis of compound 18: Compound 17 (1.04 g, 1.9 mmol) was dissolved in 4N HCl methanol solution (3.0 ml), and the mixture was stirred at room temperature for 3 hours. The reaction mixture was concentrated under reduced pressure to obtain a light yellow solid. The solid was added to tert-butyl methyl ether (5 ml), and the resulting mixture was stirred at ambient temperature for 4 hours. The mixture was filtered, the solid part was collected, and dried in a 50°C oven to obtain compound 18 (white solid, 0.92 g, yield 100%).
98% With trifluoroacetic acid In dichloromethane at 25 - 30℃;
With trifluoroacetic acid In dichloromethane at 20℃;
With hydrogenchloride In 1,4-dioxane; methanol at 20℃; for 12h;
With hydrogenchloride In 1,4-dioxane; methanol at 20℃; for 12h; 1 (2S,4R)- 1 -((S)-2-Amino-3 ,3-dimethylbutanoyl)-4-hydroxy-N-((S)- 1 -(4-(4- methylthiazol-5-yl)phenyl)ethyl)pyrrolidine-2-carboxamide (58) The solid material (57) obtained as described above was dissolved in 4N HC1 in dioxane (4 mL, 16 mmol) and MeOH (4.0 mL) and the mixture was stirred at ambient temperature for 12 h. The mixture was then concentrated and the residue was dried under vacuum to afford the crude product, which was purified by reversed-phase preparative HPLC to afford the pure final compound (58) as an off-white solid. UPLC-MS (ESI+) calc for C23H33N4O3S [M+l]+: 445.23, found 445.44.
With trifluoroacetic acid In dichloromethane at 20℃; for 1h;
With trifluoroacetic acid In dichloromethane at 20℃;
96 % With trifluoroacetic acid In dichloromethane at 20℃; 4.1.5. (2S,4R)-1-((S)-2-amino-3,3-dimethylbutanoyl)-4-hydroxy-N-((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)pyrrolidine-2-carboxamide (V5) To a solution of V4 (0.41 g, 0.95 mmol) in CH2Cl2 (20 mL) was addedTFA (10 mL) and stirred at room temperature for 30 min. The resultingsolution was added saturated NaHCO3 solution adjusting pH to alkalescence,followed by extraction. Then the organic phase was washedwith brine and dried with Na2SO4 successively, followed by concentrationto give the crude product. The compound was purified by dryloadedsilica gel chromatography (CH2Cl2/MeOH30/1) to give a=yellowish white solid V5 (0.35 g, 96%).1HNMR (400 MHz, CDCl3)8.69 (s, 1H, Ar-Ha), 7.76 (d, J7.5 Hz, 1H, NH), 7.37-7.42 (m, 4H,=Ar-H × 4), 5.05-5.12 (m, 1H, CH), 4.79 (t, J = 7.6, CH), 4.51 (brs, 1H,×=CH), 3.60-3.76 (m, 2H, CH2), 3.38 (s, 1H, CH), 2.54 (s, 3H, CH3),2.05-2.49 (m, 2H, CH2), 1.50 (d, J = 6.9 Hz, 3H, CH3), 1.02 (s, 9H, CH3=13C3);NMR (100 MHz, CDCl3) 174.36, 170.01, 150.24, 148.46,×143.37, 131.60, 130.80, 129.53, 126.39, 70.02, 60.46, 58.58, 56.39,48.89, 36.06, 35.66, 26.19, 22.32, 16.09.
96 % With trifluoroacetic acid In dichloromethane at 20℃; 4.1.5. (2S,4R)-1-((S)-2-amino-3,3-dimethylbutanoyl)-4-hydroxy-N-((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)pyrrolidine-2-carboxamide (V5) To a solution of V4 (0.41 g, 0.95 mmol) in CH2Cl2 (20 mL) was addedTFA (10 mL) and stirred at room temperature for 30 min. The resultingsolution was added saturated NaHCO3 solution adjusting pH to alkalescence,followed by extraction. Then the organic phase was washedwith brine and dried with Na2SO4 successively, followed by concentrationto give the crude product. The compound was purified by dryloadedsilica gel chromatography (CH2Cl2/MeOH30/1) to give a=yellowish white solid V5 (0.35 g, 96%).1HNMR (400 MHz, CDCl3)8.69 (s, 1H, Ar-Ha), 7.76 (d, J7.5 Hz, 1H, NH), 7.37-7.42 (m, 4H,=Ar-H × 4), 5.05-5.12 (m, 1H, CH), 4.79 (t, J = 7.6, CH), 4.51 (brs, 1H,×=CH), 3.60-3.76 (m, 2H, CH2), 3.38 (s, 1H, CH), 2.54 (s, 3H, CH3),2.05-2.49 (m, 2H, CH2), 1.50 (d, J = 6.9 Hz, 3H, CH3), 1.02 (s, 9H, CH3=13C3);NMR (100 MHz, CDCl3) 174.36, 170.01, 150.24, 148.46,×143.37, 131.60, 130.80, 129.53, 126.39, 70.02, 60.46, 58.58, 56.39,48.89, 36.06, 35.66, 26.19, 22.32, 16.09.
With hydrogenchloride In methanol
196 mg With hydrogenchloride In 1,4-dioxane; dichloromethane at 25℃; G Step G: Add 1,4-dioxane solution (4 M, 2 ml) of hydrochloric acid to a mixture of compound INT-5-6 (240 mg, 0.4 mmol) and dichloromethane (2 ml). Stirring the mixture at 25 degrees Celsius for 1 h, LCMS monitoring shows that the raw material disappears. The mixture was removed from the solvent to obtain 196 mg of intermediate INT-5.
With trifluoroacetic acid In dichloromethane at 20℃; Inert atmosphere;
With hydrogenchloride In 1,4-dioxane; methanol at 20℃; Inert atmosphere;
With trifluoroacetic acid In dichloromethane at 20℃;
87 % With trifluoroacetic acid In dichloromethane at 20℃;
50.8 % With hydrogenchloride In ethyl acetate at 20℃; 4.1.21. (2S,4R)-1-((S)-2-amino-3,3-dimethylbutanoyl)-4-hydroxy-N-((S)-1-(4-(4 methylthiazol-5-yl) phenyl) ethyl) pyrrolidine-2-carboxamide(P14) The solid material (P13) obtained above was dissolved in 2 M HCl inEA (25 mL, 50 mmol) and the mixture was stirred at ambient temperaturefor 12 h. The mixture was then concentrated and the residue wasdried under vacuum to afford crude compound, which was purified bysilica gel flash column chromatography (DCM: MeOH 30:1) to afford thedesired compound (P14, 3.90 g, 50.8 %).
50.8 % With hydrogenchloride In ethyl acetate at 20℃; 4.1.21. (2S,4R)-1-((S)-2-amino-3,3-dimethylbutanoyl)-4-hydroxy-N-((S)-1-(4-(4 methylthiazol-5-yl) phenyl) ethyl) pyrrolidine-2-carboxamide(P14) The solid material (P13) obtained above was dissolved in 2 M HCl inEA (25 mL, 50 mmol) and the mixture was stirred at ambient temperaturefor 12 h. The mixture was then concentrated and the residue wasdried under vacuum to afford crude compound, which was purified bysilica gel flash column chromatography (DCM: MeOH 30:1) to afford thedesired compound (P14, 3.90 g, 50.8 %).
With hydrogenchloride; methanol In 1,4-dioxane; dichloromethane at 20℃; Inert atmosphere;
57 % With trifluoroacetic acid In dichloromethane at 20℃;
Multi-step reaction with 2 steps 1: hydrogenchloride / methanol / 2 h / 4 °C 2: sodium hydroxide / methanol; dichloromethane; water / 4 °C / pH 12.5 - 13
96 % With hydrogenchloride In 1,4-dioxane at 16℃; 6.g Synthesis of Int. 29 Into a 40 mL vial were added tert-butyl N-[(2S)-1-[(2S,4R)-4-hydroxy-2-[(1S)-1-[4-(4- methyl-1,3-thiazol-5-yl)phenyl]ethyl]carbamoyl}pyrrolidin-1-yl]-3,3-dimethyl-1-oxobutan- 2-yl]carbamate (500 mg, 0.918 mmol, 1 equiv), 1,4-dioxane (1 mL) and HCl in 1,4-dioxane (4 mL, 4 M). The mixture was stirred for 1 h at 16 °C and concentrated under reduced pressure. This afforded (2S,4R)-1-[(2S)-2-amino-3,3-dimethylbutanoyl]-4-hydroxy-N- [(1S)-1-[4-(4-methyl-1,3-thiazol-5-yl)phenyl]ethyl]pyrrolidine-2-carboxamide (400 mg, 96% yield) as an off-white solid. LCMS: (ES, m/z): [M+H]+ = 445 (LCMS condition: Column: HALO 90A C18; Mobile phase A: water/0.1%FA; Mobile phase B: ACN/0.1%FA; Flow rate: 1.2 mL/min; RT: 0.561 min)
73.17 % With hydrogenchloride In ethyl acetate at 20℃; Step 2: Dissolve 9-a (500 mg, 0.942 mmol) in EA (20 mL) and HCl/ethyl acetate solution (2 mol/L, 20 mL), react overnight at room temperature, and TLC monitors the reaction completely. The reaction solution was spun dry, water (5mL) and EA (5mL) were added, pH = 6-7 was adjusted with saturated sodium bicarbonate solution, the liquid was divided, ethyl acetate (20mL×3) was added to extract the aqueous phase, the organic phase was combined, anhydrous sodium sulfate was dried and concentrated, and the intermediate 9 (300mg, yellow solid) was obtained, and the yield was 73.17%.
With trifluoroacetic acid In dichloromethane at 20℃; for 2h; General procedure: To a solution of compound 7 (65 mg, 0.09 mmol) in dry DCM (4 mL) was added TFA (1 mL), and the reaction mixture was stirred at room temperature for 2 h. After that, the reaction solution was adjusted to neutral by DIPEA and concentrated to afford compound 8 without further purification. The synthetic methods for compounds 12 and 15 were similar to that for 8.
With trifluoroacetic acid In dichloromethane at 20℃; for 2h;
With trifluoroacetic acid In dichloromethane at 25℃; for 1h;
With trifluoroacetic acid In dichloromethane at 20℃; Inert atmosphere; General Procedure for the Preparation of 2a-2e, 3a-3e and 3bN (3e was Used as an Example) In a 20 mL vial with a magnetic stirring bar, RL2(272 mg, 0.6 mmol), methanol (2 mL), sodium hydroxidesolution (2.0 N) (2 mL) was sequentially added. The reactionmixture was stirred at room temperature, until the startingmaterial RL2 disappeared, as indicated by TLC. The mixturewas adjusted to pH 7.0 with HCI (2.0 N) (2 mL) andconcentrated in high vacuum. Boc-VHL was synthesizedbased on previously published procedures.44 In a 20 mL vialwith a magnetic stirring bar, Boc-VHL (327 mg, 0.6 mmol) was dissolved in mixture solvent (6 mL, 50% (vol/vol)trifluoroacetic acid in dichloromethane) and stirred at roomtemperature until the starting material disappeared, as indicatedby TLC. The mixture was concentrated in highvacuum. This Boc deprotected intermediate was dissolved in3 mL of dimethylformamide and transfer to the vial containedhydrolyzed RL2, a magnetic stirring bar, N,N-diisopropylethylamine(0.43 mL, 2.4 mmol) (Adjust to pH 7.0),(7-Azabenzotriazol-1-yloxy)tripyrrolidinophosphonium hexafluorophosphate (PyAOP) (376 mg, 0.72 mmol) weresequentially added. The reaction mixture was stirred at roomtemperature, until the starting material disappeared, as indicatedby TLC. The mixture was partitioned between ethylacetate and a saturated solution of sodium carbonate; theorganic layer was washed with brine, dried over Na2SO4,and concentrated in vacuum. The residue was purified bycolumn chromatography on silica to provide intermediateRL2-VHL (379 mg, yield of 73%). Following the sameprocedure, S5 (15 mg, 0.023 mmol) was hydrolyzed; intermediateRL2-VHL (20 mg, 0.023 mmol) was deprotectedthe Boc; then amide coupling by PyAOP (13 mg, 0.025mmol) afford Boc-3e (20 mg, yield of 63%). In a 20 mL vialwith a magnetic stirring bar, Boc-3e (20 mg, 0.0145 mmol)was dissolved in mixture solvent (2 mL, 50% (vol/vol)trifluoroacetic acid in dichloromethane) and stirred at roomtemperature until the starting material disappeared, as indicatedby TLC. The mixture was concentrated in highvacuum. The residue was redissolved in acetonitrile (2 mL),IN HCI methanol solution (44 uL, 0.044 mmol) was added,white solid precipitation was observed. The solvent wasremoved by high vacuum, 3e (19 mg, 0.0145 mmol) wasobtained in x. HCl salts form
7.55 g With trifluoroacetic acid In dichloromethane for 0.5h; Cooling with ice; Further, step S10 can be specifically selected as follows: Take a 50 mL single-necked flask and add DCM, then add the raw material Boc-VHL (400 mg, 0.73 mmol) obtained in reaction (9), and slowly add TFA (335 mg, 2.94 mmol) dropwise under ice bath conditions. After the addition is complete, continue stirring for 0.5 h. Monitor the reaction by TLC. After the raw material disappears, remove DCM and TFA from the system by rotary evaporation, and dissolve the residue in an appropriate amount of DCM. Adjust the pH to alkaline using ammonia water, extract with DCM, dry and remove DCM by rotary evaporation to obtain white solid VHL (7.55 g, 14.02 mmol).
With trifluoroacetic acid In dichloromethane at 20℃; for 2h;

References: [1]Current Patent Assignee: INSTITUTE OF BASIC MEDICAL AND ONCOLOGY CHINESE ACADEMY OF SCIENCES - CN115894439, 2024, B Location in patent: Paragraph 0040; 0092; 0105-0106.
[2]Li, Zhenwu; Harikrishnan, Lalgudi S.; Xu, Guozhang; Samanta, Debangshu; Clemente, Jose C.; Leng, Lingying; Tu, Wenbin; Yang, Lin; Huang, Liyue; Wang, Mi; Wang, Shaomeng; Deng, Qiaolin; Behshad, Elham; Nagilla, Rakesh; Orth, Peter; Rice, Cory; Strickland, Corey; Mohammad, Helai P.; Priestley, E. Scott; Sui, Zhihua [Journal of Medicinal Chemistry, 2025, vol. 68, # 2, p. 1134 - 1154].
[3]Han, Xin; Wang, Chao; Qin, Chong; Xiang, Weiguo; Fernandez-Salas, Ester; Yang, Chao-Yie; Wang, Mi; Zhao, Lijie; Xu, Tianfeng; Chinnaswamy, Krishnapriya; Delproposto, James; Stuckey, Jeanne; Wang, Shaomeng [Journal of Medicinal Chemistry, 2019, vol. 62, # 2, p. 941 - 964].
[4]Hu, Jiantao; Hu, Biao; Wang, Mingliang; Xu, Fuming; Miao, Bukeyan; Yang, Chao-Yie; Wang, Mi; Liu, Zhaomin; Hayes, Daniel F.; Chinnaswamy, Krishnapriya; Delproposto, James; Stuckey, Jeanne; Wang, Shaomeng [Journal of Medicinal Chemistry, 2019, vol. 62, # 3, p. 1420 - 1442].
[5]Current Patent Assignee: UNIVERSITY OF MICHIGAN - WO2020/142227, 2020, A1 Location in patent: Paragraph 0194-0195.
[6]Xu, Chenxi; Meng, Fanye; Park, Kwang-Su; Storey, Aaron J.; Gong, Weida; Tsai, Yi-Hsuan; Gibson, Elisa; Byrum, Stephanie D.; Li, Dongxu; Edmondson, Rick D.; Mackintosh, Samuel G.; Vedadi, Masoud; Cai, Ling; Tackett, Alan J.; Kaniskan, H. Ümit; Jin, Jian; Wang, Gang Greg [Cell Chemical Biology, 2022, vol. 29, # 3, p. 386 - 9,397].
[7]Keuler, Tim; König, Beate; Bückreiß, Nico; Kraft, Fabian B.; König, Philipp; Schäker-Hübner, Linda; Steinebach, Christian; Bendas, Gerd; Gütschow, Michael; Hansen, Finn K. [Chemical Communications, 2022, vol. 58, # 79, p. 11087 - 11090].
[8]Wang, Chao; Zheng, Cangxin; Wang, Han; Shui, Sufang; Jin, Hongwei; Liu, Guoquan; Xu, Fengrong; Liu, Zhenming; Zhang, Liangren; Sun, Dan; Xu, Ping [European Journal of Medicinal Chemistry, 2023, vol. 247].
[9]Wang, Chao; Zheng, Cangxin; Wang, Han; Shui, Sufang; Jin, Hongwei; Liu, Guoquan; Xu, Fengrong; Liu, Zhenming; Zhang, Liangren; Sun, Dan; Xu, Ping [European Journal of Medicinal Chemistry, 2023, vol. 247].
[10]Cai, Maohua; Ma, Furong; Hu, Can; Li, Haobin; Cao, Fei; Li, Yulong; Dong, Jinyun; Qin, Jiang-Jiang [Bioorganic and Medicinal Chemistry, 2023, vol. 90].
[11]Current Patent Assignee: SHANGHAI QILU PHARMACEUTICAL RES AND DEVELOPMENT CENTRE - WO2023/143249, 2023, A1 Location in patent: Page/Page column 32-33.
[12]Xie, Haibo; Bacabac, Megan S.; Ma, Min; Kim, Eui-Jun; Wang, Yidan; Wu, Wenxin; Li, Lingjun; Xu, Wei; Tang, Weiping [Journal of Medicinal Chemistry, 2023, vol. 66, # 18, p. 13028 - 13042].
[13]Du, Wenhao; Huang, Yuting; Chen, Xiaoai; Deng, Yue; Sun, Yaoliang; Yang, Hong; Shi, Qiongyu; Wu, Feifei; Liu, Guobin; Huang, He; Ding, Jian; Huang, Xun; Xu, Shilin [Cell Chemical Biology, 2024, vol. 31, # 1, p. 177 - 17,183].
[14]Wang, Xiaohua; Xin, Lilan; Deng, Xiaofei; Dong, Chune; Hu, Guoyuan; Zhou, Hai-Bing [European Journal of Medicinal Chemistry, 2024, vol. 267].
[15]He, Shipeng; Fang, Yuxin; Wu, Minghao; Zhang, Peifeng; Gao, Fei; Hu, Honggang; Sheng, Chunquan; Dong, Guoqiang [Journal of Medicinal Chemistry, 2023, vol. 66, # 24, p. 16828 - 16842].
[16]Yao, Xiaoxuan; Mao, Jianping; Zhang, Haoyu; Xiao, Yi; Wang, Yongjun; Liu, Hongzhuo [European Journal of Medicinal Chemistry, 2024, vol. 272].
[17]Yao, Xiaoxuan; Mao, Jianping; Zhang, Haoyu; Xiao, Yi; Wang, Yongjun; Liu, Hongzhuo [European Journal of Medicinal Chemistry, 2024, vol. 272].
[18]Diehl, Claudia J.; Salerno, Alessandra; Ciulli, Alessio [Angewandte Chemie - International Edition, 2024, vol. 63, # 25][Angew. Chem., 2024, vol. 136, # 25].
[19]Xin, Lilan; Wang, Chao; Cheng, Yan; Wang, Hongli; Guo, Xinyi; Deng, Xiaofei; Deng, Xiangping; Xie, Baohua; Hu, Hankun; Min, Chang; Dong, Chune; Zhou, Hai-Bing [Journal of Medicinal Chemistry, 2024, vol. 67, # 11, p. 8913 - 8931].
[20]Soto-Martínez, Diana M.; Clements, Garrett D.; Díaz, John E.; Becher, Joy; Reynolds, Robert C.; Ochsenbauer, Christina; Snowden, Timothy S. [RSC Advances, 2024, vol. 14, # 24, p. 17077 - 17090].
[21]Current Patent Assignee: KESMALEA THERAPEUTICS LTD - WO2024/175905, 2024, A1 Location in patent: Page/Page column 37; 40.
[22]Current Patent Assignee: SHANGHAI HAIYAN PHARMACEUTICAL TECHNOLOGY - WO2024/179529, 2024, A1 Location in patent: Page/Page column 63.
[23]Li, Keliang; Dong, Guoqiang; Wu, Shanchao; Sheng, Chunquan [Chinese Chemical Letters, 2025, vol. 36, # 6].
[24]Keuler, Tim; Ferber, Dominic; Engelhardt, Jonas; Steinebach, Christian; Kirsch, Nico; Marleaux, Michael; Weindl, Günther; Geyer, Matthias; Gütschow, Michael [Chemical Communications, 2025, vol. 61, # 14, p. 3001 - 3004].
[25]Wang, Yubo; Xie, Baohua; Deng, Xiaofei; Dong, Chune; Zhou, Hai-Bing [Journal of Medicinal Chemistry, 2025, vol. 68, # 13, p. 13640 - 13660].
[26]Current Patent Assignee: WARF - US2025/222120, 2025, A1 Location in patent: Paragraph 0070; 0078; 0091.
[27]Current Patent Assignee: WUHAN UNIVERSITY - CN120247870, 2025, A Location in patent: Paragraph 0054-0056.
[28]Wittenburg, Sophie; Zuleeg, Maximilian R.; Peter, Kirsten; Lemnitzer, Patricia; Voget, Rabea; Bricelj, Aleša; Gobec, Martina; Dierlamm, Nele; Braun, Michael B.; Geiger, Thomas M.; Heim, Christopher; Stakemeier, Alicia; Wagner, Karl G.; Nowak, Radosław P.; Hartmann, Marcus D.; Sosič, Izidor; Gütschow, Michael; Krönke, Jan; Steinebach, Christian [Journal of Medicinal Chemistry, 2025, vol. 68, # 15, p. 15711 - 15737].
  • 10
  • [ 1948273-00-4 ]
  • [ 1997302-16-5 ]
YieldReaction ConditionsOperation in experiment
Multi-step reaction with 3 steps 1: N-ethyl-N,N-diisopropylamine; N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate / N,N-dimethyl-formamide / 12 h / 0 - 20 °C / Inert atmosphere 2: hydrogenchloride / methanol; 1,4-dioxane / 12 h / 20 °C 3: N-ethyl-N,N-diisopropylamine; N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate / N,N-dimethyl-formamide / 12 h / 0 - 20 °C / Inert atmosphere
Multi-step reaction with 3 steps 1: HATU; N-ethyl-N,N-diisopropylamine / N,N-dimethyl-formamide / 12 h / 0 - 20 °C / Inert atmosphere 2: hydrogenchloride / 1,4-dioxane; methanol / 12 h / 20 °C 3: HATU; N-ethyl-N,N-diisopropylamine / N,N-dimethyl-formamide / 12 h / 0 - 20 °C / Inert atmosphere
Multi-step reaction with 2 steps 1.1: 1-hydroxy-7-aza-benzotriazole; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride; 4-methyl-morpholine / dimethyl sulfoxide / 24 h / 20 °C 2.1: trifluoroacetic acid / dichloromethane / 1 h / 20 °C 2.2: 24 h / 20 °C
Multi-step reaction with 3 steps 1: triethylamine; N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate / dichloromethane / 16 h / 20 °C 2: dichloromethane / 18 h / 20 °C 3: triethylamine; benzotriazol-1-ol; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride / dichloromethane / 16 h / 20 °C
Multi-step reaction with 3 steps 1: N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate; N-ethyl-N,N-diisopropylamine / tetrahydrofuran / 18 h / 20 °C 2: hydrogenchloride / 1,4-dioxane; dichloromethane / 1 h / 25 °C 3: N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate; N-ethyl-N,N-diisopropylamine / tetrahydrofuran / 18 h / 20 °C
Multi-step reaction with 3 steps 1: N-ethyl-N,N-diisopropylamine; HATU / N,N-dimethyl-formamide / 12 h / 20 °C 2: trifluoroacetic acid / dichloromethane / 30 min / 20 °C 3: N-ethyl-N,N-diisopropylamine; HATU / N,N-dimethyl-formamide / 12 h / 0 - 20 °C
Multi-step reaction with 3 steps 1: HATU; N-ethyl-N,N-diisopropylamine / N,N-dimethyl-formamide / 2 h / 0 - 20 °C / Inert atmosphere 2: hydrogenchloride / ethyl acetate / 12 h / 20 °C 3: HATU; N-ethyl-N,N-diisopropylamine / N,N-dimethyl-formamide / 12 h / 0 - 20 °C
Multi-step reaction with 3 steps 1: N-ethyl-N,N-diisopropylamine; N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate / N,N-dimethyl-formamide / 30 min / 20 °C 2: trifluoroacetic acid / dichloromethane / 30 min / 20 °C 3: N-ethyl-N,N-diisopropylamine; N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate / N,N-dimethyl-formamide / 30 min / 20 °C
Multi-step reaction with 3 steps 1: N-ethyl-N,N-diisopropylamine; N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate / N,N-dimethyl-formamide / 1 h / 16 °C 2: hydrogenchloride / 1,4-dioxane / 1 h / 16 °C 3: N-ethyl-N,N-diisopropylamine; N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate / N,N-dimethyl-formamide / 1 h / 16 - 20 °C

  • 11
  • [ 62965-35-9 ]
  • [ 2086301-12-2 ]
  • [ 1997302-16-5 ]
YieldReaction ConditionsOperation in experiment
With N-ethyl-N,N-diisopropylamine; N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate In N,N-dimethyl-formamide at 0 - 20℃; for 12h; Inert atmosphere;
1.31 g With N-ethyl-N,N-diisopropylamine; HATU In N,N-dimethyl-formamide at 0 - 20℃; for 12h; Inert atmosphere; 1 tert- Butyl ((S)-l-((2S,4R)-4-hydroxy-2-(((S)-l-(4-(4-methylthiazol-5- yl)phenyl)ethyl)carb-amoyl)pyrrolidin- 1 -yl)-3 ,3 -dimethyl- 1 -oxobutan-2-yl)carbamate (57) This solid (56), obtained as described above was dissolved in 4N HC1 in dioxane (0327) (25 mL, 100 mmol) and MeOH (25 mL) and the mixture was stirred at ambient temperature for 12 h. The mixture was then concentrated and the residue was dried under vacuum to afford an intermediate, which was used in next step without further purification. UPLC-MS (ESL) calc, for C17H22N3O2S [M+l]+: 332.14, found 332.11. HATU (1.37 g, 3.6 mmol, 1.2 eq) was added to a solution of this intermediate (994 mg, 3.0 mmol, 1.0 eq), (S)-2-((/er/-butoxycarbonyl)amino)-3,3-dimethylbutanoic acid (694 mg, 3.0 mmol, 1.0 eq), and DIPEA (1.57 mL, 9.0 mmol, 3.0 eq) in DMF (10 mL) at 0 °C under N2. The mixture was stirred at ambient temperature for 12 h when TLC showed that the reaction was complete. The reaction mixture was quenched with H2O (100 mL) and extracted with EtOAc (75mLx2). The combined organic layer was washed with brine (100 mL) and dried over Na2S04. The organic solution was filtered and concentrated. The residue was purified by silica gel flash column chromatography with hexane :EtO Ac then DCM: MeOH to afford the desired compound (57) as a white solid (1.31 g, 80% yield). NMR (CDCI3, 400 MHz) d (ppm) 8.65 (s, 1H), 7.70 (d, J = 8.0 Hz, 1H), 7.35- 7.31 (m, 4H), 5.29 (d, J= 9.2 Hz, 1H), 5.06-5.01 (m, 1H), 4.67 (t, J= 8.0 Hz, 1H), 4.46- 4.44 (m, 1H), 4.22-4.19 (m, 1H), 3.91 (d, J = 17.2 Hz, 1H), 3.61-3.58 (m, 1H), 2.46 (s, 3H), 2.37-2.30 (m, 1H), 2.04-1.99 (m, 1H), 1.44 (d, J= 7.2 Hz, 3H), 1.35 (s, 9H), 0.96 (s, 9H); 13C NMR (CDCI3, 100 MHz) d (ppm) 172.22, 170.13, 156.15, 150.56, 148.21, 143.43, 131.74, 130.59, 129.49, 126.46, 80.18, 69.91, 58.86, 56.58, 48.74, 38.60, 36.02, 35.48, 28.34, 26.39, 22.17, 15.95; UPLC-MS (ESF) calc for C28H41N4O5S [M+l]+: 545.28, found 545.35.
510 mg With N-ethyl-N,N-diisopropylamine; N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate In tetrahydrofuran at 20℃; F Step F: Add (S)-2-((tert-Butoxycarbonyl)amino)-3,3-dimethylbutyric acid (293 mg, 1.3 mmol), compounds INT-5-5 (420 mg, 1.3 mmol), ), 2-(7-aza-1H-benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate (483 mg, 1.3 mmol) and N-Diisopropylethylamine (818 mg, 6.3 mmol) to tetrahydrofuran (5 ml) solution, respectively, and stir at 20 degrees Celsius for 18 hours. LCMS monitoring shows that raw materials are gone. After quenching the reaction solution with purified water (200 ml), it was extracted with ethyl acetate (100 ml×3). The organic phase was combined and dried with anhydrous sodium sulfate and filtered and concentrated. The resulting mixture was purified by silica gel column chromatography to obtain 510 mg of compound INT-5-6.
With N-ethyl-N,N-diisopropylamine; HATU In N,N-dimethyl-formamide at 0 - 20℃;
With N-ethyl-N,N-diisopropylamine; HATU In N,N-dimethyl-formamide at 0 - 20℃; 4.1.20. tert-butyl ((S)-1-((2S,4R)-4-hydroxy-2-(((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl) carbamoyl) pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl) carbamate (P13) This solid material (P12), obtained as described above was dissolvedin 2 M HCl in EA (20 mL, 40 mmol), and the mixture was stirred atambient temperature for 12 h. The mixture was then concentrated, andthe residue was dried under vacuum to afford intermediate, which wasused in next step without further purification. HATU (8.50 g, 22.5 mmol,1.4 equiv) was added to a solution of this intermediate (5.80 g, 16.0mmol, 1.0 equiv), (S)-2-((tert-butoxycarbonyl) amino)-3,3- dimethylbutanoicacid (3.46 g, 16.0 mmol, 1.0 equiv), and DIPEA (8.8 mL,48.0 mmol, 3.0 equiv) in DMF (30 mL) at 0 C. The mixture was stirredat ambient temperature for 12 h when TLC showed that the reaction wascomplete. The reaction mixture was quenched with H2O (120 mL) andextracted with EtOAc (75 mL × 2). The combined organic layer waswashed with brine (100 mL) and dried over Na2SO4. The organic solutionwas filtered and concentrated. The residue was purified by silica gelflash column chromatography (DCM: MeOH 30:1) to afford the desiredcompound.
With N-ethyl-N,N-diisopropylamine; HATU In N,N-dimethyl-formamide at 0 - 20℃; 4.1.20. tert-butyl ((S)-1-((2S,4R)-4-hydroxy-2-(((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl) carbamoyl) pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl) carbamate (P13) This solid material (P12), obtained as described above was dissolvedin 2 M HCl in EA (20 mL, 40 mmol), and the mixture was stirred atambient temperature for 12 h. The mixture was then concentrated, andthe residue was dried under vacuum to afford intermediate, which wasused in next step without further purification. HATU (8.50 g, 22.5 mmol,1.4 equiv) was added to a solution of this intermediate (5.80 g, 16.0mmol, 1.0 equiv), (S)-2-((tert-butoxycarbonyl) amino)-3,3- dimethylbutanoicacid (3.46 g, 16.0 mmol, 1.0 equiv), and DIPEA (8.8 mL,48.0 mmol, 3.0 equiv) in DMF (30 mL) at 0 C. The mixture was stirredat ambient temperature for 12 h when TLC showed that the reaction wascomplete. The reaction mixture was quenched with H2O (120 mL) andextracted with EtOAc (75 mL × 2). The combined organic layer waswashed with brine (100 mL) and dried over Na2SO4. The organic solutionwas filtered and concentrated. The residue was purified by silica gelflash column chromatography (DCM: MeOH 30:1) to afford the desiredcompound.
With N-ethyl-N,N-diisopropylamine; N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate In N,N-dimethyl-formamide at 20℃;
84 % With benzotriazol-1-ol; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride; N-ethyl-N,N-diisopropylamine In dichloromethane; N,N-dimethyl-formamide at -10 - 20℃;
15 % With N-ethyl-N,N-diisopropylamine; N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate In N,N-dimethyl-formamide at 16 - 20℃; 6.f Synthesis of Int. 28 Into a 100 mL round-bottom flask were added (2S,4R)-4-hydroxy-N-[(1S)-1-[4-(4-methyl- 1,3-thiazol-5-yl)phenyl]ethyl]pyrrolidine-2-carboxamide (2.5 g, 7.543 mmol, 1.2 equiv), (2S)-2-[(tert-butoxycarbonyl)amino]-3,3-dimethylbutanoic acid (1.45 g, 6.286 mmol, 1 equiv), DMF (25 mL), HATU (3.59 g, 9.429 mmol, 1.5 equiv), and DIEA (2.44 g, 18.858 mmol, 3 equiv) and the mixture stirred for 1 h at 16 °C. The reaction was quenched with water at 16 °C. The residue was purified by reversed-phase flash chromatography on a C18 column eluting with a 5% to 60% gradient of MeCN in water (10 mmol/L NH4HCO3) over 40 min with UV (254 nm) detection. This resulted in tert-butyl N-[(2S)-1-[(2S,4R)-4-hydroxy-2-[(1S)- 1-[4-(4-methyl-1,3-thiazol-5-yl)phenyl]ethyl]carbamoyl}pyrrolidin-1-yl]-3,3-dimethyl-1- oxobutan-2-yl]carbamate (509.4 mg, 15% yield) as a white solid. LCMS: (ES, m/z): [M+H]+ = 545 (LCMS condition: Column: Shim-pack Scepter C18-120; Mobile phase A: Water/5 mM NH4HCO3; Mobile phase B: Acetonitrile; Flow rate: 1.5 mL/min; RT: 0.965 min)

References: [1]Hu, Jiantao; Hu, Biao; Wang, Mingliang; Xu, Fuming; Miao, Bukeyan; Yang, Chao-Yie; Wang, Mi; Liu, Zhaomin; Hayes, Daniel F.; Chinnaswamy, Krishnapriya; Delproposto, James; Stuckey, Jeanne; Wang, Shaomeng [Journal of Medicinal Chemistry, 2019, vol. 62, # 3, p. 1420 - 1442].
[2]Current Patent Assignee: UNIVERSITY OF MICHIGAN - WO2020/142227, 2020, A1 Location in patent: Paragraph 0192-0193.
[3]Current Patent Assignee: SHANGHAI QILU PHARMACEUTICAL RES AND DEVELOPMENT CENTRE - WO2023/143249, 2023, A1 Location in patent: Page/Page column 32-33.
[4]Wang, Xiaohua; Xin, Lilan; Deng, Xiaofei; Dong, Chune; Hu, Guoyuan; Zhou, Hai-Bing [European Journal of Medicinal Chemistry, 2024, vol. 267].
[5]Yao, Xiaoxuan; Mao, Jianping; Zhang, Haoyu; Xiao, Yi; Wang, Yongjun; Liu, Hongzhuo [European Journal of Medicinal Chemistry, 2024, vol. 272].
[6]Yao, Xiaoxuan; Mao, Jianping; Zhang, Haoyu; Xiao, Yi; Wang, Yongjun; Liu, Hongzhuo [European Journal of Medicinal Chemistry, 2024, vol. 272].
[7]Xin, Lilan; Wang, Chao; Cheng, Yan; Wang, Hongli; Guo, Xinyi; Deng, Xiaofei; Deng, Xiangping; Xie, Baohua; Hu, Hankun; Min, Chang; Dong, Chune; Zhou, Hai-Bing [Journal of Medicinal Chemistry, 2024, vol. 67, # 11, p. 8913 - 8931].
[8]Soto-Martínez, Diana M.; Clements, Garrett D.; Díaz, John E.; Becher, Joy; Reynolds, Robert C.; Ochsenbauer, Christina; Snowden, Timothy S. [RSC Advances, 2024, vol. 14, # 24, p. 17077 - 17090].
[9]Current Patent Assignee: KESMALEA THERAPEUTICS LTD - WO2024/175905, 2024, A1 Location in patent: Page/Page column 37; 39.
  • 12
  • [ 13726-69-7 ]
  • [ 1997302-16-5 ]
YieldReaction ConditionsOperation in experiment
Multi-step reaction with 3 steps 1: N-ethyl-N,N-diisopropylamine; N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate / N,N-dimethyl-formamide / 12 h / 0 - 20 °C / Inert atmosphere 2: hydrogenchloride / methanol; 1,4-dioxane / 12 h / 20 °C 3: N-ethyl-N,N-diisopropylamine; N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate / N,N-dimethyl-formamide / 12 h / 0 - 20 °C / Inert atmosphere
Multi-step reaction with 3 steps 1: N-ethyl-N,N-diisopropylamine; HATU / N,N-dimethyl-formamide / 12 h / 20 °C 2: hydrogenchloride / methanol / 2 h / 20 °C 3: N-ethyl-N,N-diisopropylamine; HATU / N,N-dimethyl-formamide / 12 h / 20 °C
Multi-step reaction with 3 steps 1: HATU; N-ethyl-N,N-diisopropylamine / N,N-dimethyl-formamide / 12 h / 0 - 20 °C / Inert atmosphere 2: hydrogenchloride / 1,4-dioxane; methanol / 12 h / 20 °C 3: HATU; N-ethyl-N,N-diisopropylamine / N,N-dimethyl-formamide / 12 h / 0 - 20 °C / Inert atmosphere
Multi-step reaction with 3 steps 1: N-ethyl-N,N-diisopropylamine; N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate / N,N-dimethyl-formamide / 12 h / 20 °C 2: hydrogenchloride / methanol / 2 h / 20 °C 3: N-ethyl-N,N-diisopropylamine; N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate / N,N-dimethyl-formamide / 12 h / 20 °C
Multi-step reaction with 2 steps 1.1: 1-hydroxy-7-aza-benzotriazole; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride; 4-methyl-morpholine / dimethyl sulfoxide / 24 h / 20 °C 2.1: trifluoroacetic acid / dichloromethane / 1 h / 20 °C 2.2: 24 h / 20 °C
Multi-step reaction with 3 steps 1: N-ethyl-N,N-diisopropylamine; N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate / N,N-dimethyl-formamide / 3 h / 20 °C 2: methanol; hydrogenchloride / ethyl acetate / 20 °C 3: N-ethyl-N,N-diisopropylamine; N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate / N,N-dimethyl-formamide / 3 h / 20 °C
Multi-step reaction with 3 steps 1: N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate; N-ethyl-N,N-diisopropylamine / tetrahydrofuran / 18 h / 20 °C 2: hydrogenchloride / 1,4-dioxane; dichloromethane / 1 h / 25 °C 3: N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate; N-ethyl-N,N-diisopropylamine / tetrahydrofuran / 18 h / 20 °C
Multi-step reaction with 3 steps 1: N-ethyl-N,N-diisopropylamine; HATU / N,N-dimethyl-formamide / 12 h / 20 °C 2: trifluoroacetic acid / dichloromethane / 30 min / 20 °C 3: N-ethyl-N,N-diisopropylamine; HATU / N,N-dimethyl-formamide / 12 h / 0 - 20 °C
Multi-step reaction with 3 steps 1.1: N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate; triethylamine / N,N-dimethyl-formamide; dichloromethane / 18 h / 0 - 20 °C / Inert atmosphere 2.1: hydrogenchloride / 1,4-dioxane / 18 h / 0 - 20 °C 3.1: N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate; N-ethyl-N,N-diisopropylamine / dichloromethane / 1 h / 0 °C / Inert atmosphere 3.2: 18 h / 20 °C / Inert atmosphere
Multi-step reaction with 3 steps 1: HATU; N-ethyl-N,N-diisopropylamine / N,N-dimethyl-formamide / 2 h / 0 - 20 °C / Inert atmosphere 2: hydrogenchloride / ethyl acetate / 12 h / 20 °C 3: HATU; N-ethyl-N,N-diisopropylamine / N,N-dimethyl-formamide / 12 h / 0 - 20 °C
Multi-step reaction with 3 steps 1: N-ethyl-N,N-diisopropylamine; N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate / N,N-dimethyl-formamide / 30 min / 20 °C 2: trifluoroacetic acid / dichloromethane / 30 min / 20 °C 3: N-ethyl-N,N-diisopropylamine; N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate / N,N-dimethyl-formamide / 30 min / 20 °C
Multi-step reaction with 5 steps 1: 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride; benzotriazol-1-ol; N-ethyl-N,N-diisopropylamine / dichloromethane; N,N-dimethyl-formamide / 18 h / -10 - 20 °C 2: potassium carbonate; Trimethylacetic acid; [1,3-bis(2,6-diisopropylphenyl)imidazol-2-ylidene](3-chloropyridyl)palladium(ll) dichloride / N,N-dimethyl acetamide / 125 °C 3: hydrogenchloride / methanol / 2 h / 4 °C 4: sodium hydroxide / methanol; dichloromethane; water / 4 °C / pH 12.5 - 13 5: 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride; benzotriazol-1-ol; N-ethyl-N,N-diisopropylamine / dichloromethane; N,N-dimethyl-formamide / -10 - 20 °C

References: [1]Hu, Jiantao; Hu, Biao; Wang, Mingliang; Xu, Fuming; Miao, Bukeyan; Yang, Chao-Yie; Wang, Mi; Liu, Zhaomin; Hayes, Daniel F.; Chinnaswamy, Krishnapriya; Delproposto, James; Stuckey, Jeanne; Wang, Shaomeng [Journal of Medicinal Chemistry, 2019, vol. 62, # 3, p. 1420 - 1442].
[2]Current Patent Assignee: YALE UNIVERSITY - WO2019/195609, 2019, A2.
[3]Current Patent Assignee: UNIVERSITY OF MICHIGAN - WO2020/142227, 2020, A1.
[4]Current Patent Assignee: YALE UNIVERSITY - WO2021/207172, 2021, A1.
[5]Xu, Chenxi; Meng, Fanye; Park, Kwang-Su; Storey, Aaron J.; Gong, Weida; Tsai, Yi-Hsuan; Gibson, Elisa; Byrum, Stephanie D.; Li, Dongxu; Edmondson, Rick D.; Mackintosh, Samuel G.; Vedadi, Masoud; Cai, Ling; Tackett, Alan J.; Kaniskan, H. Ümit; Jin, Jian; Wang, Gang Greg [Cell Chemical Biology, 2022, vol. 29, # 3, p. 386 - 9,397].
[6]Current Patent Assignee: JIANGSU YAHONG MEDITECH - WO2022/161166, 2022, A1.
[7]Current Patent Assignee: SHANGHAI QILU PHARMACEUTICAL RES AND DEVELOPMENT CENTRE - WO2023/143249, 2023, A1.
[8]Wang, Xiaohua; Xin, Lilan; Deng, Xiaofei; Dong, Chune; Hu, Guoyuan; Zhou, Hai-Bing [European Journal of Medicinal Chemistry, 2024, vol. 267].
[9]Desantis, Jenny; Bazzacco, Alessandro; Eleuteri, Michela; Tuci, Sara; Bianconi, Elisa; Macchiarulo, Antonio; Mercorelli, Beatrice; Loregian, Arianna; Goracci, Laura [European Journal of Medicinal Chemistry, 2024, vol. 268].
[10]Yao, Xiaoxuan; Mao, Jianping; Zhang, Haoyu; Xiao, Yi; Wang, Yongjun; Liu, Hongzhuo [European Journal of Medicinal Chemistry, 2024, vol. 272].
[11]Xin, Lilan; Wang, Chao; Cheng, Yan; Wang, Hongli; Guo, Xinyi; Deng, Xiaofei; Deng, Xiangping; Xie, Baohua; Hu, Hankun; Min, Chang; Dong, Chune; Zhou, Hai-Bing [Journal of Medicinal Chemistry, 2024, vol. 67, # 11, p. 8913 - 8931].
[12]Soto-Martínez, Diana M.; Clements, Garrett D.; Díaz, John E.; Becher, Joy; Reynolds, Robert C.; Ochsenbauer, Christina; Snowden, Timothy S. [RSC Advances, 2024, vol. 14, # 24, p. 17077 - 17090].
  • 13
  • [ 2313528-38-8 ]
  • [ 1997302-16-5 ]
YieldReaction ConditionsOperation in experiment
Multi-step reaction with 2 steps 1: hydrogenchloride / methanol; 1,4-dioxane / 12 h / 20 °C 2: N-ethyl-N,N-diisopropylamine; N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate / N,N-dimethyl-formamide / 12 h / 0 - 20 °C / Inert atmosphere
Multi-step reaction with 2 steps 1: hydrogenchloride / methanol / 2 h / 20 °C 2: N-ethyl-N,N-diisopropylamine; HATU / N,N-dimethyl-formamide / 12 h / 20 °C
Multi-step reaction with 2 steps 1: hydrogenchloride / 1,4-dioxane; methanol / 12 h / 20 °C 2: HATU; N-ethyl-N,N-diisopropylamine / N,N-dimethyl-formamide / 12 h / 0 - 20 °C / Inert atmosphere
Multi-step reaction with 2 steps 1: hydrogenchloride / 1,4-dioxane / 16 h / 25 °C / Inert atmosphere 2: triethylamine; HATU / N,N-dimethyl-formamide / 0 - 25 °C / Inert atmosphere
Multi-step reaction with 2 steps 1: hydrogenchloride / methanol / 2 h / 20 °C 2: N-ethyl-N,N-diisopropylamine; N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate / N,N-dimethyl-formamide / 12 h / 20 °C
Multi-step reaction with 2 steps 1: methanol; hydrogenchloride / ethyl acetate / 20 °C 2: N-ethyl-N,N-diisopropylamine; N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate / N,N-dimethyl-formamide / 3 h / 20 °C
Multi-step reaction with 2 steps 1: dichloromethane / 18 h / 20 °C 2: triethylamine; benzotriazol-1-ol; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride / dichloromethane / 16 h / 20 °C
Multi-step reaction with 2 steps 1: hydrogenchloride / 1,4-dioxane; dichloromethane / 1 h / 25 °C 2: N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate; N-ethyl-N,N-diisopropylamine / tetrahydrofuran / 18 h / 20 °C
Multi-step reaction with 2 steps 1: trifluoroacetic acid / dichloromethane / 30 min / 20 °C 2: N-ethyl-N,N-diisopropylamine; HATU / N,N-dimethyl-formamide / 12 h / 0 - 20 °C
Multi-step reaction with 2 steps 1.1: hydrogenchloride / 1,4-dioxane / 18 h / 0 - 20 °C 2.1: N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate; N-ethyl-N,N-diisopropylamine / dichloromethane / 1 h / 0 °C / Inert atmosphere 2.2: 18 h / 20 °C / Inert atmosphere
Multi-step reaction with 2 steps 1: hydrogenchloride / ethyl acetate / 12 h / 20 °C 2: HATU; N-ethyl-N,N-diisopropylamine / N,N-dimethyl-formamide / 12 h / 0 - 20 °C
Multi-step reaction with 2 steps 1: trifluoroacetic acid / dichloromethane / 30 min / 20 °C 2: N-ethyl-N,N-diisopropylamine; N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate / N,N-dimethyl-formamide / 30 min / 20 °C
Multi-step reaction with 3 steps 1: hydrogenchloride / methanol / 2 h / 4 °C 2: sodium hydroxide / methanol; dichloromethane; water / 4 °C / pH 12.5 - 13 3: 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride; benzotriazol-1-ol; N-ethyl-N,N-diisopropylamine / dichloromethane; N,N-dimethyl-formamide / -10 - 20 °C
Multi-step reaction with 2 steps 1: hydrogenchloride / 1,4-dioxane / 1 h / 16 °C 2: N-ethyl-N,N-diisopropylamine; N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate / N,N-dimethyl-formamide / 1 h / 16 - 20 °C
8.06 g Stage #1: tert-butyl (2S,4R)-4-hydroxy-2-(((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)carbamoyl)pyrrolidine-1-carboxylate With trifluoroacetic acid for 1h; Cooling with ice; Stage #2: With N-tert-butyloxycarbonyl-L-tert-leucine; N-ethyl-N,N-diisopropylamine; N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate In dichloromethane at 20℃; for 3h; Further, step S9 can specifically be: take a 50mL single-necked flask and add DCM (50mL), then add the reaction mixture.(8)The prepared raw material (compound 12, 7.80 g, 18.07 mmol) was slowly added dropwise with TFA (8.24 g, 72.30 mmol) under ice bath conditions. After the addition was complete, the mixture was stirred for 1 h. The reaction was monitored by TLC. After the raw material disappeared, DCM and TFA in the system were removed by rotary evaporation. The residue was dissolved in an appropriate amount of DCM, and the pH was adjusted to alkaline with ammonia. The mixture was extracted with DCM, dried, and most of the DCM was removed by rotary evaporation. An appropriate amount of anhydrous DCM (30 mL) was added, followed by DIPEA (0.09 g, 72.30 mmol), HATU (7.56 g, 19.88 mmol), and Boc-Tle-OH (4.60 g, 19.88 mmol). After the addition was complete, the mixture was stirred at room temperature for 3 h. After the raw material was completely eliminated by TLC monitoring, it was extracted with DCM, dried by rotary evaporation, and then purified by column chromatography with dichloromethane/methanol (V/V=30:1) as the mobile phase, yielding a white solid product Boc-VHL (8.06 g, 14.79 mmol).

References: [1]Hu, Jiantao; Hu, Biao; Wang, Mingliang; Xu, Fuming; Miao, Bukeyan; Yang, Chao-Yie; Wang, Mi; Liu, Zhaomin; Hayes, Daniel F.; Chinnaswamy, Krishnapriya; Delproposto, James; Stuckey, Jeanne; Wang, Shaomeng [Journal of Medicinal Chemistry, 2019, vol. 62, # 3, p. 1420 - 1442].
[2]Current Patent Assignee: YALE UNIVERSITY - WO2019/195609, 2019, A2.
[3]Current Patent Assignee: UNIVERSITY OF MICHIGAN - WO2020/142227, 2020, A1.
[4]Current Patent Assignee: KYMERA THERAPEUTICS - WO2020/206424, 2020, A1.
[5]Current Patent Assignee: YALE UNIVERSITY - WO2021/207172, 2021, A1.
[6]Current Patent Assignee: JIANGSU YAHONG MEDITECH - WO2022/161166, 2022, A1.
[7]Current Patent Assignee: HINOVA PHARMACEUTICALS - WO2023/280237, 2023, A1.
[8]Current Patent Assignee: SHANGHAI QILU PHARMACEUTICAL RES AND DEVELOPMENT CENTRE - WO2023/143249, 2023, A1.
[9]Wang, Xiaohua; Xin, Lilan; Deng, Xiaofei; Dong, Chune; Hu, Guoyuan; Zhou, Hai-Bing [European Journal of Medicinal Chemistry, 2024, vol. 267].
[10]Desantis, Jenny; Bazzacco, Alessandro; Eleuteri, Michela; Tuci, Sara; Bianconi, Elisa; Macchiarulo, Antonio; Mercorelli, Beatrice; Loregian, Arianna; Goracci, Laura [European Journal of Medicinal Chemistry, 2024, vol. 268].
[11]Yao, Xiaoxuan; Mao, Jianping; Zhang, Haoyu; Xiao, Yi; Wang, Yongjun; Liu, Hongzhuo [European Journal of Medicinal Chemistry, 2024, vol. 272].
[12]Xin, Lilan; Wang, Chao; Cheng, Yan; Wang, Hongli; Guo, Xinyi; Deng, Xiaofei; Deng, Xiangping; Xie, Baohua; Hu, Hankun; Min, Chang; Dong, Chune; Zhou, Hai-Bing [Journal of Medicinal Chemistry, 2024, vol. 67, # 11, p. 8913 - 8931].
[13]Soto-Martínez, Diana M.; Clements, Garrett D.; Díaz, John E.; Becher, Joy; Reynolds, Robert C.; Ochsenbauer, Christina; Snowden, Timothy S. [RSC Advances, 2024, vol. 14, # 24, p. 17077 - 17090].
[14]Current Patent Assignee: KESMALEA THERAPEUTICS LTD - WO2024/175905, 2024, A1.
[15]Current Patent Assignee: WUHAN UNIVERSITY - CN120247870, 2025, A Location in patent: Paragraph 0051-0053.
  • 14
  • [ 62965-35-9 ]
  • [ 2086301-13-3 ]
  • [ 1997302-16-5 ]
YieldReaction ConditionsOperation in experiment
85.6% With N-ethyl-N,N-diisopropylamine; N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate In N,N-dimethyl-formamide at 20℃; for 3h; 1.1.3 (2S,4R)-4-hydroxy-2-(((S)-1-(4-(4-methylthiazole-5-yl)phenyl)ethyl)carbamoyl)pyrrolidine hydrochloride (Compound C-9) (14.15g, 39mmol), (S)-2-((tert-butoxycarbonyl)amino)-3,3-dimethylbutyric acid (compound C-10) (9.79g, 43mmol), diisopropylethylamine (30.83g, 240mmol) was added to N, N-Dimethylformamide (70mL), stir well. At room temperature, HATU (17.55g, 47mmol) was added to the system and stirred for 3 hours. Add 200mL of water to the reaction solution to quench, there is a white solid product precipitation, filtration, filtrate with ethyl acetate extraction, organic phase and then washed with saturated sodium chloride aqueous solution 2-3 times, organic phase with anhydrous sodium sulfate drying, filtering, concentrated filtrate, to obtain oily crude products. Column chromatography purification (petroleum ether: ethyl acetate = 1:1~0:1) was combined with a white solid product to give a product ((S)-1-((2S,4R)-4-hydroxy-2-((S)-1-(4-(4-methylthiazole-5-yl)phenyl)ethyl) carbamoyl)pyrrolidine-1-yl)-3,3-dimethyl-1-oxobutane-2-yl) carbamic acid tert-butyl ester (compound C-11) (17.94g, yield 85.6%).
84% With N-ethyl-N,N-diisopropylamine; HATU In N,N-dimethyl-formamide at 20℃; for 12h; 6 Step 6: Preparation of tert- butyl ((S)-l-((2S,4R)-4-hydroxy-2-(((S)-l-(4-(4- methylthiazol-5-yl)phenyl)ethyl)carbamoyl)pyrrolidin-l-yl)-3, 3-dimethyl- l-oxobutan-2- yl)carbamate Into a 25-mL round-bottom flask, was placed (2S)-2-[(tert-butoxy)carbonyl] amino- 3, 3 -dimethylbutanoic acid (2.0 g, 8.65 mmol, 0.99 equiv) in N,N-dimethylformamide (30 mL). N-ethyl-N-isopropylpropan-2-amine (3.4 g, 3.00 equiv), o-(7- Azabenzotriazol- 1 -yl)-N,N,N',N’- te-tramethyluronmm hexafluorophosphate (5.0 g, 1.50 equiv), (2S,4R)-4-hydroxy-N-[(lS)-l-[4- (4-methyl-l,3-thiazol-5-yl)phenyl]ethyl]pyrrolidine-2-carboxamide hydrochloride (3.2 g, 8.70 mmol, 1.00 equiv). The resulting solution was stirred for 12 hours at room temperature. The resulting solution was extracted with ethyl acetate (60 mL x 3) and washed with water (100 mL x 2). The organic layers combined and dried, concentrated under vacuum. The residue was applied onto a silica gel column with ethyl acetate/petroleum ether (1:3). This resulted in 4.0 g (84%) of tert-butyl N - [(2S )- 1 - [(2S ,4R)-4-hydroxy-2- [ [( 1 S )- 1 - [4-(4-methyl- 1 ,3 -thiazol-5- yl)phenyl]ethyl]carbamoyl]pyrrolidin-l-yl]-3, 3-dimethyl- l-oxobutan-2-yl]carbamate as a yellow solid. LC/MS (ESI) m/z: 545.30 [M+l] +.
84% With N-ethyl-N,N-diisopropylamine; HATU In N,N-dimethyl-formamide at 20℃; for 12h; 6 Step 6: Preparation of tert- butyl ((S)-1-((2S,4R)-4-hydroxy-2-(((S)-1-(4-(4- methylthiazol-5-yl)phenyl)ethyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2- yl)carbamate Into a 25-mL round-bottom flask, was placed (2S)-2-[(tert-butoxy)carbonyl]amino- 3,3-dimethylbutanoic acid (2.0 g, 8.65 mmol, 0.99 equiv) in N,N-dimethylformamide (30 mL). N-ethyl-N-isopropylpropan-2-amine (3.4 g, 3.00 equiv), o-(7-Azabenzotriazol-1-yl)-N,N,N',N'- te-tramethyluronium hexafluorophosphate (5.0 g, 1.50 equiv), (2S,4R)-4-hydroxy-N-[(1S)-1-[4- (4-methyl-1,3-thiazol-5-yl)phenyl]ethyl]pyrrolidine-2-carboxamide hydrochloride (3.2 g, 8.70 mmol, 1.00 equiv). The resulting solution was stirred for 12 h at room temperature. The resulting solution was extracted with ethyl acetate (60 mL x 3) and washed with water (100 mL x 2). The organic layers combined and dried, concentrated under vacuum. The residue was applied onto a silica gel column with ethyl acetate/petroleum ether (1:3). This resulted in 4.0 g (84%) of tert- butyl N-[(2S)-1-[(2S,4R)-4-hydroxy-2-[[(1S)-1-[4-(4-methyl-1,3-thiazol-5- yl)phenyl]ethyl]carbamoyl]pyrrolidin-1-yl]-3,3-dimethyl-1-oxobutan-2-yl]carbamate as a yellow solid. LC/MS (ESI) m/z: 545.30 [M+1] +.
84% With N-ethyl-N,N-diisopropylamine; N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate In N,N-dimethyl-formamide at 20℃; for 12h; 6 Step 6: Preparation of tert-butyl ((S)-1-((2S,4R)-4-hydroxy-2-(((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)carbamate Into a 25-mL round-bottom flask, was placed (2S)-2-[(tert-butoxy)carbonyl]amino-3,3-dimethylbutanoic acid (2.0 g, 8.65 mmol, 0.99 equiv) in N,N-dimethylformamide (30 mL). N-ethyl-N-isopropylpropan-2-amine (3.4 g, 3.00 equiv), o-(7-Azabenzotriazol-1-yl)-N,N,N',N'-te-tramethyluronium hexafluorophosphate (5.0 g, 1.50 equiv), (2S,4R)-4-hydroxy-N-[(1S)-1-[4-(4-methyl-1,3-thiazol-5-yl)phenyl]ethyl]pyrrolidine-2-carboxamide hydrochloride (3.2 g, 8.70 mmol, 1.00 equiv). The resulting solution was stirred for 12 hours at room temperature. The resulting solution was extracted with ethyl acetate (60 mL x 3) and washed with water (100 mL x 2). The organic layers combined and dried, concentrated under vacuum. The residue was applied onto a silica gel column with ethyl acetate/petroleum ether (1:3). This resulted in 4.0 g (84%) of tert-butyl N-[(2S)-1-[(2S,4R)-4-hydroxy-2-[[(1S)-1-[4-(4-methyl-1,3-thiazol-5-yl)phenyl]ethyl]carbamoyl]pyrrolidin-1-yl]-3,3-dimethyl-1-oxobutan-2-yl]carbamate as a yellow solid. LC/MS (ESI) m/z: 545.30 [M+1] +
76% With triethylamine; HATU In N,N-dimethyl-formamide at 0 - 25℃; Inert atmosphere; 5 Step 5: Tert-butyl N-[(2S)-1-[(2S,4R)-4-hydroxy-2-[[(1S)-1-[4-(4-methyl-1,3-thiazol- 5-yl)phenyl]ethyl]carbamoyl]pyrrolidin-1-yl]-3,3-dimethyl-1-oxobutan-2-yl]carbamate. To a stirred mixture of (2S)-2-[(tert-butoxycarbonyl)amino]-3,3-dimethylbutanoic acid (27.7 g, 120 mmol) and TEA (45.3 mL, 448 mmol) in DMF (400 mL) were added (2S,4R)-4-hydroxy-N-[(1S)- 1-[4-(4-methyl-1,3-thiazol-5-yl)phenyl]ethyl]pyrrolidine-2-carboxamide hydrochloride (40.0 g, 109 mmol) and HATU (53.7 g, 142 mmol) in portions at 0 °C under nitrogen atmosphere. The resulting mixture was stirred for 3 h at 25 °C under nitrogen atmosphere. The reaction was quenched by the addition of water (300 mL) at 25 °C. The resulting mixture was extracted with EtOAc (3 x 300 mL). The combined organic layers were washed with brine (3 x 300 mL), dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by trituration with EtOAc (300 mL). The precipitated solids were collected by filtration and washed with EtOAc (2 x 40.0 mL). This resulted in the title compound as a light yellow solid (50.0 g, 76%): 1H NMR (400 MHz, CD3OD) d 8.90 (s, 1H), 7.50-7.36 (m, 4H), 6.40 (d, J = 9.3 Hz, 1H), 5.02 (p, J = 7.0 Hz, 1H), 4.62 (t, J = 8.3 Hz, 1H), 4.46 (s, 1H), 4.34-4.27 (m, 1H), 3.87 (d, J = 11.1 Hz, 1H), 3.76 (dd, J = 10.9, 4.0 Hz, 1H), 2.50 (s, 3H), 2.24 (dd, J = 13.2, 7.8 Hz, 1H), 2.06-1.93 (m, 1H), 1.56-1.48 (m, 3H), 1.46 (s, 9H), 1.03 (s, 9H); LC/MS (ESI, m/z): [(M + H)]+ = 545.40.
66.6% With N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate In N,N-dimethyl-formamide at 25 - 30℃; for 16h; Inert atmosphere; Alkaline conditions;
9.8 g With N-ethyl-N,N-diisopropylamine; N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate In dichloromethane at 20℃; for 16h; Step-f: Synthesis of tert-butyl ((S)-1-((2S,4R)-4-hydroxy-2-(((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)carbamate (17f) To a solution of (2S,4R)-4-hydroxy-N-((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)pyrrolidine-2-carboxamide hydrochloride (10.0 g, 27.24 mmol) and (S)-2-((tert-butoxycarbonyl)amino)-3,3-dimethylbutanoic acid (6.29 g, 27.24 mmol) in DCM (150 mL) at 0 °C was added HATU (12.4 g, 32,69 mmol) followed by dropwise addition of DIPEA (25.0 mL, 136.2 mmol) and stirred for 16 h at RT. Then the reaction mixture was poured into ice cold water and the resulting mixture was extracted with DCM (2 X 500 mL). The combined organic layer was washed with water (200 mL), saturated sodium bicarbonate solution (100 mL), brine (200 mL), dried over anhydrous sodium sulphate and concentrated under vacuum to give the crude product which was washed with chilled acetone and filtered to afford the title compound (9.8 g, 67.5 %) which was used in the next step without further purification. 1H NMR (400 MHz, DMSO-d6): d 8.97 (s, 1H), 8.38 (d, J = 6.4 Hz, 1H), 7.44-7.31 (m, 4H), 6.38 (d, / = 8.4 Hz, 1H), 5.10 (s, 1H), 4.91-4.88 (m, 1H), 4.28 (bs, 1H), 4.14 (d, / = 8.8 Hz, 1H), 3.62-3.58 (m, 2H), 2.45 (s, 3H), 2.08-2.00 (m, 2H), 1.78-1.76 (m, 1H), 1.48 (s, 9H), 1.44 (d, J = 6.9 Hz, 3H), 0.93 (s, 9H); LC-MS: m/z 545.3 (M+l)+.
1.873 g Stage #1: N-tert-butyloxycarbonyl-L-tert-leucine With N-ethyl-N,N-diisopropylamine; N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate In dichloromethane at 0℃; Inert atmosphere; Stage #2: (2S,4R)-4-hydroxy-N-((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)pyrrolidine-2-carboxamide hydrochloride In dichloromethane at 20℃; Inert atmosphere; 4.6.6. Tert-butyl ((S)-1-((2S,4R)-4-hydroxy-2-(((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)carbamate (54) Under nitrogen atmosphere, to a stirred solution of (S)-2-((tertbutoxycarbonyl)amino)-3,3-dimethylbutanoic acid (0.953 g, 4.123mmol) in dry DCM (10.5 mL), DIPEA (1.8 mL, 10.307 mmol) and HATU(1.834 g, 4.824 mmol) were added at 0 C. After 1 h, 52 (0.910 g, 2.473mmol) was added slowly. The mixture was stirred for 18 h at roomtemperature. Then, DCM (50 mL) was added to the reaction mixture andwas washed with 10 % citric acid (12 mL) twice, saturated NaHCO3solution (12 mL) twice, water (12 mL) twice, and brine (20 mL) once.The organic phase was dried over anhydrous Na2SO4 and concentratedunder reduced pressure to afford the desired compound as a yellow oil(1.873 g) which was used directly for the next step.
1.873 g Stage #1: N-tert-butyloxycarbonyl-L-tert-leucine With N-ethyl-N,N-diisopropylamine; N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate In dichloromethane at 0℃; Inert atmosphere; Stage #2: (2S,4R)-4-hydroxy-N-((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)pyrrolidine-2-carboxamide hydrochloride In dichloromethane at 20℃; Inert atmosphere; 4.6.6. Tert-butyl ((S)-1-((2S,4R)-4-hydroxy-2-(((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)carbamate (54) Under nitrogen atmosphere, to a stirred solution of (S)-2-((tertbutoxycarbonyl)amino)-3,3-dimethylbutanoic acid (0.953 g, 4.123mmol) in dry DCM (10.5 mL), DIPEA (1.8 mL, 10.307 mmol) and HATU(1.834 g, 4.824 mmol) were added at 0 C. After 1 h, 52 (0.910 g, 2.473mmol) was added slowly. The mixture was stirred for 18 h at roomtemperature. Then, DCM (50 mL) was added to the reaction mixture andwas washed with 10 % citric acid (12 mL) twice, saturated NaHCO3solution (12 mL) twice, water (12 mL) twice, and brine (20 mL) once.The organic phase was dried over anhydrous Na2SO4 and concentratedunder reduced pressure to afford the desired compound as a yellow oil(1.873 g) which was used directly for the next step.

References: [1]Current Patent Assignee: JIANGSU YAHONG MEDITECH - WO2022/161166, 2022, A1 Location in patent: Page/Page column 30; 32-34.
[2]Current Patent Assignee: YALE UNIVERSITY - WO2019/195609, 2019, A2 Location in patent: Paragraph 00485-00486.
[3]Current Patent Assignee: YALE UNIVERSITY - WO2020/51564, 2020, A1 Location in patent: Paragraph 1069; 1070.
[4]Current Patent Assignee: YALE UNIVERSITY - WO2021/207172, 2021, A1 Location in patent: Paragraph 00237.
[5]Current Patent Assignee: KYMERA THERAPEUTICS - WO2020/206424, 2020, A1 Location in patent: Paragraph 0001129.
[6]Li, Zhenwu; Harikrishnan, Lalgudi S.; Xu, Guozhang; Samanta, Debangshu; Clemente, Jose C.; Leng, Lingying; Tu, Wenbin; Yang, Lin; Huang, Liyue; Wang, Mi; Wang, Shaomeng; Deng, Qiaolin; Behshad, Elham; Nagilla, Rakesh; Orth, Peter; Rice, Cory; Strickland, Corey; Mohammad, Helai P.; Priestley, E. Scott; Sui, Zhihua [Journal of Medicinal Chemistry, 2025, vol. 68, # 2, p. 1134 - 1154].
[7]Current Patent Assignee: AURIGENE ONCOLOGY - WO2019/207538, 2019, A1 Location in patent: Page/Page column 85-86.
[8]Desantis, Jenny; Bazzacco, Alessandro; Eleuteri, Michela; Tuci, Sara; Bianconi, Elisa; Macchiarulo, Antonio; Mercorelli, Beatrice; Loregian, Arianna; Goracci, Laura [European Journal of Medicinal Chemistry, 2024, vol. 268].
[9]Desantis, Jenny; Bazzacco, Alessandro; Eleuteri, Michela; Tuci, Sara; Bianconi, Elisa; Macchiarulo, Antonio; Mercorelli, Beatrice; Loregian, Arianna; Goracci, Laura [European Journal of Medicinal Chemistry, 2024, vol. 268].
 

Historical Records

Technical Information

Categories